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Abstract
The European Commission asked EFSA for a scientiﬁc evaluation on the risk to human health of the
presence of furan and methylfurans (2-methylfuran, 3-methylfuran and 2,5-dimethylfuran) in food.
They are formed in foods during thermal processing and can co-occur. Furans are produced from
several precursors such as ascorbic acid, amino acids, carbohydrates, unsaturated fatty acids and
carotenoids, and are found in a variety of foods including coffee and canned and jarred foods.
Regarding furan occurrence, 17,056 analytical results were used in the evaluation. No occurrence data
were received on methylfurans. The highest exposures to furan were estimated for infants, mainly
from ready-to-eat meals. Grains and grain-based products contribute most for toddlers, other children
and adolescents. In adults, elderly and very elderly, coffee is the main contributor to dietary exposure.
Furan is absorbed from the gastrointestinal tract and is found in highest amounts in the liver. It has a
short half-life and is metabolised by cytochrome P450 2E1 (CYP2E1) to the reactive metabolite,
cis-but-2-ene-1,4-dialdehyde (BDA). BDA can bind covalently to amino acids, proteins and DNA. Furan
is hepatotoxic in rats and mice with cholangioﬁbrosis in rats and hepatocellular adenomas/carcinomas
in mice being the most prominent effects. There is limited evidence of chromosomal damage in vivo
and a lack of understanding of the underlying mechanism. Clear evidence for indirect mechanisms
involved in carcinogenesis include oxidative stress, gene expression alterations, epigenetic changes,
inﬂammation and increased cell proliferation. The CONTAM Panel used a margin of exposure (MOE)
approach for the risk characterisation using as a reference point a benchmark dose lower conﬁdence
limit for a benchmark response of 10% of 0.064 mg/kg body weight (bw) per day for the incidence of
cholangioﬁbrosis in the rat. The calculated MOEs indicate a health concern. This conclusion was
supported by the calculated MOEs for the neoplastic effects.
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Summary
The European Commission asked the European Food Safety Authority (EFSA) for a scientiﬁc
evaluation on the risk to human health of the presence of furan and methylfurans (2-methylfuran,
3-methylfuran and 2,5-dimethylfuran) in food. To address this request, the EFSA Panel on
Contaminants in the Food Chain (CONTAM) decided that the opinion should comprise the:
• evaluation of the toxicity of furan, and 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran,
collectively known as methylfurans, for humans considering all relevant toxicological endpoints;
• estimation of the dietary exposure of the European Union (EU) population to furan,
2-methylfuran, 3-methylfuran and 2,5-dimethylfuran from food, including the consumption
patterns of speciﬁc groups of the population if appropriate;
• assessment of the human health risks for the EU population, including speciﬁc groups of the
population if appropriate, as the consequence of the estimated dietary exposure.
Furan, 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran are volatile compounds that are formed
in foods during thermal processing. Furan can be formed in food from a variety of precursors including
ascorbic acid, amino acids, carbohydrates, unsaturated fatty acids and carotenoids. Food characteristics,
processing and cooking conditions, and the losses which mainly occur due to evaporation in the
preparation of the food at the level of the consumer, determine the ﬁnal concentration in the food as
consumed.
Chronic dietary exposure to furan was estimated using a data set containing 9,663 samples provided
by governmental organisations and 7,393 samples provided by commercial organisations. The data sets
were comparable and were merged for the assessment. The highest concentrations of furan were found
in whole roasted coffee beans, with a mean value of 4,579 lg/kg. High mean concentrations of furan
were also found in ground roasted coffee (2,361 lg/kg), unspeciﬁed coffee solids (2,186 lg/kg), coffee
imitates for brewing (1,922 lg/kg), instant coffee powder (310 lg/kg) and instant coffee imitates
(127 lg/kg). Mean concentrations ranging from 20 to 57 lg/kg were found in composite foods
(prepared salads, cereal-based and vegetable-based), ready-to-eat meals for infants and young
children, soy sauce, bread and rolls, raw pasta, breakfast cereals, ﬁne bakery wares and spirits.
Occurrence data for 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran were not provided, and from
the available literature data on the co-occurrence of furan and methylfurans, a 2-methylfuran/furan and
3-methylfuran/furan ratio was calculated only for coffee, infant cereals, jarred baby-food and cereal
ﬂakes. Co-occurrence data on 2,5-dimethylfuran were too limited to derive such a ratio.
The highest exposures to furan were estimated in the youngest population group, i.e. infants. The
mean dietary exposures calculated for infants ranged from 0.14 to 0.99 lg/kg body weight (bw) per
day (minimum lower bound (LB) to maximum upper bound (UB)). Regarding the 95th percentile
exposures, which refer to highly exposed consumers within a given dietary survey and age class, the
highest estimates were also observed for infants ranging from 0.27 to 1.8 lg/kg bw per day (minimum
LB to maximum UB). Chronic dietary exposure of adults, elderly and very elderly was estimated to be
on average between 0.11 and 0.75 lg/kg bw per day (minimum LB to maximum UB) and the 95th
percentile was between 0.2 and 1.27 lg/kg bw per day (minimum LB to maximum UB) depending on
the survey and age group. Ready-to-eat meals for infants and small children are the main contributor
to the dietary exposure of infants. For adults, elderly and very elderly, the exposure is mainly driven by
coffee. Grains and grain-based products are the food group contributing most for toddlers, other
children and adolescents, and it is also the second largest contributor in all other age classes. The
inﬂuence of reheating commercially processed foods on furan concentrations is limited and depends on
the consumer behaviour. Regarding the formation of furan during home cooking, a speciﬁc scenario
based on toasting bread did not impact on the overall outcome of the exposure assessment. The
inclusion of methylfurans, however, may signiﬁcantly increase exposure. For the exposure scenario for
the sum of furan, 2-methylfuran and 3-methylfuran, estimates for adults, elderly and very elderly
showed the highest increase compared to the baseline scenario. This exposure was mainly driven by
the high concentrations of 2-methylfuran in coffee (four times higher than furan).
After oral exposure to rats, furan is rapidly and extensively absorbed from the gastrointestinal (GI)
tract, distributed throughout the body and extensively metabolised. The major contributor to the
metabolism of furan is cytochrome P450 2E1 (CYP2E1), resulting in opening of the furan ring and
formation of cis-but-2-ene-1,4-dialdehyde (BDA) which is very reactive. BDA has never been directly
measured. However, results with trapping agents and the identiﬁcation of urinary and biliary
metabolites provide strong evidence that BDA is indeed a prime reactive intermediate in the
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metabolism of furan. BDA reacts readily with amino acids, glutathione (GSH) and biogenic amines and
it has direct reactivity towards DNA. However, the data suggest that due to BDA reactivity with protein
and non-protein amino and thiol residues, access to DNA in vivo is restricted.
No oral studies have been performed with any of the three methylfurans considered in this opinion
to address their kinetics in animals, but it is anticipated that they will be absorbed from the GI tract.
Non-extractable association of 2-methylfuran with protein and DNA in the liver was reported after
intraperitoneal (i.p.) administration. For 2-methyl- and 3-methylfuran, data from in vitro studies are
available that show that they may become associated (non-extractable) with lung and liver microsomal
proteins. The reactive metabolic intermediates of 2-methylfuran and 3-methylfuran are the cis-enedials
3-acetylacrolein (4-oxopent-2-enal) and 2-methylbut-2-enedial, respectively. For 2,5-dimethylfuran ring
opening results in the formation of a reactive intermediate, the cis-enedione 3(Z)-hexene-2,5-dione.
Similar to BDA, the reactive intermediate formed from 2,5-dimethylfuran reacts readily with amino
acids and with GSH and the corresponding structures for the adducts formed have been reported. For
2- and 3-methylfuran metabolites, only very limited information is available, but from the structures of
their primary metabolites and from studies with scavengers, it is anticipated that these will react with
tissue components in a similar way to the primary metabolites of furan and 2,5-dimethylfuran.
In experiments of a duration of up to 90 days, furan is strongly hepatotoxic and moderately
nephrotoxic in rodents when applied by oral gavage. Rats seem to be more sensitive towards furan
than mice. Furan leads to characteristic changes in serum markers related to hepatotoxicity as well as
severe histopathological damage in the liver. After 90 days, signiﬁcant increases in serum thyroid
hormones were observed along with severe histopathological changes in the liver of male rats after a
daily dose of 0.12 mg/kg bw, given 5 days a week.
In long-term studies, furan was associated with toxicity in the liver. Cholangioﬁbrosis was observed
in rats as an early and sensitive response with signiﬁcant increases after 36 weeks at doses of
0.44 mg/kg bw and above. In mice, hepatocellular adenoma/carcinoma occurred at 104 weeks at
doses of 4 mg/kg bw and above. In rats, cholangiocarcinomas were observed at the top dose of
8 mg/kg bw. No relevant malignancies were observed at doses at or below 2 mg/kg bw up to
104 weeks.
Furan did not induce gene mutations in bacteria. In the majority of the in vitro studies in
mammalian cells, furan was able to induce chromosomal aberrations and sister chromatid exchanges;
contrasting results were reported on the requirement for microsomal activation. BDA forms DNA
adducts at the exocyclic N atom of the deoxycytosine, deoxyguanosine and deoxyadenosine
nucleosides in in vitro model systems and in DNA from Salmonella Typhimurium TA104. BDA was able
to directly induce mutations in bacteria and strand breaks and mutations in mammalian cells in vitro.
In rodents, furan induced very low levels of DNA adducts in liver and kidney. The chemical structures
of these adducts could not be deﬁned but were not identical to those induced by BDA in in vitro model
systems. Conﬂicting data were reported for the induction of DNA breaks in the liver. These breaks,
likely reﬂecting oxidative stress-induced DNA damage, occurred at doses showing mild liver toxicity.
Chronic exposure to furan induced chromosomal damage in proliferating splenocytes from mice and
rats. The DNA lesions responsible for these effects remain undeﬁned. No clear induction of base
substitutions was observed in transgenic rat models. A weak mutagenic activity was suggested by a
single study in a transgenic mouse model. An excess of GC > TA transversions was observed at codon
61 of the Ha-ras oncogene in furan-induced liver tumours in mice. It is uncertain whether these
mutations are the consequence of oxidative damage to DNA or reﬂect an expansion of pre-existing
spontaneous Ha-ras mutations.
Histological changes in the testes, prostate gland, Leydig cells and seminal vesicles were observed
in Wistar rats at 2 mg/kg bw (lowest dose tested) and above given during weaning and post-puberty.
No histological effects in reproductive organs were observed in adult rats and mice up to 8 mg/kg bw.
Furan induces oxidative stress. The binding of BDA to a range of target molecules leads ultimately
to cell and tissue damage, mitochondrial dysfunction and ﬁbrosis, primarily in the liver. There is clear
evidence for the involvement of indirect mechanisms in the carcinogenic mode of action of furan.
These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all of
these effects being accompanied by tissue damage. There is limited evidence of a direct mechanism
(i.e. direct interaction with DNA) in the carcinogenic action of furan. The contributing factors in
carcinogenesis are likely to vary according to dose, duration of exposure and degree of severity of liver
cellular damage, inﬂammation and compensatory proliferation.
The liver is the primary target organ with respect to acute and short-term (< 90 days) toxicity of
2- and 3-methylfuran in rodents. There is also indication for kidney toxicity of 3-methylfuran after
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90 days of exposure. Liver toxicity in male rats given 3-methylfuran (28 or 90 days) or 2-methylfuran
(28 days) by gavage was found to be the most sensitive adverse endpoint for both compounds.
Their toxic potency was reported to be in the same order of magnitude as that for furan. No
information on the genotoxic properties of 3-methylfuran and limited information for 2-methylfuran
and 2,5-dimethylfuran is available. Both 2-methylfuran and 2,5-dimethylfuran showed negative results
in bacteria. There is some evidence that both compounds induce chromosomal damage in mammalian
cells in vitro and there is little evidence that 2,5-dimethylfuran can induce DNA breaks in vivo.
As there are few data available on the effect of furan in humans, the CONTAM Panel used data
from experimental animals for the hazard characterisation. For non-neoplastic effects, the CONTAM
Panel selected the BMDL10 of 0.064 mg/kg bw per day (correcting for the applied dose regimen of
5 days per week) for the induction of cholangioﬁbrosis in male rats after 2 years as reference point.
For neoplastic effects, the CONTAM Panel considered that the combined data set from two studies on
the incidence of hepatocellular adenomas and carcinomas in female mice after 2 years is the most
robust data set to derive a reference point and selected the BMDL10 of 1.31 mg/kg bw per day
(correcting for the applied dose regimen of 5 days per week). In view of some indications for a direct
genotoxic mechanism in the carcinogenic mode of action of furan, the CONTAM Panel decided that it
was not appropriate to establish a tolerable daily intake (TDI) and used a margin of exposure (MOE)
approach. The available information was insufﬁcient to identify a reference point for the methylfurans.
However, it was considered appropriate to assume dose additivity for hepatotoxicity of furan, 2-
methylfuran and 3-methylfuran in the rat.
For non-neoplastic effects, the calculated MOEs are below 100 in a number of dietary surveys,
particularly for the high percentile exposure estimates for the younger age groups (infants and
toddlers) and adults (including elderly). The CONTAM Panel concluded that these MOEs indicate a
health concern. The CONTAM Panel noted that, with the exception of some surveys, the calculated
MOEs for neoplastic effects of furan are smaller than 10,000, which, in accordance with the guidance
given by the Scientiﬁc Committee, would indicate a health concern. However, there is uncertainty
regarding the carcinogenic mode of action of furan. The CONTAM Panel considered the resulting MOEs
for hepatocellular adenomas and carcinomas as supporting evidence for its conclusion, based on the
hepatotoxicity of furan, that the current exposure to furan indicates a health concern. Based on a
scenario for chronic dietary exposure to the sum of furan, 2-methylfuran and 3-methylfuran, MOE
values for the incidence of cholangioﬁbrosis were calculated. From these MOE values, it becomes clear
that methylfurans may add signiﬁcantly to the overall exposure and therefore increase the concern for
hepatotoxicity.
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of furan
is moderate and that the assessment is likely to be conservative. For methylfurans, due to a lack of
data, no full assessment could be performed and the uncertainties in the assessment are large.
The CONTAM Panel recommends producing additional data on the occurrence of methylfurans in
food as well as data on the changes of furan and methylfurans concentrations during the distinct
stages of coffee preparation for all coffee types. Furthermore, the CONTAM Panel recommends
performing studies in vivo on the effect of furan on the genome to clarify the carcinogenic mode of
action. Further information is also needed on the toxicity, including the genotoxic properties, of
methylfurans.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
BACKGROUND
Furan is formed in foods during thermal processing. It occurs in a variety of foods such as coffee,
canned and jarred foods including baby food containing meat, and various vegetables. 2-Methylfuran
and 3-methylfuran, have been found concurrently with furan, and apparently are also formed during
thermal processing and are likely to undergo a similar metabolic fate to furan.
The Scientiﬁc Panel on Contaminants in the Food Chain adopted on 7 December 2004 a report on
provisional ﬁndings on furan in food.1 They concluded from the available data that there is a relatively
small difference between possible human exposures and the doses in experimental animals that
produce carcinogenic effects, probably by a genotoxic mechanism. However, a reliable risk assessment
would need further data on both toxicity and exposure.
In the meantime, EFSA published
• on 2 December 2009, an external scientiﬁc report on furan in heat processed food products
including home cooked food products and ready-to-eat products.2
• on 18 December 2009, an external scientiﬁc/technical report on consumer exposure to furan
from heat-processed foods and kitchen air.3
• on 22 August 2011, a scientiﬁc report with an update on furan levels in food from monitoring
years 2004–2010 and exposure assessment.4
Furan was evaluated at the meeting of the Joint FAO/WHO Expert Committee on Food Additives
(JECFA) which was held in Rome, Italy, from 16 to 25 February 2010.5 The Committee concluded that
the estimated margins of exposure (MOE) (480–960) indicate a human health concern for a
carcinogenic compound that might act via a DNA-reactive genotoxic metabolite.
Furthermore, the study report of the latest furan carcinogenicity bioassay, supported by an
interagency agreement between the US National Institute of Environmental Health Sciences (NIEHS)/
National Toxicology Program (NTP) and the US Food and Drug Administration (FDA) has been ﬁnalised
and is now available (NCTR, 2015).
TERMS OF REFERENCE
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks the
European Food Safety Authority (EFSA) for a scientiﬁc opinion on the human health risks related to the
presence of furan and methylfurans in food.
1.2. Interpretation of the Terms of Reference
The EFSA Panel on Contaminants in the Food Chain (CONTAM) concluded this opinion should
comprise the:
a) evaluation of the toxicity of furan, and 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran,
collectively known as methylfurans, for humans considering all relevant toxicological
endpoints;
b) estimation of the dietary exposure of the European Union (EU) population to furan, and
2-methylfuran, 3-methylfuran and 2,5-dimethylfuran, collectively known as methylfurans, from
food, including the consumption patterns of speciﬁc groups of the population if appropriate;
c) assessment of the human health risks for the EU population, including speciﬁc groups of the
population if appropriate, as the consequence of the estimated dietary exposure.
1 Report of the Scientiﬁc Panel on Contaminants in the Food Chain on provisional ﬁndings on furan in food, EFSA Journal 2004;
137:1–20, Available online: http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/137.pdf
2 http://www.efsa.europa.eu/sites/default/ﬁles/scientific_output/ﬁles/main_documents/1e.pdf
3 http://www.efsa.europa.eu/sites/default/ﬁles/scientific_output/ﬁles/main_documents/30e.pdf
4 EFSA Journal 2011;9(9):2347 http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/2347.pdf
5 WHO Technical Report Series, No. 959, 2011, Evaluation of certain contaminants in food (Seventy-second report of the Joint
FAO/WHO Expert Committee on Food Additives). Available online: http://whqlibdoc.who.int/trs/WHO_TRS_959_eng.pdf?ua=1
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1.3. Supporting information for the assessment
1.3.1. Chemical and physical properties
1.3.1.1. Chemical properties
Furan [CAS-number 110-00-9, C4H4O, molecular weight (MW) 68.07 g/mol] is the parent
compound of ﬁve-membered heterocycles containing one oxygen atom. Its structure is stabilised by
resonance due to the delocalisation of the electrons of carbon and oxygen present in the p-orbital in a
6p-electron system. Its chemical structure is shown in Figure 1.
Furan is highly susceptible to electrophilic aromatic substitution, mainly at the a-position, yielding
for instance 2-alkylfurans (Hoydonckx et al., 2012). It is not clear to what extent such reactions are
relevant in foods, as in general, furan is considered to be stable in foods. Hoydonckx et al. (2012)
summarised the main chemical reactions applied to furan, but these are not relevant in a food context.
The compound is highly ﬂammable and may also form explosive peroxides. It is characterised by an
ethereal odour.
2-Methylfuran [CAS-number 534-22-5, C5H6O, MW 82.1 g/mol] is also aromatic in nature, and its
chemical properties are comparable to those of furan, although it should be noted it is more prone to
electrophilic aromatic substitution (Hoydonckx et al., 2012). Its chemical structure is shown in
Figure 1. It is reported to be characterised by a medium strength, chocolate like odour.
3-Methylfuran [CAS-number 930-27-8, C5H6O, MW 82.1 g/mol] (for structure see Figure 1) is the
analogue of 2-methylfuran. Like furan and 2-methylfuran, 3-methylfuran is also aromatic in nature. It
can be supposed that its chemical properties are similar, but information is scarce.
2,5-dimethylfuran [CAS-number 625-86-5, C6H8O, MW 96.1 g/mol] is particularly studied because
of its potential use as a liquid fuel as it can be produced from biomass-derived fructose (Roman-
Leshkov et al., 2007). This dimethylfuran is known as a potent scavenger of singlet oxygen (Noguchi
et al., 1977; Mongin et al., 2016) and hydroxyl radicals (Okada and Okajima, 1998).
2-Z-Butenedial (commonly referred to as cis-but-2-ene-1,4-dialdehyde (BDA)) [CAS-number
3675-13-6, C4H4O2, MW 84.1 g/mol] has been identiﬁed as a key metabolite of furan (Chen et al., 1995).
In view of its highly reactive character, it is synthesised in situ via the oxidative ring opening of furan using
dimethyloxirane (Adger et al., 1991).
1.3.1.2. Physical properties
Furan is a colourless liquid with a density of 0.94 g/cm3 (20°C), a melting point of 85°C and a
boiling point of 31.4°C at 101 kPa (760 mmHg). At 20°C, its vapour pressure is 66 kPa and at 25°C
80 kPa. Its solubility in water at 25°C is 10 g/L, and in acetone, benzene, ether and ethanol is greater
than 100 g/L. The log Kow is 1.34 (Hoydonckx et al., 2012; NTP, 2014). It can darken upon storage.
2-Methylfuran is a colourless liquid with a density of 0.92 g/cm3 (20°C), a melting point of 88.7°C
and a boiling point of 63–64°C at 101 kPa. At 20°C, its vapour pressure amounts 16 kPa (Hoydonckx
et al., 2012). Its solubility in water at 20°C is 3 g/L and the log Kow amounts to 1.85.
6 It is readily
soluble in organic solvents.
3-Methylfuran is a colourless liquid with a density of 0.92 g/cm3 (18°C) and a boiling point of
65.5°C at 101 kPa (Asahina et al., 1924). On standing, it can turn yellow (Burness, 1956). The log Kow
Figure 1: Chemical structures of furan, 2-methylfuran, 3-methylfuran, 2,5-dimethylfuran and 2-Z-
butenedial
6 http://www.thegoodscentscompany.com/data/rw1023171.html (Accessed: 30 June 2016)
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is 1.91 and the solubility in water is 3.03 g/L, as estimated using US-EPA EPI-suite.7 SciFinder8
reported an estimated solubility in water of 4.4 g/L and an estimated vapour pressure of 21 kPa
(25°C). According to The Good Scents Company, 3-methylfuran is soluble in ethanol, but further details
are not provided.9 2,5-Dimethylfuran is a colourless to yellow liquid with a density of 0.90 g/cm3
(20°C) and a boiling point of 94–96°C (Terent’ev and Kazitsyna, 1949) It has an estimated vapour
pressure of 8 kPa at 25°C. Its (experimental) log Kow is 2.24 and from this value the solubility in water
can be estimated to be approximately 1.5 g/L (US-EPA-EPI-suite). However, SciFinder8 reported an
estimated solubility in water of 4.3 g/L. According to The Good Scents Company, 2,5-dimethylfuran is
soluble in ethanol and propylene glycol, but further details are not provided.9
BDA is a major primary metabolite of furan (see Section 3.1.1.3), and for this reason, some
information on this metabolite is presented here. Its boiling point was reported to be 54–61°C (1 kPa)
(Hufford et al., 1952). In the absence of experimentally determined properties, the following
estimations were obtained, using US-EPA EPI-suite: a vapour pressure of 0.5 kPa (25°C), log Kow 0.14
and a solubility in water of 9.8 g/L. However, different values were reported on SciFinder,8 namely a
vapour pressure of 0.08 kPa (25°C), and a solubility in water of 124 g/L.
1.3.2. Analytical methods
Currently, no ofﬁcial standard methods are available for the analysis of furan and methylfurans in
foods. Neither are there certiﬁed reference materials available. In 2008, the European Commission
organised a proﬁciency test for furan using baby food as a sample in which 22 laboratories
participated with 16 returning satisfactory results (Kubiak et al., 2008a,b). Commercial proﬁciency tests
for furan using coffee or baby foods samples are organised by organisations such as Fapas.10 No
proﬁciency tests were identiﬁed for methylfurans.
Laboratories use their in house-validated analytical methods. Three analytical approaches are used
most often for the determination of furan and methylfuran in foods. All of them are based on a mass-
spectrometric (MS) detection and quantiﬁcation using stable isotope dilution assays with d4-furan,
d3-2-methylfuran and d3-3-methylfuran for, respectively, furan, 2-methylfuran and 3-methylfuran
based on selective ion monitoring (SIM). For 2,5-dimethylfuran, the use of deuterated analogues is not
applied, probably because analytical standards are not available commercially. Separation is
accomplished by capillary gas chromatography (GC).
The approaches differ in the isolation of the volatile analytes from the matrix. In the Goldmann et al.
(2005) method, solid-phase microextraction (SPME) (using typically a carboxen/polydimethylsiloxane
ﬁbre) is used in combination with cryofocusing. Bianchi et al. (2006) used a similar approach but
omitted the cryofocusing step. Becalski et al. (2005, 2010) used a static headspace approach without
the use of SPME, which is similar to the method proposed by FDA (2004b). The static head space
approach and the use of SPME both proved to be ﬁt for purpose as observed in a proﬁciency test
organised by the Joint Research Centre of the European Commission in 2008 (Kubiak et al., 2008a,b).
The limits of detection (LOD) of these methods typically range from 5 lg/kg to as low as 0.01 lg/kg,
and limits of quantiﬁcation (LOQ) from 25 lg/kg to 0.03 lg/kg (Kubiak et al., 2008a,b) for furan. For
methylated furans, similar limits were reported (e.g. Becalski et al. (2010) reported an LOD for
2-methylfuran amounting 0.05 lg/kg). These analytical limits are dependent upon the food matrix
analysed (Becalski et al., 2016). Becalski et al. (2010) also reported the presence of trace amounts of
furan present in blank samples and therefore considered only samples with concentrations exceeding
1 lg/kg as relevant.
Special care should be taken during the analysis because of the high volatility of the analyte and
the internal standards. In addition, the possibility of artefactual furan formation should be considered.
Adams et al. (2012) reported the artefactual furan formation on the SPME ﬁbre from volatile
precursors, especially at high ﬁbre desorption temperatures. Also the additional formation of furan
during the equilibration of the sample in the headspace vials has been reported (Senyuva and
Gokmen, 2005).
7 US EPA. [2012]. Estimation Programs Interface SuiteTM for Microsoft® Windows, v 4.11. United States Environmental
Protection Agency, Washington, DC, USA. Available online: https://www.epa.gov/tsca-screening-tools/epi-suitetm-estimation-
program-interface#what (Accessed: 30 June 2016)
8 Predicted with Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2017 ACD/Labs)
9 http://www.thegoodscentscompany.com/data/rw1435541.html (Accessed: 30 June 2016)
10 http://fapas.com/
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M€ark et al. (2006) used proton-transfer reaction mass spectrometry (PTR-MS) as an analytical tool
to quantify furan and methylfuran. This technique could even be applied as an on-line quality
monitoring system as no chromatographic separation of the analytes is required.
1.3.3. Previous assessments
Furan was evaluated by the International Agency for Research on Cancer (IARC) (IARC, 1995). The
IARC concluded that the evidence in humans for the carcinogenicity of furan was inadequate but there
was sufﬁcient evidence in experimental animals to classify furan as ‘possibly carcinogenic to humans’
(Group 2B).
In 2000, the US National Academy of Sciences (NAS) published a monograph on furan as an
airborne contaminant in spacecraft and concluded that ‘. . .furan, or an active metabolite of furan,
affects DNA indirectly through a mechanism involving cytotoxicity and does not react directly with the
DNA in target cells’. In assessing the risk of furan-induced cancers, the assumption was made that ‘an
exposure concentration that adequately controls the risk of cholangiocarcinomas will also control
leukemias and hepatocellular adenomas and carcinomas’. Biliary hyperplasia induced by furan in male
rats in a 13 week NTP study (NTP, 1993) was used as a precursor lesion to the cholangiocarcinomas.
From these data, a benchmark dose lower conﬁdence limit for 1% increase in cancer incidence
(BMDL01) of 0.09 mg/kg body weight (bw) per day was calculated (NAS, 2000).
During investigations relating to a review of a petition for certain uses of irradiation in food, the US
Food and Drug Administration (FDA) identiﬁed furan in a number of foods that undergo heat
treatment, such as canned and jarred foods. In May 2004, the FDA published a request for submission
of data and information on furan (FDA, 2004a). The EFSA CONTAM Panel considered this as an
emerging issue in food safety and decided to compile a scientiﬁc report comprising all the available
data at the time on methods of analysis, occurrence, formation, exposure and toxicity (EFSA, 2004).
From the limited data available at the time, the EFSA CONTAM Panel concluded that the weight of
evidence indicates that furan-induced carcinogenicity is probably attributable to a genotoxic
mechanism. However, chronic toxicity leading to regenerative cell proliferation may indirectly amplify
the tumour response. Furthermore, the CONTAM Panel concluded that there was a relatively small
difference between possible human exposures and the doses in experimental animals that produce
carcinogenic effects. However, for a reliable risk assessment, further data would be needed on both
toxicity and exposure.
JECFA evaluated furan at its 72nd meeting in 2010 (FAO/WHO, 2011). The Committee concluded
that furan is hepatotoxic and hepatocarcinogenic in rats and mice and considered carcinogenicity the
critical endpoint for use in human health risk assessment. The Committee performed a benchmark
dose (BMD) analysis of liver tumour incidence data from an oral bioassay in mice. The calculated
benchmark dose lower conﬁdence limits for 10% increase in cancer incidence (BMDL10) ranged from
1.34 to 1.89 mg/kg bw per day. The Committee used the value of 1.34 mg/kg bw per day, adjusted to
0.96 mg/kg bw per day to account for the dosing schedule used in the study, as the reference point to
calculate MOEs. Dietary exposure estimates for mean exposure of the general population was 1 lg/kg
bw per day and for high exposure 2 lg/kg bw per day, inclusive of children. The resulting MOEs were
between 960 and 480 for the average and high dietary exposures, respectively. The Committee
considered that these MOEs indicate a human health concern for furan which is a carcinogenic
compound that might act via a DNA-reactive genotoxic metabolite.
In 2012, the Norwegian Food Safety Authority published a risk assessment of furan exposure in the
Norwegian population (VKM, 2012). On the basis of the available data, the VKM considered that the
rat cholangiocarcinomas may be relevant for assessing human risk from furan and concluded that a
genotoxic mechanism in furan-induced carcinogenesis cannot be excluded. There was a high incidence
(near 100%) of cholangiocarcinomas at all doses tested after a 2-year treatment with furan (NTP,
1993). Since this endpoint showed a dose–response relationship after 9 months of exposure, the VKM
chose this as the critical endpoint. They calculated a BMDL10 of 0.14 mg furan/kg bw per day. In
applying a correction factor of 7 for shorter than full life-time study duration (9 months instead of
2 years), a point of departure of 0.02 mg/kg bw per day was chosen. The resulting MOEs for 12-
month infants were between 29 and 13, and in adults, between 74 and 26 for average and high
dietary exposures, respectively.
In addition, a number of risk assessments are available in which national exposure assessments
were carried out (e.g. Lachenmeier et al., 2009; Bakhiya and Appel, 2010a,b; Minorczyk et al., 2012;
Scholl et al., 2012a,b; Waizenegger et al., 2012; Health Canada, 2016).
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1.3.4. European legislation
In order to protect public health, Article 2 of the Council Regulation (EEC) No 315/9311 stipulates
that, where necessary, maximum tolerances for speciﬁc contaminants shall be established. Thus, a
number of maximum tolerances for contaminants, natural plant toxicants as well as for process
contaminants such as 3-monochloropropane-1,2-diol are currently laid down in Commission Regulation
(EC) No 1881/200612. Furan in food is currently not covered by this EU Regulation.
Commission Recommendation 2007/196/EC13 recommended that Member States should perform
monitoring of the presence of furan in foodstuffs that have undergone heat treatment during the years
2007 and 2008. Results of this monitoring were published in an EFSA report (EFSA, 2011d), and
included data for commercial foodstuffs as purchased without any further preparation14 and
commercial foodstuffs analysed as consumed after further preparation in the laboratory.15
Both 2-methylfuran and 2, 5-dimethylfuran were on the Union list of ﬂavourings and source
materials for use in food and their conditions of use. However, they were removed from the Union list
by Commission Regulation (EU) 246/201416, since their applications had been withdrawn by the
industry. ‘The Good Scents Company’ (a website maintained by the ﬂavourings industry) reported that
3-methylfuran is not for use in ﬂavourings.9
1.3.5. Precursors of furan and methylfurans in food
Furan can be formed in food from a variety of precursors including ascorbic acid, amino acids,
carbohydrates, unsaturated fatty acids and carotenoids. The pathways described below have been
investigated in model systems and have been conﬁrmed for foods. These pathways have been
simpliﬁed for clarity in Figures 2–6. The conditions for the formation of furan and methylfurans have
been described in Section 3.2.3.
The formation from unsaturated fatty acids and probably carotenoids originated from the formation
of 4-hydroxyalk-2-enals, particularly 4-hydroxy-but-2-enal, which is produced from the oxidation of
but-2-enal which in turn can be produced from the oxidation of polyunsaturated omega-3 fatty acids
(Owczarek-Fendor et al., 2010b) (Figure 2). 4-Hydroxyalk-2-enals and other lipid peroxidation products
are known to occur in palatable foods (Frankel, 2012).
Furan formation was reported during the thermal degradation of serine and cysteine (Perez Locas
and Yaylayan, 2004). The formation pathway from serine involves the formation of acetaldehyde and
glycolaldehyde which are both prone to aldol-condensation giving rise to the crucial intermediate
2-deoxyaldotetrose, which upon cyclisation and dehydration yields furan (Figure 3). Cysteine is
supposed to react with a similar pathway (Perez Locas and Yaylayan, 2004).
Figure 2: Suggested formation pathway of furan from polyunsaturated lipids (adapted from Perez
Locas and Yaylayan, 2004; Owczarek-Fendor et al., 2010b)
11 Council Regulation (EEC) No 315/93 of 8 February 1993 laying down Community procedures for contaminants in food. OJ L
37, 13.2.1993, p. 1–5.
12 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
13 Commission Recommendation (EC) No 2007/196 of 28 March 2007 on the monitoring of the presence of furan in foodstuffs.
OJ L 88, 29.3.2007, p. 56–57.
14 Commercial foodstuffs as purchased disregarding any further preparation, e.g. coffee powder, juices, jars and cans not heated
before consumption.
15 Commercial foodstuffs analysed as consumed after further preparation in the laboratory,: e.g. brewed coffee, canned and
jarred products heated before consumption. If available, preparation should follow label instructions. Food prepared at home
on basis of fresh ingredients (e.g. vegetable soup with fresh vegetables, home-made Irish stew) is not subject of this
monitoring programme.
16 Commission Recommendation (EU) No 246/2014 of 13 March 2014 amending Annex I to Regulation (EC) No 1334/2008 of
the European Parliament and of the Council as regards removal from the Union list of certain ﬂavouring substances. OJ L 74,
14.3.2014, p. 58–60.
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Other amino acids can also give rise to the formation of furan. Aspartic acid, alanine and threonine
can degrade to acetaldehyde, but require an external source of glycolaldehyde (e.g. sugars) to form
the 2-deoxyaldotetrose intermediate (Perez Locas and Yaylayan, 2004).
Although amino compounds will favour the formation of furan from sugars (via the Maillard
reaction), sugars on their own are able to generate furan. Various pathways have been suggested
involving both the recombination of sugar fragmentation products from the intact sugar skeleton
(Limacher et al., 2008) and the degradation of the intact sugar skeleton (Limacher et al., 2008; Van
Lancker et al., 2011). The fragmentation pathway involves mainly the condensation of acetaldehyde
and glycolaldehyde (Limacher et al., 2008). The formation from the intact sugar skeleton involves
various parallel pathways, which depend on the type of sugar (Limacher et al., 2008). These reactions
involve the formation of deoxy-intermediates via dehydration reaction followed by cyclisation reactions
and further dehydration. Finally, losses of mainly the C1 and C2 carbons of the sugar chain result in
the formation of furan. The formation of furan in dry heating conditions is typically much higher than
in pressure sterilisation conditions (Figure 4).
Furan formation from ascorbic acid is believed to start with the hydrolytic ring opening of ascorbic
acid and elimination of water to form 4-deoxyascorbic acid. This intermediate can generate 2-
deoxyaldotetrose. Alternatively, 4-deoxyascorbic acid can result in the formation of 2-furfural which in
turn is a furan precursor (Limacher et al., 2007) (Figure 5).
Figure 3: Suggested formation pathway of furan from serine (adapted from Perez Locas and
Yaylayan, 2004; Limacher et al., 2008)
Figure 4: Suggested formation pathway of furan from hexoses (adapted from Limacher et al., 2008)
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The formation of methylfurans in food has received considerably less attention, although it was
recently shown that 2-methylfuran was the dominant furan in coffee (Becalski et al., 2016).
Accordingly, the formation of methylfurans is less well understood. For 2-methylfuran, a pathway
based on the aldol condensation of the Strecker aldehydes lactaldehyde (originating from threonine)
and acetaldehyde – similar to the glycoaldehyde/acetaldehyde pathway for furan – has been suggested
(M€ark et al., 2006) (Figure 6). Indeed, as model systems devoid of amino acids produced little or no
methylfurans (M€ark et al., 2006; Limacher et al., 2008), the presence of amino acids seems to play a
key role in their formation. Limacher et al. (2007) reported the formation of 2-methylfuran from the
degradation of ascorbic acid, but acknowledged it was a minor degradation pathway. M€ark et al.
(2006) reported the formation of methylfuran from linolenic acid in the presence of a-tocopherol or
ferric ions. On basis of the ﬁndings of Adams et al. (2011), showing in model systems that a,b-
unsaturated aldehydes are potential precursors of the corresponding alkylated furans under roasting
conditions, it could be suggested that 2-pentenal may be a relevant precursor formed via the oxidation
of linolenic acid. The formation pathway from 2-pentenal proceeds similarly to the formation of furan
outlined in Figure 2, requiring oxidative conditions. Adams et al. (2011) moreover showed that amino
acids, such as phenylalanine catalyse the formation of alkylfurans from their corresponding a,b-
unsaturated aldehydes, although the impact for 2-methylfuran from 2-pentenal was not signiﬁcant. No
methylfuran formation was observed from linoleic acid in the presence of ferric ions or butylated
hydroxytoluene (M€ark et al., 2006).
Figure 5: Suggested formation pathway of furan from ascorbic acid (adapted from Limacher et al., 2007)
Figure 6: Suggested formation pathway of 2-methylfuran (adapted from M€ark et al., 2006)
Furan and methylfurans in food
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2017;15(10):5005
1.3.6. Production, use and environmental fate
1.3.6.1. Industrial production and use
Furan is produced by decarbonylation of furfural using Pd catalysis. It can also be manufactured by
partial oxidation of 1,3-butadiene. It is mainly used for the production of a-acetylfuran, 2,5-dimethoxy-
2,5-dihydrofuran, 2,2-difurylpropane, 2,2-di(tetrahydrofurfuryl)propane, pyrrole derivatives and
thiophene. It is used as an intermediate in the production of pharmaceuticals, agricultural chemicals,
lacquers and stabilisers or as a solvent for resins (IARC, 1995; Hoydonckx et al., 2012).
2-Methylfuran is used as a solvent and as a raw material in the production of antimalarial drugs
(chloroquine), methylfurfural, nitrogen and sulfur heterocycles, and functionally substituted aliphatic
compounds. It is produced as a side product of furfuryl alcohol production.
2,5-Dimethylfuran is a potential biofuel that can be obtained from bio-based sources, such as
fructose, via consecutive dehydration and hydrogenolysis reactions (Roman-Leshkov et al., 2007).
Furan and 2-methylfuran are also considered as potential biofuels (Liu et al., 2014).
1.3.6.2. Environmental fate
Furan and methylfurans are released into the atmosphere mainly from anthropogenic sources.
Important sources are exhaust gas from diesel and gasoline engines and combustion of waste and
biomass (e.g. wood) (IARC, 1995; Villanueva et al., 2009; Tapia et al., 2011). In addition to air, furan
has been detected in river water and industrial efﬂuents (IARC, 1995).
2. Data and methodologies
The CONTAM Panel applied the general principles for the assessment of chemicals in food as
described by WHO/IPCS (2009) and any EFSA guidance documents pertaining to risk assessment and
relevant for the present assessment (see Appendix A.3).
2.1. Supporting information for the assessment and information to be
used in the dietary exposure assessment
2.1.1. Collection, selection of evidence
A search for recent reviews was conducted to identify scientiﬁc publications dealing with methods
of analysis, chemistry, formation in food, exposure and occurrence of furan in food. Since it was
expected to receive only limited information on the occurrence of methylfurans in food during the
EFSA call for data (see Section 2.3.1), a search for original studies was also carried out. It was noted,
that the information on dietary exposure of furan and methylfurans and on formation and methods of
analysis of methylfurans was not sufﬁciently covered by the reviews. Therefore, speciﬁc searches were
also conducted for these topics (see Appendix A, Section A.1). During the development of the
exposure assessment, the Working Group (WG) identiﬁed the need for data on the inﬂuence of coffee
preparation on furan levels in liquid coffee. An additional search was conducted to retrieve this
information (see Appendix A, Section A.1).
The literature search was performed in May 2016 (March 2017 for information on coffee). Web of
Science17 and PubMed18 were identiﬁed as databases appropriate for retrieving literature for the
present evaluation. The references resulting from the literature search were imported and saved using
a software package (EndNote19), which allows effective management of references and citations.
Additionally, reviews and relevant scientiﬁc evaluations by national or international bodies were
considered for the current risk assessment, i.e. IARC (1995), NAS, 2000, FDA (2004a), FAO/WHO
(2011) and VKM, 2012. When relevant papers were identiﬁed during the risk assessment process (e.g.
from other studies or reviews), they were also considered.
The references obtained were screened using title and abstract to identify relevant literature.
17 Web of Science (WoS), formerly ISI Web of Knowledge, Thomson Reuters. Available online: http://thomsonreuters.com/
thomson-reuters-web-of-science/
18 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI), National
Library of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health and
Human Services. Available online: http://www.ncbi.nlm.nih.gov/pubmed/
19 EndNote X5, Thomson Reuters. Available online: http://endnote.com/
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The VCF database20 on volatile compounds in food was consulted to identify papers on the
occurrence of methylfurans.
EFSA also organised an Info Session with invited stakeholders to support the work of the CONTAM
Panel and its working group in drafting this scientiﬁc opinion. The aim of this meeting was to collect
information and data which are not readily available in the public domain regarding dietary exposure,
home-cooking and toxicity. Further information is available in EFSA’s Register of Questions.21
2.1.2. Appraisal of evidence
The information retrieved was screened and evaluated by relevant domain experts from the
CONTAM WG on furan in food and was used for the present assessment.
2.2. Hazard identiﬁcation and characterisation
2.2.1. Collection and selection of evidence
EFSA outsourced an extensive literature search related to the toxicity of furan and its methyl
analogues (contract: RC/EFSA/BIOCONTAM/2016/02). The aim of the assignment was to identify and
collect all relevant literature regarding furan, 2-methylfuran and 3-methylfuran covering the following
areas:
• Area 1: Data on toxicokinetics (absorption, distribution, metabolism and excretion (ADME)) in
experimental animals and humans and from in vitro studies.
• Area 2: Data on oral toxicity in experimental animals.
• Area 3: Data on in vitro and in vivo genotoxicity and mode of action (MoA).
• Area 4: Data on observations in humans (including epidemiological studies, case reports and
biomarkers of exposure).
The used methodology and the results are detailed in NFI (2017).
In addition to the literature searches outsourced by EFSA, a search for studies regarding the
toxicity of 2,5-dimethylfuran and the genotoxicity of BDA was conducted (see Appendix A,
Section A.2). The literature search was performed in June 2016 using Web of Science17 and PubMed.18
The references resulting from the literature search were imported and saved using a software package
(EndNote19), which allows effective management of references and citations.
It was regularly checked (last check May 2017) whether new papers had become available during
the development of this scientiﬁc opinion.
Reviews, relevant scientiﬁc evaluations and toxicity studies by national or international bodies were
also considered for the current risk assessment (see Section 2.1.1). When relevant papers were
identiﬁed during the risk assessment process (e.g. from other studies or reviews), they were also
considered.
In addition, an Info Session with invited stakeholders was organised (see Section 2.1.1).
2.2.2. Appraisal of evidence
The information retrieved has been screened and evaluated by relevant domain experts from the
CONTAM WG on furan in food and has been used for the present assessment. Any limitations in the
information used are documented in this scientiﬁc opinion.
Selection of the scientiﬁc papers for inclusion or exclusion was based on consideration of the extent
to which the study was relevant to the assessment or on general study quality considerations (e.g.
sufﬁcient details on the methodology, performance and outcome of the study, on dosing, substance
studied and route of administration and on statistical description of the results), irrespective of the
results. Appendix A, Section A.2.3, provides an overview of the scientiﬁc papers (excluding abstracts
and reviews) that emerged from the literature searches and seemed to be related to the toxicity and
toxicokinetics of furan and methylfurans but upon examination were not included in the opinion as
they did not meet the criteria stated above.
20 http://www.vcf-online.nl/VcfHome.cfm
21 See mandate documents at: http://registerofquestions.efsa.europa.eu/roqFrontend/questionsListLoader?mandate=M-2016-0012
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2.2.3. Benchmark dose analysis
Benchmark dose analysis was done according to EFSA guidance (EFSA Scientiﬁc Committee, 2017)
and using the R package bmdModeling (see Appendix C).
2.3. Occurrence data submitted to EFSA
2.3.1. Data collection and validation
At the time of receiving the request for the scientiﬁc opinion from the European Commission, data
on 2-methylfuran and 3-methylfuran were not available in the EFSA Chemical Occurrence database,
and available data on furan were limited. The EFSA Evidence Management Unit (DATA Unit) initiated
an ad hoc collection of data to compile occurrence data on furan, 2-methylfuran and 3-methylfuran
levels in food.22 The European national food authorities and similar bodies, research institutions,
academia and food business operators were invited to submit data. As 2,5-dimethylfuran was not
included in the initial request from the European Commission, the submission of occurrence data for
2,5-dimethylfuran was not requested by EFSA.
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of food
consumption and occurrence data’. In accordance with Commission Recommendation 2007/196/EC13 on
the monitoring of the presence of furan in foodstuffs, data providers were also requested to indicate
whether commercial foodstuffs were analysed as purchased, disregarding any further preparation, or
whether they were analysed as consumed after further preparation in the laboratory.
All data on furan and its methyl analogues in food available in the EFSA database by the end of
November 2016 were used for the present assessment. Data received after this date were not
included.
2.3.2. Data analysis
The data received were carefully evaluated by EFSA in view of cleaning and validating the data.
Special attention was paid to the identiﬁcation of duplicates and to the accuracy of different
parameters such as ‘Analytical methods’, ‘Reporting unit’ and the coding of the different samples under
FoodEx classiﬁcation. The available information was also carefully analysed in order to identify those
samples that were analysed either as purchased or as consumed. Upon identiﬁcation of potential
inconsistencies, data providers were contacted to provide further clariﬁcation. The outcome of the data
analysis is shown in Section 3.2.1.
The left-censored data (analytical data below the LOD/LOQ) were treated by the substitution
method as recommended in the ‘Principles and Methods for the Risk Assessment of Chemicals in Food’
(WHO/IPCS, 2009). The same method is described in the EFSA scientiﬁc report ‘Management of left-
censored data in dietary exposure assessment of chemical substances’ (EFSA, 2010b), as an option in
the treatment of left-censored data. The guidance suggests that the lower bound (LB) and upper
bound (UB) approach should be used for chemicals likely to be present in the food (e.g. naturally
occurring contaminants, nutrients and mycotoxins). At the LB, results below the LOQ or LOD were
replaced by zero; at the UB, the results below the LOD were replaced by the LOD and those below the
LOQ were replaced by the value reported as LOQ. Additionally, a middle bound (MB) approach was
used by assigning a value of LOD/2 or LOQ/2 to the left-censored data. The use of different cut-off
values on the reported LOQs was also evaluated in order to reduce the uncertainty associated to the
exposure estimations.
2.4. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database) provides
a compilation of existing national information on food consumption at individual level. It was ﬁrst built in
2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the Comprehensive
Database is used are published in the Guidance of EFSA (EFSA, 2011a). The latest version of the
Comprehensive Database23 was used with subjects classiﬁed in different age classes as follows:
22 http://www.efsa.europa.eu/en/data/call/160216b
23 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb
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• Infants: < 12 months old
• Toddlers: ≥ 12 months to < 36 months old
• Other children: ≥ 36 months to < 10 years old
• Adolescents: ≥ 10 years to < 18 years old
• Adults: ≥ 18 years to < 65 years old
• Elderly: ≥ 65 years to < 75 years old
• Very elderly: ≥ 75 years old.
Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’
(≥ 15 years to ≤ 45 years old; Latvia) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old; Greece).
Overall, the food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-h dietary recalls or dietary records covering from 3 to 7 days per subject. As a
result of the differences in the methods used for data collection, direct country-to-country comparisons
can be misleading.
2.5. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food groups (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about 1,800 items
(food names or generic food names) at the fourth level.
In 2011, a new version of FoodEx, named FoodEx2, was developed and is described in the scientiﬁc
document ‘Report on the development of a Food Classiﬁcation and Description System for exposure
assessment and guidance on its implementation and use’ (EFSA, 2011c). The last release of FoodEx2
complements the previous hierarchical classiﬁcation system of basic codes with more detailed food
levels and gives the possibility of reporting additional information through the use of facets and facet
descriptors such as processing or packaging (EFSA, 2015).
As the occurrence data were submitted to EFSA according to the FoodEx classiﬁcation and only part
of the food consumption data are currently coded according to the FoodEx2 classiﬁcation, the
occurrence data and the food consumption data were grouped at the most relevant level of the
FoodEx classiﬁcation. Where available, the FoodEx2 classiﬁcation and its facet descriptors were also
used to better identify consumption data referring to very speciﬁc foods such as commercially
processed foods (e.g. canned and jarred foods) or toasted bread.
2.6. Exposure assessment
The CONTAM Panel considered that only chronic dietary exposure had to be assessed. As
suggested by the EFSA WG on Food Consumption and Exposure (EFSA, 2011a), dietary surveys with
only 1 day per subject were excluded from the current assessment because they are not adequate to
assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary studies, when
the protocol prescribed more reporting days per individual, were also excluded from the chronic
exposure assessment. When, for one particular country and age class, two different dietary surveys
were available only the most recent one was used.
For calculating the chronic dietary exposure, food consumption and body weight data at the
individual level were accessed in the Comprehensive Database. Occurrence data and consumption data
were linked at the relevant FoodEx level (see also Section 2.5). For each individual of the selected
surveys, the mean occurrence values of the different food samples collected (pooled European
occurrence data) were combined with the average daily consumption of the corresponding food items,
and the resulting exposures per food were summed in order to obtain the total chronic exposure at
individual level (standardised by using the individual body weight). The mean and the 95th percentile
of the individual exposures were subsequently calculated for each dietary survey and each age class
separately.
Before linking the consumption data to the corresponding occurrence data, the following
adjustments to the consumption data were made to reduce uncertainty and reach more accurate
exposure estimates:
Furan and methylfurans in food
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2017;15(10):5005
• Consumption events for cereal-based food for infants and young children were adjusted by a
factor of 0.25 (when reconstituted with water) or 0.15 (when reconstituted with milk) when
the eating occasions were reported as consumed (liquid) since the occurrence data also
referred to the analysis of the food as purchased.
• A number of consumption events reported for unspeciﬁed potatoes and potatoes products,
unspeciﬁed alcoholic beverages or unspeciﬁed non-alcoholic beverages was reclassiﬁed to a
food category that was considered more appropriate for the assessment of furan.
• A number of consumption events for boiled potatoes, main-crop potatoes and new potatoes
referred to powders, ﬂakes, dried products or instant products. In view of the analysis on
commercially processed products, classiﬁcation as mashed potato powder was considered
more appropriate for the assessment of furan.
• Where a consumption event for a speciﬁc coffee beverage (e.g. cappuccino) was prepared
from an instant powder, this consumption event was reclassiﬁed to the instant coffee
beverages as this is considered more appropriate in the framework of the current assessment.
• Legume vegetables, which are normally part of the vegetables and vegetable products, were
reclassiﬁed to legumes (dried or green) in order to better match the available occurrence data
for furan.
• Human milk was not considered for the assessment due to lack of data available.
All analyses were made using the SAS Statistical Software (SAS enterprise guide 5.1).
2.7. Risk characterisation
The CONTAM Panel applied the general principles of the risk characterisation process for chemicals
in food as described by WHO/IPCS (2009) and the relevant EFSA guidance documents (see
Appendix A.3).
3. Assessment
The CONTAM Panel noted that the available information on 2-methylfuran, 3-methylfuran and 2,5-
dimethylfuran is limited and these compounds are therefore only described when information is
available.
3.1. Hazard identiﬁcation and characterisation
The CONTAM Panel noted that due to the high volatility of furan at room temperature, the handling
of any furan preparation for treatment or sampling for analysis with/of furan is considered as critical.
In some studies, it cannot be excluded that the outcome may have been inﬂuenced by losses of furan
due to this effect. This issue is addressed in the uncertainty Section 3.5.
3.1.1. Toxicokinetics
The kinetics of furan and to a lesser extent also 2-methylfuran, 3-methylfuran and 2,5-
dimethylfuran have been studied in rodents, in hepatocyte cultures, in subcellular fractions and in
various chemical model systems.
3.1.1.1. Absorption
A. Furan
Oral exposure
After administration of [2,5-14C] furan (chemical and radiochemical purity both ≥ 99%) to male
F344 rats at a dose level of 8 mg/kg bw (~ 0.37 MBq/kg bw), furan was quickly absorbed from the
gastrointestinal (GI) tract to an extent of at least 80%. This estimate is based on excretion of
radioactivity in exhaled air and urine and retention of radioactivity in tissues at 24 h post-dosing.
Radioactivity in faeces (22% of the dose) was not characterised and may have contained some
unabsorbed furan (Burka et al., 1991).
Inhalation exposure
In dogs, approximately 95% of the inhaled furan is retained in the body and this percentage
decreased to 91% when ventilation rate was increased. An inverse relationship was observed between
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retention and concentration in inhaled air (Egle and Gochberg, 1979a). Since absorption is virtually
complete, the CONTAM Panel considered that the differences related to inhalation rate or
concentration as reported by the study authors were of no biological signiﬁcance.
B. Methylfurans
Inhalation exposure
In dogs, approximately 89% of the inhaled 2-methylfuran is retained in the body and this
percentage decreased to 83% when ventilation rate was increased (Egle and Gochberg, 1979b). For
2,5-dimethylfuran, retention values of 63% decreasing to 57% were recorded with increasing
ventilation rates. However, the limited set-up of the experiments in this report and the high absorption
of the substances do not allow ﬁrm conclusions on dependency on inhalation rate. The
Panel considered that the slight differences related to inhalation rate were of no biological signiﬁcance.
For 2-methylfuran and 2,5-dimethylfuran, the retention was not dependent on the concentration
applied (Egle and Gochberg, 1979b).
3.1.1.2. Distribution
A. Furan
In vivo kinetics of furan in blood and liver were studied by Churchwell et al. (2015) in rats for up to
8 h after a single oral exposure to 0.92 mg (= 13.5 lmol) unlabelled furan/kg bw. The highest blood
concentration (63 pmol/mL) was observed at 15 min post-dosing (the 1st time point). In the liver, Cmax
(547 pmol/g tissue) was observed 30 min post-dosing. Over the observation period, liver
concentrations were on average approximately six times higher than concentrations in blood, but
concentrations in liver varied strongly between animals and between lobes. After 8 h, no furan could
be detected in either blood or liver (LOD: ~ 0.75 pmol/mL in blood and ~ 1 pmol/g tissue in liver)
The distribution of furan-related radioactivity retained after 24 h in various tissues in rats was
studied after gavage dosing with 14C-labelled furan (8 mg/kg bw (118 lmol/kg bw; 0.37 MBq/kg bw).
The tissue distribution of total radioactivity (in percentage of the dose) was: liver 13%, kidney 0.45%,
large intestine 0.13%, small intestine 0.15%, stomach (forestomach + glandular stomach) 0.09%,
blood 0.42% and lung 0.02%. In total, the radioactivity in these tissues comprised 15 % of the dose
after 24 h. Remaining tissues contained additional radioactivity approximating to 4% of the dose. No
furan could be extracted from the blood, and from the liver, only 20% of the radioactivity could be
extracted, but similar to blood this fraction did not contain furan. Seven days after treatment, the
radioactivity had almost returned to the LOD. In a repeated dosing study (daily single dose for
8 days), 24 h after the last dose, concentrations in the liver were up by a factor of 4, and in blood and
kidney up by a factor of 7 as compared to the concentrations after one dose (Burka et al., 1991).
After intraperitoneal (i.p.) administration of 4.1 mmol/kg bw furan to mice (ca. 280 mg/kg bw in
sesame oil), furan levels were approximately 120, 490 and 50 nmol/g tissue in the kidney and
approximately 190, 120 and 40 nmol/g tissue in the liver at 1, 2 or 5 h post-dosing, respectively. No
metabolites or other tissues were examined (Wiley et al., 1984).
B. Methylfurans
After i.p. administration of 4.1 mmol/kg bw 3-methylfuran to mice (ca. 336 mg/kg bw in sesame
oil), methylfuran concentrations were approximately 150, 380 and 50 nmol/g tissue in the kidney and
approximately 240, 410 and 60 nmol/g tissue in the liver at 1, 2 or 5 h post-dosing, respectively. No
metabolites or other tissues were examined (Wiley et al., 1984).
Rats were dosed with 14C-labelled 2-methylfuran via i.p. injection at dose levels of 50–200 mg/kg bw
(Ravindranath et al., 1986). At 12 h post-dosing, total radioactivity was approx. four times higher in
liver than in kidneys, and about 7 or 10 times higher in liver than in blood and lungs, respectively, at all
dose levels. Peak levels of total radioactivity after a dose of 100 mg labelled 2-methylfuran were
reached after 2 h in kidneys, blood and lungs, but only after 8 h in the liver. Protein-associated
radioactivity reached a maximum value in all tissues after 8 h. Again, the liver had higher levels of total
and non-extractable radioactivity than the other three tissues. At 24 h post-dosing, the concentration of
total 14C had fallen to 58%, 67% or 83% of the peak levels in liver, kidneys and lungs.
The liver had the highest levels of 14C-associated with DNA (equivalent to approximately 35 nmol
2-methylfuran/mg DNA at an i.p. dose of 200 mg/kg). Minimal association of 14C with DNA was
observed in the lungs. The peak of DNA associated 14C in the liver (32 nmol/mg DNA after 100 mg/kg
bw) occurred at 1 h post-dosing and in the kidneys at 4 h post-dosing. At 24 h post-dosing, the
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DNA-associated 14C-levels had dropped to 51% or 63% of the peak levels in liver and kidney,
respectively (Ravindranath et al., 1986).
3.1.1.3. Metabolism
A. Furan
Figure 7 shows a graphical representation of the metabolites and adducts of furan.
Oral administration of 14C-labelled furan to rats resulted in an elimination of 26% of the dose as
exhaled carbon dioxide. In addition, approximately 10% of the dose could not be extracted from liver
tissue components (protein; DNA) and 20% of the dose was eliminated as urinary metabolites (Burka
et al., 1991). The authors speculated that the carbon dioxide was formed after oxidative ring opening
of furan. Although no direct evidence was available at that time, the authors suggested that similar to
2- and 3-methylfuran (Ravindranath et al., 1984), furan itself could be converted into a reactive
intermediate BDA and the formation of this dialdehyde was later conﬁrmed in studies with rat liver
microsomes using a trapping agent. No evidence for the formation of an epoxide was obtained, thus if
such an intermediate was to play a role, it has to be very short-lived (Chen et al., 1995).
B. Methylfurans
Ravindranath et al. (1984) showed that rat lung and liver microsomes can bioactivate 2- and
3-methylfuran into reactive species. Using semicarbazide as a trapping agent, the reactive metabolites
were identiﬁed as 3-acetylacrolein (= 4-oxopent-2-enal) for 2-methylfuran and 2-methylbut-2-enedial
for 3-methylfuran. Similar studies with 2-methylfuran (Ravindranath and Boyd, 1985) showed that
kidney microsomes can also bioactivate 2-methylfuran. 3-Acetylacrolein is very reactive towards
microsomal protein and strongly inhibits bioactivation of 2-methylfuran leading to the conclusion that
2-methylfuran is a suicide substrate for cytochrome P450 (CYP). 2-Methylfuran bioactivation by liver
microsomes was strongly induced after pretreatment with phenobarbital, but not 3-methylcholanthrene,
and inhibited by piperonyl butoxide and even more by N-octylimidazole (Ravindranath and Boyd, 1985).
Palmen and Evelo (1996) demonstrated that in aqueous incubates, 2-methylfuran has no direct
reactivity with glutathione (GSH). 2-Methylfuran triggered partial depletion of GSH in haemolysates and
also in intact human erythrocytes; in the latter case, only when co-incubated with a (rat) microsomal
bioactivating system. The authors concluded that 2-methylfuran has to be bioactivated in order to
deplete GSH, and that reactive metabolites can be generated in the erythrocyte cytosol, or in
microsomal systems.
From general knowledge on biotransformation, it can be predicted that the alkylfurans may also be
oxidised at the side-chain resulting in the formation of furyl alcohols, which can be further oxidised to
give the corresponding aldehydes and acids. However, these additional routes of metabolism and their
consequences for the toxicity of the substances have not been studied.
C. Enzymes involved in furan biotransformation
As demonstrated using inducers or inhibitors of CYPs, the major contributor to the metabolism of
furan is CYP2E1 (previously known as CYP-J) (Garle and Fry, 1990; Carfagna et al., 1993; Parmar and
Burka, 1993). A fair correlation was observed between the conversion of p-nitrophenol, a standard
substrate for CYP2E1 and the metabolism of furan in human microsomal incubations. Using various
human recombinant CYPs, it was demonstrated that CYP2E1 was at least 5–10 times more active than
CYP2D6, 3A4, 2J2, 1A2 and 2B6 forms. Minimal catalytic activity was observed for various other CYP
forms (Gates et al., 2012). Parmar and Burka (1993) demonstrated that CYP-catalysed
biotransformation of furan results in inactivation of CYPs and that CYP2E1 is more heavily affected
than other CYPs. A mechanistic explanation for CYP inactivation, based on quantum chemical methods
involving the generation of furan-epoxide and covalent binding of this intermediate to the haem centre
and nucleophilic amino acid residues has been suggested by Taxak et al. (2013). From metabolism
studies with 2-methylfuran with inducers and inhibitors of CYP2E1 (Ravindranath and Boyd, 1985), it
may be anticipated that also this alkylated furan and possibly also 3-methylfuran are metabolised
predominantly by CYP2E1, but contrary to furan, studies with puriﬁed CYP enzymes are not available
for these two alkylfurans. Therefore, there is no direct evidence for an involvement of CYP2E1 in the
biotransformation of 2- and 3-methylfuran.
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Structural elements related to furan or BDA are in bold. Red-coloured atoms belong to the abbreviated part of the
molecules. Molecules with underlined names have been reported to occur in urine or bile after in vivo administration of furan
to animals. Cys, Glu, Gln and Lys: cysteine, glutamate, glutamine and lysine; NAC: N-acetylcysteine, NAL: N-acetyllysine;
NAT: N-acetyltransferase, BDA: cis-but-2-enedial; GSH or G: glutathione; dA deoxyadenosine; dG deoxyguanosine; dC
deoxycytidine. Note that the Figure contains some representative structures especially from substances observed in vivo.
Several structures that were only observed in vitro or in chemical systems have not been included in the presentation.
Figure 7: Metabolites and adducts of furan (compiled after Moro et al. (2012a,b), Peterson et al.
(2011), Byrns et al. (2002), Neuwirth et al. (2012) and Phillips et al. (2014))
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3.1.1.4. Binding of furan and methylfuran metabolites to tissue components
A. Binding to amino acids, glutathione and biogenic amines
Furan metabolites
BDA is a reactive a,b-unsaturated dialdehyde, which has reactivity towards tissue components such
as free amino acids and proteins. Garle and Fry (1990) demonstrated that rat liver microsomes can
metabolise furan to a GSH-reactive substance, which they did not further identify. Also, in hepatocytes
in vitro, GSH can be depleted after exposure to furan (Carfagna et al., 1993), which is also indicative
(but not deﬁnitive proof) of interaction of furan metabolites with this scavenger molecule. In chemical
model systems, BDA reacted with GSH to form several complex (cyclic) structures, but in microsomal
systems, only two bis-GSH-BDA adducts (an N-alkyl-3- and an N-alkyl-2-thiopyrrole adduct) were
observed (Chen et al., 1997). Additionally, a mono-GSH-BDA adduct has been observed in microsomal
incubations with furan (Peterson et al., 2005). This mono-GSH-BDA adduct was observed in urine of
rats treated with furan, indicating that also in vivo furan is converted to BDA. No urinary elimination of
bis-GSH-BDA adducts was observed, but since these have a MW of around 660 g/mol, these could be
preferentially excreted via the bile (Peterson et al., 2006). Metabolites found in rat bile, however, do not
seem to include the bis-GSH-BDA adducts that were reported by Chen et al. (1997) and Peterson et al.
(2006). Possible breakdown products of these have been reported such as cysteinylglycinyl-BDA-GSH,
cysteinyl-BDA-GSH or cysteinylglycinyl-BDA-glutamate (Hamberger et al., 2010). Among the observed
mono-GSH adducts, cyclic reaction products were observed in which the thiol group had reacted with
the double bond in BDA and a primary nitrogen had reacted with the two aldehydes, resulting in the
formation of an N-alkylated pyrrole or pyrrolinone moiety in microsomal incubates (Peterson et al.,
2005) and in rat urine or bile (Peterson et al., 2006; Hamberger et al., 2010).
Apart from reactions with GSH, BDA has also been demonstrated to be reactive towards amino acids
with primary amino groups in the side chain or/and to cysteine. As with the cyclic GSH conjugates these
adducts contain N-alkylated pyrrole or pyrrolinone moieties resulting e.g. from interaction with the amino
groups from lysine or glutamine with the two aldehyde functions. Lysine-BDA-cysteine adducts as well
as adducts of the N-acetylated forms of these amino acids (N-acetyllysinyl-BDA-N-acetylcysteinyl
(NAL-BDA-NAC)) have been demonstrated to be formed in chemical model systems (Chen et al., 1997). In
concordance with this, BDA adducts of N-acetylated lysine and cysteine were formed in human
microsomal incubates (Gates et al., 2012) and could be detected in rat bile (Hamberger et al., 2010) after
exposure in vivo. In chemical model systems, BDA together with GSH, can also react with other amines,
such as asparagine, ornithine, putrescine, cadaverine, spermine or spermidine (Peterson et al., 2011). In
contrast, in incubates of furan with rat hepatocytes next to mono-GSH-BDA, adducts of GSH-BDA with
ornithine (both at the Nd- amino and the Na-amino; ~ 50% and ~ 25% of the total amount of amine
adducts measured, respectively), lysine (Ne-amino ~ 20%; Na-amino ~ 2%), spermidine (N1-amino ~ 8%)
and putrescine (< 1%) but no adducts to asparagine, cadaverine or spermine were found (Peterson et al.,
2011). Lu et al. (2009) reported occurrence of a GSH-BDA-glutamine adduct in media of furan-treated rat
hepatocytes. Human hepatocytes (freshly isolated or cryopreserved) have higher or similar capacity to
metabolise furan than rat and mouse hepatocytes (Kedderis and Held, 1996; Gates et al., 2014). In media
of cryopreserved human and cryopreserved rat and mouse hepatocytes incubated with furan, the BDA
adducts observed are similar as those reported by Peterson et al. (2011), but they vary in the amounts
formed (Gates et al., 2014). Also, between hepatocytes from different human donors, there was a great
difference in rate of formation of BDA adducts formation, despite similar levels of hepatocellular CYP2E1
activity (Gates et al., 2014). Therefore, these authors speculated that in humans alternative metabolic
routes may be active to scavenge BDA (e.g. scavenging of the a,b-unsaturated dialdehyde BDA by various
CYPs) before it can react with e.g. GSH or amino acids. Of the amino-adducts in urine from rats exposed to
furan, next to NAC-BDA-lys, lower levels of NAC-BDA-spermidine, but no ornithine adducts could be found
(Peterson et al., 2011). For the cysteine-containing adducts also the corresponding sulfoxides have been
reported in bile of rats and in urine of rats, mice and humans (Kellert et al., 2008b; Lu et al., 2009;
Hamberger et al., 2010; Peterson et al., 2011; Grill et al., 2015). Lu and Peterson (2010) provided
evidence that the cys-BDA-lys adduct is an important intermediate in the formation of the N-acetylated,
de-aminated or sulfoxidated urinary metabolites of furan in vivo.
Urinary and biliary metabolites of furan could have arisen from reaction of BDA with GSH and free
amino acids (cysteine, lysine and ornithine) in the cytosol (Kellert et al., 2008b; Hamberger et al.,
2010). Based on the ratio of Ne-lysine-adducts over Na-lysine-adducts, the lysine adducts are mainly
formed with the Ne-amino group, rather than with the Na-amino group. Based on changes in this ratio
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over time after furan exposure, Lu et al. (2009) argued that these lysine adducts arise from direct
adduct formation with free lysine, especially shortly after exposure, but that at later points in time the
observed adduct arises from degradation of BDA-damaged proteins.
Methylfurans metabolites
Ravindranath et al. (1984) showed that reactive metabolites from 2- and 3-methylfuran can bind
(non-extractable) to microsomal proteins. Cysteine was a very efﬁcient scavenger of the reactive
metabolite of 2-methylfuran and to a lesser extent also GSH and semicarbazide (as a model
compound). N-acetylcysteine was less effective than GSH and lysine was a less effective scavenger than
semicarbazide. Effective scavenging of acetylacrolein by cysteine was also observed in in vivo studies in
rats exposed to 100 mg 2-methylfuran /kg bw i.p. after treatment with various modulators of liver GSH
synthesis (diethylmaleate (DEM), buthionine sulfoximine (BSO) and/or oxothiazolidinecarboxylate
(OTZ)) (Ravindranath and Boyd, 1991).
Bile of rats dosed i.p. with 60 mg/kg bw of 2,5-dimethylfuran contained a NAL-dimethylpyrrole-GSH
conjugate after addition (ex vivo) of NAL to the bile sample. No GSH-containing precursor for this
metabolite could be detected, and also no other GSH-containing conjugates with a putative reactive
intermediate moiety were found in the bile, using liquid chromatography with tandem mass
spectrometry (LC–MS/MS). The same pyrrole-containing conjugate was also observed in microsomal
incubates fortiﬁed with NAL and GSH and in a system in which 2,5-dimethylfuran was chemically
oxidised with subsequent treatment of the reaction products with NAL and GSH. However, no
information was obtained as to the chemical nature of the reactive primary intermediate (Li et al., 2015).
From similar in vitro studies but using 4-bromobenzylamine instead of NAL, Wang et al. (2014b)
concluded that the reactive intermediate formed from 2,5-dimethylfuran by chemical or enzymatic
oxidation could be (3Z)-hex-3-ene-2,5-dione.
B. Binding to proteins
Furan
Parmar and Burka (1993) reported non-extractable binding of 14C-furan metabolites to proteins in
microsomal incubates, with concomitant loss of enzymatic activities. The radioactivity became
associated with CYP apoproteins as well as to the haem moieties. The level of binding depended on
pretreatment of rats with a range of CYP-activity modiﬁers before microsome isolation and on the
presence of scavenging agents (e.g. primary amines and GSH).
Burka et al. (1991) observed that approximately 13% of the dose of 14C was still present in the
liver 24 h after an oral dose of 8 mg/kg bw to rats. About 80% of this was non-extractable and
assumed to be covalently bound to tissue macromolecules, in particular to liver proteins.
Using immunoblotting on hepatocyte protein extracts, Lu et al. (2009) also demonstrated that the
GSH-BDA is sufﬁciently stable and reactive to become bound to proteins. The GSH-BDA adduct may
also migrate outside the cell and react with lysine or glutamine in cell culture media. Therefore, the
authors further argued that BDA-GSH adducts could also react with nucleophiles elsewhere in the
tissue or in the body.
Phillips et al. (2014) studied the reactivity of BDA in the presence or absence of GSH against
cytochrome c in aqueous solutions. With BDA alone, the predominant addition was 66 g/mol, which
corresponds to a pyrrolinone-modiﬁcation of lysine (lys-BDA) that may occur at various locations in the
protein. To a much lower extent also additions of 48 (e.g. lys-BDA-lys cross-link) or 84 g/mol (e.g.
linear lys-BDA-mono-adduct) were observed. Other tentatively identiﬁed adducts were with glutamine,
histidine and arginine residues. Multiple adducts were also observed, (i.e. several BDA molecules
reacted with different amino acid residues within one cytochrome c molecule) and adducts to adjacent
lysine residues condensed further into bicyclic pyrrole-pyrrolinone adducts. The addition of GSH to the
incubates decreased the overall extent of adduct formation, and increased the mass of the protein
with an addition of 355 g/mol. In the latter incubates, still some non-GSH containing adducts were
observed, but these were far less abundant than GSH-BDA adducts. The 355 g/mol adducts were
identiﬁed as GSH-BDA-lys adducts, again at several positions in the protein. The sites of lysine adduct
formation were more selective for GSH-BDA than for BDA itself (either in the absence or in presence of
GSH). In the presence of GSH, double adducts (two times a 66 g/mol addition) and an addition of
84 g/mol were much less abundant than in the absence of GSH. The authors noted that cytochrome c
has only two cysteine residues and both are already associated with the haem group of cytochrome c.
Therefore, they considered that for cytochrome c the formation of a cys-BDA-lys crosslink is unlikely.
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Nunes et al. (2016) treated rats daily with 0, 0.92, 2 or 4.4 mg furan/kg bw by gavage for 90, 180
or 360 days. In tryptic digests of liver histone H2B, a GSH-BDA-modiﬁed lysine 107 residue was
observed, which was absent in the livers of the non-exposed animals. The amount of GSH-BDA-
modiﬁed peptide was dose-related. No BDA-modiﬁed (i.e. without the GSH moiety) peptides were
seen. In recombinant human histone H2B homologue, incubated in vitro with BDA in the absence of
GSH, no BDA-modiﬁed lysine residue at position 108 (homologous to the rat lysine 107 residue) was
observed. However, in incubates of histone octamer or free human histone H2B with BDA + GSH, the
GSH-BDA-modiﬁed lysine residue 108 was found in a concentration-dependent way. The authors
suggested that GSH-BDA has a higher reactivity towards proteins than BDA itself, and speculated that
the higher reactivity of GSH-BDA might also result in reactivity towards DNA bases. However, no data
to support this are available and the results regarding reactivity towards proteins of free BDA as
compared to GSH-BDA are also opposite to those of Phillips et al. (2014; see above).
Methylfurans
2,5-Dimethylfuran (0, 20, 35 or 70 mg/kg bw) was given to male mice by i.p. injection. Adduct
formation was studied in proteins in liver, kidneys, heart, serum and lungs at different time-points up
to 36 h post-dosing. 2,5-Dimethylfuran adducts with cysteine- (at the SH group) and lysine- (at the Ne
position) residues were found in all tissues examined but in liver proteins they were the most
abundant. The occurrence of the adducts in liver proteins reached a peak at 2 h post dosing and
decreased gradually thereafter. Adduct formation was dose-related and also corresponded with serum
alanine aminotransaminase (ALT) activity. The same lysine or cysteine adducts could be detected in
supernatants of liver microsomes from non-exposed mice, treated with 2,5-dimethylfuran in the
presence of lysine or cysteine. No adducts were found in the absence of reduced nicotinamide adenine
dinucleotide phosphate, demonstrating that enzymatic activity is necessary for this bioactivation of
2,5-dimethylfuran (Wang et al., 2015).
C. Binding to DNA
Formation of BDA-nucleoside adducts has been extensively characterised. In chemical model
systems, BDA reacts with the puriﬁed nucleosides deoxycytosine (dC), deoxyguanosine (dG) and
deoxyadenosine (dA), but not deoxythymidine (dT), to form pairs of diastereomeric adducts. At
pH = 6.5, BDA reacted only with dC, and this reaction was not pH dependent (Byrns et al., 2002).
Reaction of BDA with dG and dA was pH-dependent, in particular for dG, but at pH 7.0–7.5 there still
was a preference of adduct formation of dC over the purines. At pH 8.0, BDA reaction rates with these
nucleosides are in the order dG > dC >> dA (Byrns et al., 2002).
A general mechanism for the nucleoside adduct formation is proposed involving reaction of the C1
atom of BDA with the exocyclic N atom of the nucleoside (N4 of dC, N2 of dG and N6 of dA) followed by
addition of the adjacent endocyclic nitrogen atoms (N3 of dC, N1 of dG and dA) at the BDA double bond
and a subsequent ring closure of the added element to result in formation of an oxadiazabicyclo(3.3.0)-
octaimine ring system (Gingipalli and Dedon, 2001; Byrns et al., 2002). While adducts with dC are stable
(half-lives of 96 h at pH 2.8, 275 h at pH 7.4 and 13 h at pH 12), adducts with dG and dA rearrange
quickly (half-lives of 2.2–3.4 h for dG and 6 h for dA at pH 7.4; Gingipalli and Dedon, 2001; Byrns et al.,
2002) and the initial ethano-adducts of dG and dA decompose to form substituted etheno-acetaldehyde
adducts. These secondary adducts retain a reactive aldehyde with the potential to form crosslinks. The
etheno-acetaldehyde adducts also retain the BDA-carbon atoms (Byrns et al., 2004, 2006).
Bohnert et al. (2004) provided additional kinetic and spectroscopic data of the reactions of cis- and
trans-BDA. Several products were observed after reaction of BDA (both isomers) with dA and dC at pH
7.4 in aqueous buffer systems. Apart from the mono-adducts that were also found by Byrns et al.
(2002), these included an additional pair of ﬂuorescent compounds with similar high-performance
liquid chromatography (HPLC) retention times and with identical mass, each of which contains two
molecules of BDA. The ﬂuorescent adducts of dA contained the oxadiazabicyclo(3.3.0)-octaimine ring
system (see above), which was also found in the dC adducts. The reaction of trans-BDA with dC
produced two interchanging diastereomers at reaction rates that were nearly 10-fold faster than the
reaction with the cis-isomer. However, it was noted that trans-BDA is an endogenous oxidation product
of deoxyribose and not a metabolite of furan.
The preferred reactivity of BDA with dC rather than dG and dA, as reported by Byrns et al. (2002)
was also observed by Pluskota-Karwatka et al. (2015). Similar oxadiazabiclyclooctaimine adducts were
reported as before. Pluskota-Karwatka et al. (2015) also mentioned that the BDA-dC adduct can be
converted into deoxyuridine by loss of the adducted BDA and subsequent deamination.
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Sviatenko et al. (2012) applied quantum chemical computer assisted analysis to study the chemical
interaction between BDA and dA. A similar technique was applied to study the interactions between
BDA and dG (Sviatenko et al., 2014). For the reactions of BDA with dA and dG, the authors calculated
that the primary reaction products would consist of four diastereoisomeric adducts for each nucleoside
(for an example of these structure see Figure 7). Upon acidic or basic hydrolysis, the primary adducts
of BDA-dA and BDA dG, respectively, are converted into more stable secondary adducts that contain
free aldehyde groups. Calculated UV and NMR spectra of the primary and secondary adducts as well as
the predicted structures match well with experimental observations from published literature.
BDA-dC and -dA adducts were also found in puriﬁed DNA treated with BDA and in DNA of
Salmonella Typhimurium TA104 after exposure to BDA (Byrns et al., 2006).
Upon extensive extraction of rat liver homogenates and removal of the proteins, no radioactivity
was associated with the residual liver DNA, not even after a (massive) i.p. dose of 243.5 MBq/kg bw
(8 mg furan/kg bw; 2.07 GBq/mmol) of radioactive furan. This would indicate either absence or a low
extent of binding of furan to DNA or an unstable nature of possible furan adducts (Burka et al., 1991).
Following administration by gavage of a single dose (0.1 or 2 mg/kg bw; 1.11 or 22.2 MBq/kg bw;
0.74 GBq/mmol) of [3,4-14C]-furan to F344 rats, a dose-dependent increase of 14C was found in liver
DNA at levels of 1.6 or 32.5 adducts/108 nucleotides at 2 h post-dosing. The authors suggested that
furan radioactivity was covalently bound to DNA. Metabolic incorporation into DNA bases during DNA
synthesis occurred only to a minor extent. From differences in MS peaks, the authors concluded that
the DNA adducts induced by furan in vivo were not the BDA-dC, -dG or -dA adducts that have been
reported in in vitro studies, but their identity could not further be established. Binding of furan to DNA
was also reported in the kidneys at half the levels observed in the liver. Screening studies for the
presence of DNA-BDA cross-links did not provide information that such cross-links were formed, either
in vivo or in BDA-calf thymus incubates (Neuwirth et al., 2012).
The ability of BDA to form DNA adducts in the liver was investigated by Churchwell et al. (2015) in
Fisher 344 rats administered furan by gavage (single doses ranging from 0.92 to 9.2 mg/kg). In
addition, rats were gavaged (5 days per week) with 4.4 mg/kg bw for different lengths of time
(45–360 days). Following both single dose or repeated exposure regimens, at 24 h after the last dose,
livers were collected and analysed for the presence of BDA-dC adducts by LC–MS/MS. The BDA-dC
levels did not increase (LOD: 0.4 adducts per 108 nucleotides) compared to the level present in liver
DNA from control animals (1–2 adducts per 108 nucleotides).
In chemically deﬁned systems, oligonucleotides containing a single-furan-modiﬁed nucleoside were
selectively oxidised at the furan moiety to a reactive BDA-like aldehyde. Fast and efﬁcient formation of an
interstrand DNA cross-link was observed in the presence of a complementary DNA strand (Halila et al.,
2005; Stevens and Madder, 2009). However, the BDA-derived nucleoside adducts observed in vitro by
Gingipalli and Dedon (2001) and Byrns et al. (2002, 2004) in single DNA strands have chemical structures
that differ from the reactive BDA moieties that ultimately are formed upon oxidation of the furan-modiﬁed
oligonucleotides as described by Halila et al. (2005) and Stevens and Madder (2009). Therefore, the
relevance for the in vivo toxicity of furan of the observed interstrand cross-linking in oligonucleotides in
the experimental designs from Halila et al. (2005) and Stevens and Madder (2009) is not clear. On the
other hand, according to Stevens and Madder (2009), the adducts in the complementary oligonucleotide
strands resemble the adducts formed by direct reaction of BDA with nucleotides.
3.1.1.5. Elimination
A. Furan
After a single oral dose of 8 mg [14C]-furan/kg bw (0.37 MBq/kg bw) in rats, 11% of the dose was
exhaled as unchanged furan within the ﬁrst hour post-dosing and an additional 3% was exhaled during
the next 23 h (Burka et al., 1991). Exhaled carbon dioxide represented 26% of the dose. Urine
contained 20% of the dose and comprised more than 10 peaks representing mixtures of metabolites,
but these could not be further identiﬁed. The faeces contained 22% of the dose (not characterised).
After 8 days of repeated dosing, the fraction of the dose eliminated via urine, increased from 20% to
33%. No change was observed in the extent of faecal elimination. Radioactivity from the liver was
eliminated with a half-life of 1.8 days. For blood and kidney, no half-lives could be estimated. Hamberger
et al. (2010) reported that in rats orally dosed with 5 mg furan/kg bw, several metabolites could be
detected in bile. Some of these reached a peak within 1 h of dosing; others continued to increase in the
bile during the 4 h observation period. The presence of parent furan was not studied. No indication was
given or could be obtained as to the fraction of the dose that was eliminated via this route.
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In a study by Churchwell et al. (2015), over the 8 h period of observation, the concentration in
blood decreased log-linearly with a half-life of 1.3 h. The elimination in liver showed 2 log-linear
phases with half-lives of 0.55 and 0.62 h, respectively. However, it is debatable whether this small
difference has any biological meaning, given the high variability in furan concentrations in the liver.
A rapid elimination of furan from blood was also reported by Becalski et al. (2013), who gavage-
dosed rats with 2.9 mg/kg bw deuterated furan in corn oil. At 0.5 h post-dosing, furan blood levels
were approximately 13–42 ng/g and at 1.5 h post-dosing, these levels had dropped to approximately
5 ng/g. Over the next 4.5 h, the furan blood concentration declined gradually to background level.
3.1.1.6. Biomarkers/biomonitoring
Kellert et al. (2008b) argued that estimation of human exposure to furan from concentration data in food
is not reliable, because of the volatility of furan. They advocated a biomarker approach for furan exposure
estimation. They treated rats with furan (0 or 40 mg/kg bw; n = 5) and analysed the urinary metabolite
proﬁle by principal component analysis. They observed a treatment-related increase in mass spectrometer
peaks for 13 compounds. For seven of these, the increase was statistically signiﬁcant. Five urinary
metabolites could be identiﬁed, all of them contained BDA in the form of a pyrrole nucleus. The pyrrole was
formed by condensation of BDA with the Ne-amino-group of lysine or the Na-amino-group of the glutamic
acid moiety in GSH. In four of these metabolites, the double bond in BDA had also reacted with GSH-thiol.
One of these four products was an S-methylated b-lyase cleavage product. Two of the metabolites found
(NAL-BDA and NAL-BDA-NAC) were also observed in urine from control animals. The authors could not
explain this observation, but argued that presence of furan in the feed was not a likely source.
The adducts of BDA with GSH or the cysteine-BDA-lysine crosslink adducts and downstream
reaction products thereof (N-acetylated; S-oxidated, b-lyase cleaved followed by S-methylation) have
been proposed as possible biomarkers for furan exposure (Kellert et al., 2008b; Lu and Peterson,
2010). Kellert et al. (2008b) further argued that the pattern of lysine-containing adducts as eliminated
via urine indicated that these are formed from BDA interaction with proteins, rather than with free
amino acids, thereby being indicative of markers of past exposure, because shortly after exposure only
a decrease in urinary excretion rate was observed for several GSH-BDA conjugates, while the
elimination of the lysine adducts did not show a decrease between 24 and 48 h post-exposure.
Becalski et al. (2013) demonstrated that furan in animal feed does not contribute to the furan body
burden in rats. Administration of 120 ng/kg bw of deuterated furan to rats did not result in detectable
levels of labelled furan in blood or liver, while native furan was found at 0.09–0.18 ng/g blood or
0.04–0.12 ng/g liver. The labelled dose corresponded to 20 ng/animal. This is an exposure similar to
that resulting from the consumption of control feed with a background furan content of approximately
2 ng/g feed. Based on this, the authors speculated that furan was formed from an endogenous source.
If substantiated, endogenous formation of furan is likely to have implications regarding biomonitoring.
Grill et al. (2015) analysed the urine of smoking and non-smoking human subjects (one cohort
from Minnesota, one from Shanghai and one from Singapore) for the presence of furan metabolites. A
BDA-Ne-lysine adduct and its N-acetylated conjugate were observed and also NAC-BDA-lys together
with the corresponding sulfoxide. The BDA-lys adducts were the most abundant metabolites and were
clearly elevated in urine from smokers as compared to non-smokers in the Shanghai and Singapore
cohorts, but not in the Minnesota cohort. Interference with other components in the urine hampered
its quantiﬁcation in 50% of the urine samples, notably all from USA, while the samples where the
metabolite could be properly quantiﬁed were from Shanghai or Singapore. A similar rise in NAC-BDA-
lys adduct and its sulfoxide was observed in smokers’ urine. For the USA samples, the concentration of
NAC-BDA-lys sulfoxide was much higher than for the Asian samples. The urinary level of NAC-BDA-lys
dropped signiﬁcantly during the ﬁrst 20 days after cessation of smoking, but remained higher than the
level in urine from non-smokers during the following 60 days, which the authors considered to be an
indication of slow release from furan-damaged proteins. In urine from furan-treated rats and mice, the
metabolic pattern for furan metabolites was different from that in humans: in rats and mice also
NAL-BDA-NAC and their sulfoxides were observed, which were not seen in human urine. In mice urine,
the prime metabolite was NAC-BDA, while in rats the prime metabolite was the NAL-BDA adduct. The
non-acetylated BDA-lys adduct was not detectable in either mice or rat urine.
Mochalski and Unterkoﬂer (2016) determined 19 volatile substances among which furan,
2-methylfuran and 3-methylfuran in the urine of 10 male and 9 female volunteers. Urine samples were
collected in glass vials, which were immediately closed after urine production. Volatiles were analysed
using headspace microextraction and GC-SRI-TOF-MS. The three furans were found in all samples.
Analytical results are given in Table 1.
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For furan, the levels ranged from 1.06 to 28.8 nmol/L (median 11.3 nmol/L) or from 0.1 to
4.75 nmol/mmol creatinine (median 0.87 nmol/mmol). For 2-methylfuran and 3-methylfuran, the
concentrations ranged from 1.74 to 6.88 nmol/L (median 4.06 nmol/L) and from 1.03 to 5.59 nmol/L
(median 2.97 nmol/L), respectively. No information was provided as to the possible source of the
furans found, apart from the statement that all volunteers were non-smokers. It was not stated
whether there was a gender difference in urinary excretion of furans.
Two limited studies measuring urinary and plasma levels of furan were identiﬁed (Jun et al., 2008;
Lee et al., 2009); however, the reported levels were inconsistent and therefore of limited value for this
opinion.
3.1.1.7. Physiologically based pharmacokinetic (PBPK) modelling
Based on data from inhalation absorption studies and data on rate of metabolism of furan in
hepatocyte suspensions, Kedderis et al. (1993) developed a PBPK model for rats. The model predicted
that for an oral bolus dose of 8 mg/kg bw in rats, 84% of the dose would be metabolised and 16% of
the dose would be exhaled unchanged, which is similar to the extent of metabolism and exhalation of
furan in rats as observed by Burka et al. (1991) after the same oral bolus dose. The model also
predicted that in rats for furan blood concentrations of 1 lM, the rate-limiting step in the metabolism
is the hepatic blood ﬂow, rather than the maximum metabolic capacity of the liver. From the data
presented, it can be calculated that the metabolism becomes saturated (90% of Vmax) at a blood
concentration of 3.6 lM using a Km of 0.4 lM as determined in rat hepatocyte suspensions.
This model was modiﬁed to predict liver dosimetry in mice, rats and humans (Kedderis and Held,
1996). Metabolic parameters used were for Vmax 48, 18 or 19–44 nmol/h per 10
6 isolated hepatocytes,
and for Km values 1.0, 0.4 or 2.1–3.3 lM, for mice, rats and humans (3 samples), respectively. The
modiﬁed models predicted absorption of furan from inhaled air containing 10 ppm (27.8 mg/m3) for
4 h to be 4.1, 1.4 or 0.4 mg/kg bw, resulting in a liver exposure to furan metabolites of 1,075, 480 or
168 lM for mice, rats and humans. According to the humanised model, for air concentrations up to
300 ppm (830 mg/m3) the exposure of the liver to furan metabolites is not dependent on Vmax but
only on hepatic blood ﬂow, that restricts the availability of substrate for biotransformation. The authors
argue that induction status of CYP2E1 is therefore not relevant for individual differences in the rate of
hepatic furan bioactivation in humans. Kedderis (1997) also applied the humanised model for the
estimation of hepatic furan bioactivation for an oral furan bolus dose of 2 mg/kg bw. For this route,
the extent of bioactivation of furan would be ﬂow-limited and independent on the CYP2E1 induction
status of the liver. However, the modelling conditions for the latter prediction were not reported,
especially not with respect to the furan absorption rate from the GI tract. Nevertheless, the conclusion
that the metabolic clearance rate of furan depends on the delivery of furan to the liver, rather than on
hepatic CYP2E1 activity, was supported by a generic PBPK model (Poulin and Krishnan, 1998).
3.1.1.8. Summary and discussion
After oral exposure of rats, furan is rapidly and extensively absorbed from the GI tract and distributed
throughout the body. At 24 h after exposure, major tissues where furan-related material can be found
are liver and kidneys and to a lesser extent lungs and intestines. Furan is extensively metabolised in the
body and from a dose of 8 mg/kg bw to the rat, only 11% was exhaled as unchanged furan. The
remainder was eliminated as carbon dioxide or as polar metabolites in urine or bile/faeces. At 24 h post-
dosing, no unchanged furan could be detected in liver or blood of rats, and this is in line with the very
short half-life of the substance in these tissues: approximately 40 min in liver and approximately 1.3 h in
blood. Although at 24 h post-dosing some furan-related material could be extracted from liver tissue,
80% of the residual material in the liver appeared to be non-extractable. Extensive non-extractable
association of furan and 2-methylfuran in the liver was also reported after i.p. administration. For
Table 1: Levels of furan, 2-methylfuran and 3-methylfuran in urine as reported by Mochalski and
Unterkoﬂer (2016)
Compound
Concentration in urine range (median) Limit of detection
(nmol/L)nmol/L nmol/mmol creatinine
Furan 1.06–28.8 (11.3) 0.1–4.75 (0.87) 1.0
2-Methylfuran 1.74–6.88 (4.06) 0.2–0.93 (0.34) 0.1
3-Methylfuran 1.03–5.59 (2.97) 0.12–0.92 (0.24) 0.1
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2-methyl and 3-methylfuran, data from in vitro studies are available that show that they may become
associated (non-extractable) with lung and liver microsomal proteins.
No oral studies have been performed with 2- or 3-methylfuran or with 2,5-dimethylfuran to address
their kinetics in animals, but inhalation studies in dogs with furan and 2-methylfuran and to a lesser
extent also with 2,5-dimethylfuran indicate that these three alkylated furans will be absorbed from the
gastrointestinal tract but the extent of this is unclear.
As indicated above, the major route for elimination of furan is via metabolic conversion. By analogy
with 2-methylfuran and 3-methylfuran, it was suggested that this metabolism would involve opening of
the furan ring to result in the formation of a very reactive cis-enedial intermediate, i.e. BDA. This
metabolite has never been directly measured. However, results with trapping agents and the
identiﬁcation of urinary and biliary metabolites, in comparison to reaction products of BDA with various
biomacromolecules or amino acids in puriﬁed chemical model systems, provide strong evidence that
BDA is indeed a prime reactive intermediate in the metabolism of furan. The corresponding reactive
metabolic intermediates of 2- and 3-methylfuran are the cis-enedials 3-acetyl acrolein (4-oxopent-2-
enal) and 2-methylbut-2-enedial, respectively. Also for 2,5-dimethylfuran, ring opening results in the
formation of a reactive intermediate, 3(Z)-hexene-2,5-dione. Induction-inhibition studies, but also
studies with various recombinant CYPs indicate that CYP2E1 is by far the most important (but not
exclusively) monooxygenase that catalyses the conversion of furan into BDA.
As a result of its reactivity, BDA reacts very quickly with amino acids and GSH. The same applies for
the reactive intermediate formed from 2,5-dimethylfuran. For the intermediates of 2-methyl- and
3-methylfuran, reactivity towards amino acids and GSH has not been studied in great depth. However,
it may be anticipated based on structural similarity and similar reactivity towards scavengers such as
semicarbazide, cysteine, NAC and microsomal proteins, that these will react with tissue components in
a similar way to the primary metabolites of furan and 2,5-dimethylfuran. A plethora of low molecular
weight reaction products has been reported. Reactive (alkyl)furan metabolites may react with:
1) amino acids (in particular lysine): reacts with the two terminal aldehyde groups of BDA to
give a cyclic pyrrole derivative. This reaction may involve the side chain terminal amino
group of the amino acid or the amino acid in a-position to the carboxylic acid. For these
reaction products, the corresponding N-acetylated forms have been reported. BDA can also
react with free amino groups in proteins (in particular from lysine). The same reactions have
been reported for the cis-enedione formed from 2,5-dimethylfuran.
2) GSH or cysteine: react directly with the double bond in these a,b-unsaturated carbonyls at
their thiol group. The latter reaction does not take away the reactivity of the two aldehydes,
and consequentially, these GSH or cysteine adducts may react further, either with the amino
groups from free amino acids or with amino groups protruding from protein amino acid
residues. Since cysteine or GSH have several reactive functional groups, also bicyclic adducts
have been reported, in which the thiol group is connected to the BDA double bond and the
free amino group has reacted with the two BDA aldehydes, resulting in a pyrrole ring.
Reactivity of BDA towards biogenic amines has also been reported.
As a result of the reactivity towards amino acids, GSH, biogenic amines and proteins, the urinary
excretion is biphasic: in ﬁrst instance, the main excretion of urinary furan metabolites consists of
metabolites that were formed from BDA and free amino acids or GSH within the cell, but later on the
urinary excretion of furan-related material is a result from protein turn-over that liberates the furan-
damaged amino acid residues. Also, the elimination of furan (radioactivity) from, e.g. liver is biphasic
with a rapid elimination of non-bound radioactivity and a slower and more prolonged elimination of
protein-bound furan.
More intriguing is the possibility of furan metabolites reacting with DNA, which could be an
important factor in the genotoxicity and formation of tumours. Studies in chemical model systems have
demonstrated that BDA can readily react with dC and to a lesser extent dG and dA, but not dT. Again,
a plethora of reaction products was obtained. While BDA-dC is rather stable (with a half-life of about
300 h at pH = 7.4), the adducts of dG and dA rearrange rather quickly with half-lives of 2.2–3.4 h for
dG and 6 h for dA at physiological pH. Nevertheless, these adducts retain the BDA-carbon atoms and
this should reveal their presence in studies in which radioactive furan is given to animals in vivo. When
puriﬁed DNA or bacterial cultures are exposed to BDA, DNA adduct formation can be demonstrated.
Although it is clear that BDA has direct reactivity towards DNA, it is not clear from the available
data that BDA-DNA adducts will be formed after exposure of rats to furan in vivo. In earlier in vivo
studies with rats, at 24 h post-dosing, furan radioactivity in liver was associated with protein but not
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with DNA, not even when a dose as high as 243.5 MBq/kg bw (8 mg/kg; 2.07 GBq/mmol) was
administered. In a study in which rats were treated with furan, using accelerator mass spectrometry,
the presence of DNA adducts in the liver (1.6 or 32 adducts per 108 nucleotides) and kidneys (0.5 or
13 adducts per 108 nucleotides) at 2 h post-dosing with 0.1 or 2 mg radiolabelled furan/kg bw (1.11
or 22.2 MBq/kg bw; 0.74 GBq/mmol), respectively, was demonstrated. However, the adducts observed
could not be identiﬁed as either BDA-dC, BDA-dG or BDA-dA adducts. The possibility was suggested
that the observed adducts were related to DNA-DNA or DNA-protein cross-links, but no deﬁnitive
evidence for this was presented. In another study in rats, no increase in BDA-dC levels (LOD: 0.4
adducts per 108 nucleotides) above the level present in commercial control DNA and in liver DNA from
control animals (~ 1–2 adducts per 108 nucleotides) was observed in livers of rats following
administration after a single dose of furan (ranging from 0.92 to 9.2 mg/kg), as well as after repeated
dosing (5 days per week) with 4.4 mg/kg bw for 45–360 days, as determined using LC–MS/MS. In any
case, the potency of covalent binding to DNA in vivo is not very high or the reaction products are very
short-lived. The data further suggest that BDA reacts readily with protein and non-protein amino and
thiol residues in liver, thereby restricting access to DNA.
Based on the studies in rats, and on furan metabolism rates measured in rodent and human
hepatocytes, a PBPK model has been constructed for rats, mice and humans. Applying this model, the
rate of exhalation of furan in rats after an oral bolus dose was well described. The model further
predicts that after an oral bolus dose of 2 mg/kg bw the exposure of the liver to furan metabolites
depends on the blood ﬂow to the liver rather than the metabolic capacity of the liver since at the
blood concentrations reached, the metabolic capacity of the liver is far from saturated. The efﬁcient
metabolism of furan will result in an effective ﬁrst-pass elimination and will therefore limit the systemic
exposure to furan after oral intake. The bioactivation of furan depends less on the liver CYP2E1 activity
(the main furan-metabolising enzyme) than on liver blood ﬂow. Activity of GSH conjugating enzymes
may be of less relevance, because BDA has a high rate of spontaneous reactivity towards GSH.
It has been argued that estimation of furan exposure based on concentration in foods is not reliable,
and biomarkers of exposure might be an alternative. However, from the available kinetics data, it is not
possible to conclude on a methodology to reliably estimate exposure to furan in humans from the
excretion of furan or furan metabolites. The main reason for this is that there is no information as to the
quantity of metabolites in human excreta, not for total amounts of metabolites and also not for individual
metabolites. Even for rats, this information is not available, since virtually all metabolism studies have
focused only on qualitative determination and identiﬁcation of furan metabolites in urine or bile and did
not pay attention to quantitative aspects of metabolism and excretion. Nevertheless, several studies have
suggested that three metabolites might be good candidates for biomonitoring furan exposure: NAL-BDA-
NAC, its sulfoxidation product and the sulfoxidated a-keto-derivative of NAC-BDA-lys. The urinary
metabolite pattern may also provide information on the level of past exposure, because several
metabolites seem to emerge from protein breakdown rather than direct adduct formation to small
biomolecules (amino acids; GSH), which are probably more rapidly eliminated. However, further work is
needed to validate the use of these metabolites as biomarkers of exposure. A few studies have also tried
to monitor unmetabolised furan in human blood and urine. In many samples furan was not detectable. In
addition, the volatility of furan requires very stringent treatment of samples, because otherwise artiﬁcially
low furan levels might result. Given the short half-life of furan, at least in rats, but probably also in
humans, looking at unchanged furan would only provide an indication for very recent exposure to furan.
It is further noted that furan may also be formed endogenously, which may need to be taken into account.
Concluding remarks
After oral administration, furan is extensively oxidised in the liver to form a reactive intermediate
metabolite BDA. BDA may be further metabolised to carbon dioxide. Alternatively, it can spontaneously
react with free amino- or thiol groups in low molecular weight tissue components (e.g. GSH, cysteine,
lysine and other amino acids and biogenic amines). The resulting reaction products can be eliminated
from the body via urine or bile. A study with oral dosing indicated that approx. 55% of an oral gavage
dose may be eliminated via these two routes, predominantly within the ﬁrst 24 h after exposure. The
rate of metabolism is determined by the delivery of furan to the liver, and not by its enzymatic
capacity. From the data available, it may be assumed that the fraction of an oral dose that is
converted to BDA will be dose dependent, but this has not been studied. The relative extent of
formation and elimination of the BDA secondary reaction products has not been investigated, but
several of these (e.g. NAL-BDA-NAC) have been suggested to be useful biomarkers of exposure. BDA
can form adducts with protein (including histones) after exposure to furan in vivo, especially with
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lysine, and form adducts with free nucleosides (in particular with deoxyribose guanosine, -cytosine and
–adenine) and DNA adducts in puriﬁed DNA and bacteria. In one in vivo study, binding of furan to DNA
has been reported, but this result could not be reproduced in another study. The DNA adducts found
were different from the BDA adducts formed with the free nucleosides and could not be identiﬁed. No
DNA-DNA cross-links have been reported.
In addition, for 2-methyl-, 3-methyl- and 2,5-dimethylfuran, oxidative opening of the furan ring has
been reported with similar reactivity towards amino acids and GSH. For these alkylfurans, also
oxidation of the methyl-ring substituent groups may be expected, but there are no quantitative or
qualitative studies available that address these routes of biotransformation.
The relevance of these ﬁndings for the toxicity and genotoxicity of furan and the alkylfurans will be
discussed in Sections 3.1.2.4 and 3.1.4.
3.1.2. Toxicity in experimental animals
3.1.2.1. Acute toxicity (single exposure)
In adult male Sprague–Dawley rats and male Swiss mice, furan was injected i.p., while another group
of adult male Swiss mice inhaled air enriched with furan vapour (Egle and Gochberg, 1979a). The i.p. LD50
values were 5.2 mg/kg bw in rats and 7.0 mg/kg bw in mice. The LC50 value as a vapour was 0.12 mg/L
in mice. In the lungs, ﬂuid accumulation and inﬂammatory reactions were found after inhalation.
Wiley et al. (1984) injected furan i.p. in male ICR mice. Twenty-four hours after a dose of
347 mg/kg bw, the animals were sacriﬁced. Histopathological inspection revealed slight proximal
tubular necrosis of the kidneys and massive centrilobular necrosis of the liver. Dosage of 3-methylfuran
(254 mg/kg bw) claimed to be ‘equimolar’ was reported not to lead to signiﬁcant damage in these
organs. The CONTAM Panel noted that the dose levels mentioned in the abstract and in the text are
inconsistent and not equimolar. The CONTAM Panel noted that the dose level for furan by far exceeded
the LD50 value reported by Egle and Gochberg (1979a).
Bronchiolar necrosis was observed 8 h after i.p. application of 100–200 mg/kg bw of 3-methylfuran
to NIH Swiss mice (age and gender not speciﬁed) (Boyd et al., 1978). Gammal et al. (1984)
administered 213 or 254 mg/kg bw of 3-methylfuran i.p. to adult male ICR mice. After 24 h, severe
bronchiolar necrosis was observed.
3.1.2.2. Subacute and subchronic toxicity (< 90 days duration)
A. Furan
Several short-term toxicity studies with furan were identiﬁed, which are described below and
summarised in Table 2.
Wilson et al. (1992) published results from treatment of male mice or male and female rats at the
highest NTP bioassay dose in each species (15 mg/kg bw per day or 8 mg/kg bw per day,
respectively) 5 days a week by gavage. In male and female rats, necrosis and inﬂammation were
observed along the subcapsular visceral surface of the left or caudate liver lobes after one week. A
similar picture was evident in mice after 3 weeks. After 6 weeks of furan treatment, male and female
rats exhibited bile duct hyperplasia and metaplasia in the areas of ﬁbrosis along the subcapsular
visceral surface of the left or caudate liver lobes. This was not observed in mice. The fold increase in
hepatocyte labelling index (DNA synthesis) in treated animals relative to the combined controls
measured at weeks 1, 3 and 6 was 25-, 12- and 3-fold in male mice, 3-, 9- and 7-fold in male rats,
and 13-, 11- and 16-fold in female rats, respectively.
In a study carried out for the NTP (1993), adult F344/N rats and B6C3F1 mice were treated with furan,
dissolved in corn oil, by gavage. Groups of ﬁve male rats received doses of 0, 5, 10, 20, 40 or 80 mg of
furan/kg bw per day and groups of ﬁve female rats and ﬁve mice of each sex received doses of 0, 10, 20,
40, 80 and 160 mg/kg bw per day over 16 days, 5 days a week. All male and female mice and female
rats which had received 160 mg/kg bw, all male and female rats and all male and four out of ﬁve female
mice which had received 80 mg/kg bw per day, and three out of ﬁve male mice which had received
40 mg/kg bw per day died by day 8. All furan-treated animals showed motor inactivity or reduced activity.
Final mean body weights of male rats which had received 20 mg/kg bw per day and of male and female
rats which had received 40 mg/kg bw were signiﬁcantly lower than in the controls. Final mean body
weights of male mice which had received 10 or 20 mg/kg bw per day were signiﬁcantly greater than
controls. At necropsy, mottled and enlarged livers were observed in male rats after 20, 40 or 80 mg/kg
bw and in female rats after 40, 80 or 160 mg/kg bw. No treatment-related lesions were observed in mice.
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In a second experiment carried out for the NTP (1993), groups of 10 rats of each sex and groups
of 10 female mice received 0, 4, 8, 15, 30 or 60 mg of furan per kg bw in corn oil by gavage 5 days
per week for 13 weeks. Groups of 10 male mice received 0, 2, 4, 8, 15 or 30 mg of furan per kg bw in
corn oil by gavage 5 days per week for 13 weeks. Nine male and four female rats that received
60 mg/kg bw died before the end of the experiment. There were no treatment-related deaths in mice.
Signiﬁcantly lower ﬁnal mean body weights were observed in male rats that received 15 or 30 mg/kg
bw, in female rats that received 60 mg/kg bw and in male mice that received 30 mg/kg bw compared
to controls. Relative and absolute liver weights were increased in all furan-treated groups in both
species, as were relative and absolute kidney weights in all furan-treated groups of female rats.
Thymus weights were decreased in all furan-treated groups of rats. In rats, furan administration
resulted in bile duct hyperplasia, cholangioﬁbrosis, cytomegaly and degeneration of hepatocytes, and
nodular hyperplasia of hepatocytes. Kidney tubular dilatation and necrosis were observed in rats that
received 30 or 60 mg/kg bw. In rats, exposed to 60 mg/kg bw furan, thymic atrophy and testicular or
ovarian atrophy were also observed. In mice, similar hepatic lesions were found in all furan-treated
dose groups, while bile duct hyperplasia and cholangioﬁbrosis were observed in groups of mice
receiving 30 or 60 mg/kg bw.
The CONTAM Panel noted that even at the lowest dose levels (4 mg/kg bw in rats; 2 mg/kg bw in
mice), signiﬁcant hepatic lesions were found.
Sirica et al. (1994b) applied 45 mg furan/kg bw by gavage to young adult male Fischer 344 rats
over 6 weeks, 5 days a week. Furan reduced liver weight and led to pronounced cholangioﬁbrosis with
associated metaplasia mainly found in the right liver lobe together with biliary cirrhosis. In contrast to
normal cholangiolar structures, the metaplastic cholangia-like cells were surrounded by a basement
membrane positive for both laminin and type IV collagen. The cells were stained positive for gamma-
glutamyl transpeptidase and cytokeratin 8, while cytokeratin 19 was strongly expressed in all of the
biliary epithelial cells, but in just some of the metaplastic cells.
In a ﬁrst experiment, 50-day-old female B6C3F1 mice received furan by daily gavage, 5 days per
week over a period of 3 weeks (15 days of treatment) at doses of 4, 8 or 15 mg/kg bw per day
(Fransson-Steen et al., 1997). In a second experiment, 15 mg/kg bw furan was initially applied by
gavage for three consecutive days followed by 2 weeks with ﬁve consecutive days per week and over
a ﬁnal week with two consecutive days. Thus, animals were exposed for ﬁve and two consecutive days
immediately prior to necropsy in the ﬁrst and second experiments, respectively. In the second
experiment, a separate group received 100 mg/kg of the non-speciﬁc CYP-inhibitor, aminobenzotriazole
(ABT), 7 days per week beginning 5 days before the start of furan dosing.
In the ﬁrst experiment, ALT and sorbitol dehydrogenase24 (SDH) were measured in the serum and
the apoptotic index in the liver, and all were signiﬁcantly increased at 8 mg/kg bw and above. At the
two highest dose levels, histopathological examination revealed minor subcapsular inﬂammation as
well as sporadic necrosis. In the second experiment, 15 mg/kg bw furan resulted in a signiﬁcant
increase in liver weight, while serum levels of ALT, SDH and total bile acids were increased at this dose
level. Co-treatment with ABT attenuated these effects while it caused a mild lipid vacuolisation of the
liver. The labelling index of hepatocellular nuclei was increased signiﬁcantly at 15 mg/kg bw, the
apoptotic index at 8 and 15 mg/kg bw. Co-treatment with ABT abrogated these effects completely.
Moser et al. (2009) treated female B6C3F1 mice with 0.5 1, 2 and 4 mg furan/kg bw by gavage
over 3 weeks, 5 days per week. There was a dose-dependent and signiﬁcant hepatotoxicity (measured
as serum ALT) at and above 0.5 mg/kg bw and a mild subcapsular inﬂammation of the liver at the
lowest dose. Cell proliferation as measured by 5-bromo-2-deoxyuridine (BrdU) incorporation was
enhanced at 8 mg/kg bw applied in a long-term carcinogenicity study.
Cordelli et al. (2010) gave furan by daily gavage over 28 days, 5 days a week, to male B6C3F1
mice at dose levels of 2, 4, 8 and 15 mg/kg bw per day. The animals were sacriﬁced and the livers
were removed for further investigation, 24 h after the last gavage. Histopathological inspection
revealed some necrosis and regenerative hyperplasia (at 8 and 15 mg/kg bw) and an increase in
apoptotic ﬁgures (at 15 mg/kg bw). Furthermore, at the highest dose level, an increase in nuclear
ploidy was found. DNA methylation and the number of c-H2AX foci were unchanged. At the highest
dose level, overexpression of DNA damage response-related genes was noted. At a very high single
dose level of 250 mg/kg bw diffuse alteration of liver parenchyma with areas of necrosis and steatosis
in surrounding hepatocytes was found 3 h after application.
24 The CONTAM Panel noted that the enzyme is called ‘sorbital dehydrogenase’ in the paper, and assumed it is sorbitol
dehydrogenase.
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Hickling et al. (2010b) administered furan to adult male Sprague–Dawley Crl CD1 BR rats by
gavage in corn oil at 30 mg/kg bw (ﬁve daily doses per week, per gavage in corn oil). After 8 h, 1, 3,
7, 10, 12 and 20 days, and 1, 2 and 3 months of treatment, animals were sacriﬁced and livers were
examined. The administration of furan caused centrilobular and subcapsular injury (necrosis) and
subsequent proliferation of hepatocytes. Later, a rapid proliferation of ductular cells expanding into the
parenchymal area accompanied by a subtype of liver ﬁbroblasts occurred. The ductular structures
either differentiated into hepatocytes or transformed into ductular cholangioﬁbrotic structures.
Mally et al. (2010) treated male Fischer 344 rats orally (gavage) at doses of 0.1, 0.5 and 2 mg/kg
bw for 28 days (5 days per week), with an interim sacriﬁce after 5 days of treatment. An off-dose
recovery group (0 and 2 mg/kg bw dose groups only) was kept for additional 2 weeks (recovery
period) after the end of the 4-week treatment period. Statistically signiﬁcant proliferative changes were
restricted to rats treated with furan at 2 mg/kg bw. An approximate twofold and threefold increase in
BrdU labelling above background was observed in the low- (0.1 mg/kg bw) and mid- (0.5 mg/kg bw)
dose group, respectively. Furthermore, the authors observed an increased mitotic activity in the
subcapsular regions of the left and caudate lobe accompanied by an occasional apoptotic cell and
inﬂammatory foci with accumulation of mononuclear cells.
Selmanoglu et al. (2012) treated juvenile male Wistar rats by gavage with 2, 4 or 8 mg/kg bw per
day over 90 days. A 7 days per week dose schedule was applied (Karacaoglu, 2016, E-mail
communication, 25 October 2016). Reduced liver weights and signiﬁcant changes in serum ALT,
alkaline phosphatase (ALP) and low-density lipoprotein (LDL) were observed at 4 mg/kg bw and
above. At the lowest dose level (2 mg/kg bw), hepatic tumour necrosis factor (TNF)-a was signiﬁcantly
increased and numerous histopathological alterations of the liver as well as morphological changes of
the glomerula (kidney) were found.
Gill et al. (2010) treated male and female Fischer 344 rats over 90 days by gavage with 0.03, 0.12,
0.5, 2.0 and 8.0 mg/kg bw per day, 5 days per week. The liver was found to be the major target
organ with changes in serum enzymes, increased liver weight and various histological lesions (pattern
and severity changing with the dose level). There was a signiﬁcant increase in serum thyroxine (T4)
and triiodothyronine (T3) in males. The CONTAM Panel noted that there was no clear dose response
for changes in T3. The increase in thyroid hormones was not accompanied by histological thyroid
changes. At a dose level above 0.5 mg/kg bw, changes in clinical biochemistry and haematological
parameters were observed, while mild histopathological alterations in the liver were observed at a
dose level of > 0.12 mg/kg bw per day and at 0.12 mg/kg bw per day and above in the caudate lobe.
At this dose level, serum T4 was increased signiﬁcantly in male rats, and further increased with
increasing furan doses.
Gill et al. (2011) published a study where male and female B6C3F1 mice were treated by gavage
over 90 days with 0.03, 0.12, 0.5, 2.0 and 8.0 mg/kg bw per day, 5 days per week. Serum ALT was
increased at the highest dose level and liver weights were increased at the highest dose in females
only. At the two highest dose levels, histological changes in the liver were observed in both sexes and
also at 0.5 mg/kg bw in males. For the kidney, clinical parameters were also altered, but they were not
accompanied by histological changes. At 0.5 mg/kg bw, blood urea nitrogen (BUN) was decreased in
both sexes. The CONTAM Panel noted that the levels reported for controls (10.96–11.45 g/L) are not
in agreement with published data for BUN in mice (e.g. 80–330 mg/L; University of Minnesota
Reference Values, https://www.ahc.umn.edu/rar/refvalues.html). In male mice, Gill et al. (2011) found
an increase in blood phosphorous (controls: 0.8–0.9 mmol/L) at a dose of 0.12 mg/kg bw of furan.
The CONTAM Panel noted that phosphorous measurement in serum is highly vulnerable to blood
sample handling. Likewise, haemolysis can cause an up to 30% increase in phosphorous
measurements (UK Association for Clinical Biochemistry, 201225). Upon request, the corresponding
author stated that the dimension given in the paper was erroneous and should read mmol/L instead of
g/L (Gill, 2017, e-mail communication, 31 January 2017).
Karacaoglu et al. (2012) treated male Wistar rats with 2, 4 and 8 mg/kg bw by gavage over
90 days. A 7 days per week dose schedule was applied (Karacaoglu, 2016, e-mail communication, 25
October 2016). At the highest dose, there was signiﬁcant congestion in the islets of Langerhans in the
pancreas, while the organ weights of adrenal glands and pancreas were unchanged.
Kockaya et al. (2012) treated young male Wistar rats orally (gavage) with doses of 2, 4 and 8 mg/kg
bw per day for 90 days. A 7 days per week dose schedule was applied (Karacaoglu, 2016, E-mail
communication, 25 October 2016). At the end of the experiment, thymus of the rats were examined
25 http://www.acb.org.uk/Nat%20Lab%20Med%20Hbk/Phosphate.pdf
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morphologically, histopathologically and immunohistochemically. At the two highest doses, relative
thymus weights were decreased signiﬁcantly. A histopathological examination revealed various changes
in the thymus at these dose levels including enlargement of interstitial connective tissue, decrease in
thymic lymphocyte counts and haemorrhage.
Alam et al. (2017) treated male Sprague–Dawley rats by gavage with 16 mg/kg bw over 30 days.
Furan treatment resulted in signiﬁcantly elevated red blood cell count, haemoglobin, white blood cell
count, lymphocytes and granulocytes and reduced phagocytic parameters in white blood cells. It
decreased serum total protein, albumin, globulin, immunoglobulin M (IgM), IgG and interleukin 4 (IL4),
with a signiﬁcant increase in serum TNFa and 8-oxodeoxyguanosine. In the spleen, furan decreased
the GSH content and GST activity and increased the malondialdehyde levels. Histopathologically, furan
led to a moderate depletion in splenic lymphoid cells.
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Table 2: Effects of orally administered furan (by gavage) in acute, subacute and subchronic (≤90 days) studies in experimental animals
Species (number of
animals per group)
Dosage
(mg/kg bw)
Duration/time of
observation
Outcome(a)
NOAEL (LOAEL)
in mg/kg bw
per day(b)
Reference
B6C3F1/CrIBR male
mouse (5)
Fischer 344/CrIBR male
rat (5)
Single 30 (rats), 50
(mice)
12, 24, 48 h, 4 and
8 days
Increased plasma liver enzymes after 12 h
and later
LI increased after 48 h
One dose level only Wilson et al. (1992)
B6C3F1/CrIBR male
mouse (5)
Fischer 344/CrIBR male
rat (5)
Single, 15, 27, 39. 50
(mice) 0, 8, 15, 22, 30
(rats)
24 h Increased plasma liver enzymes at
27 mg/kg bw (male mice) and
15 mg/kg bw (male rats)
(15; mice) (8; rats)
B6C3F1/CrIBR male
mouse (5)
Fischer 344/CrIBR male and
female rat (5)
30 (rats), 50 (mice) 6 weeks, 5 days a
week
Hepatic necrosis and inﬂammation, bile duct
hyperplasia and metaplasia in rats
One dose level only
B6C3F1/CrIBR male
mouse (5)
Fischer 344/CrIBR male
rat (5)
30 (rats), 50 (mice) 1, 3 and 6 weeks,
5 days a week
increased hepatocellular LI (proliferation) One dose level only
B6C3F1 male and female
mouse (5)
Fischer 344 male and female
rat (5)
0, 5, 10, 20, 40 or
80 mg (male rats)
0, 10, 20, 40, 80 and
160 (mice and female
rats)
16 days, 5 days a
week
Rats (observation): mottled and enlarged
livers
Mice: no organ changes
Range-ﬁnding study NTP (1993)
B6C3F1 male and female
mouse (10)
Fischer 344 male and female
rat (10)
0, 4, 8, 15, 30 or 60
(rats and female mice)
0, 2, 4, 8, 15 or 30
(male mice)
13 weeks, 5 days a
week
Increase in relative and absolute liver
weight, histopathological changes in the
liver
(2; male mice) (4; rats
and female mice)
NTP (1993)
Fischer 344 male rat (3–6) 45 6 weeks, 5 days a
week
Reduced liver weight, cholangioﬁbrosis,
biliary metaplasia, biliary cirrhosis
One dose level only Sirica et al. (1994b)
B6C3F1 female mouse (6–11) 4, 8 and 15 3 weeks, 5 days a
week
Increase in serum ALT, SDH, apoptotic
index, subcapsular inﬂammation
4 Fransson-Steen et al.
(1997)
15 3–5 days a week over
2 weeks – 2 days
(15 days in total)
Increase in liver weight, serum ALT,
SDH and bile acids
One dose level only
B6C3F1 female mouse (15) 0.5, 1, 2 and 4 3 weeks, 5 days a
week
Increased serum ALT, subcapsular
inﬂammation
(0.5) Moser et al. (2009)
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Species (number of
animals per group)
Dosage
(mg/kg bw)
Duration/time of
observation
Outcome(a)
NOAEL (LOAEL)
in mg/kg bw
per day(b)
Reference
B6C3F1 male mouse (3–11) 2, 4, 8 and 15 28 days, 5 days a
week
Hepatic necrosis, hepatocellular
proliferation
4 Cordelli et al. (2010)
Sprague–Dawley Crl CD1 BR
male rat (3–5)
30 8 h, 1, 3, 7, 10, 12
and 20 days, and 1, 2
and 3 months, 5 days
a week
Hepatic necrosis, hepatocellular and biliary
proliferation
one dose level only Hickling et al. (2010b)
Fischer 344 male rat (3–5) 0.1, 0.5, 2 28 days, 5 days a
week
Increased DNA synthesis, increased
subcapsular mitosis, apoptosis and
inﬂammation
(0.1) Mally et al. (2010)
Wistar juvenile male rat (8) 2, 4 and 8 90 days, 7 days a
week
Increased hepatic TNF-a (2) Selmanoglu et al.
(2012)
Fischer 344 male and female
rat (12)
0.03, 0.12, 0.5, 2 and
8
90 days, 5 days a
week
Increase in serum T4 in males(c) 0.03 Gill et al. (2010)
B6C3F1 male and female
mouse (16)
0.03, 0.12, 0.5, 2 and
8
90 days, 5 days a
week
Distinct histopathological changes,
changes in clinical blood parameters
(BUN and phosphorous in serum)(c)
0.12 Gill et al. (2011)
Wistar male rat (8) 2, 4 and 8 90 days, 7 days a
week
Islet of Langerhans congestion 4 Karacaoglu et al.
(2012)
Wistar juvenile male rat (8) 2, 4 and 8 90 days, 7 days a
week
Decrease in relative thymus weight,
histological changes in the thymus
2 Kockaya et al. (2012)
Sprague–Dawley male (10) 16 30 days(d) Changes in blood cells, blood cell
phagocytic activity, serum immune
parameters, oxidative stress in the spleen,
changes in splenic lymphoid cells
One dose level only Alam et al. (2017)
ALP: alkaline phosphatase; ALT: alanine aminotransaminase; BUN: blood urea nitrogen; LDL: low-density lipoprotein; LI: labelling index; LOAEL: lowest-observed-adverse-effect level;
NOAEL: no-observed-adverse-effect level; SDH: sorbitol dehydrogenase; TNF: tumour necrosis factor.
(a): Most sensitive endpoint given in bold.
(b): LOAEL (in italics) or NOAEL (in bold) for the most sensitive endpoint affected schedule.
(c): See comments under ‘Summary’.
(d): Information on dose regimen not available.
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B. Methylfurans
The CONTAM Panel identiﬁed three short-term toxicity studies on methylfurans, which are described
below. All the no-observed-adverse-effect levels (NOAEL) mentioned in this section are based on
limited data and should therefore be considered as preliminary.
Gill et al. (2014) treated male Fischer 344 rats (n = 10/group) by gavage with 0.4, 1.5, 3, 6, 12
and 25 mg 2-methylfuran/kg bw per day over 28 days, 5 days a week. Mild histological hepatic lesions
such as apoptotic hepatocytes, abnormally pigment Kupffer cells and inﬂammatory inﬁltrations were
observed at 1.5 mg/kg bw and increased in severity with increasing dose levels. Furthermore, serum
cholesterol and T3, T4 were also increased at this dose level. In the thyroid gland, no histopathological
changes were found. The CONTAM panel noted that the dose responses for T3 and cholesterol were
rather ﬂat, while there was a dose-dependent statistically signiﬁcant increase of T4 at lower doses
which disappeared at higher doses (inconsistent dose response). Thus, a NOAEL of 0.4 mg/kg bw per
day could be identiﬁed by the CONTAM Panel. A slight increase in peripheral eosinophils observed at
this dose level could not be conﬁrmed at higher dosage.
Gill et al. (2015) treated male Fischer 344 rats (n = 10/group) by gavage with 0.1, 0.3, 1.5, 3, 6,
12 and 25 mg 3-methylfuran/kg bw per day over 28 days, 5 days a week. Statistically signiﬁcant
histological changes of the liver were noted at 1.5 mg/kg bw per day and gross changes were noted
beginning at 3 mg/kg bw per day. At the highest dose, alterations in serum enzyme activities
indicating hepatic toxicity were observed. There was also a signiﬁcant increase in serum T3 and T4
without histopathological changes in the thyroid. From these data, a NOAEL of 0.3 mg/kg bw per day
could be derived for hepatic histopathological changes in the rat.
Gill et al. (2017, in preparation) treated male and female Fischer 344 rats (n = 12/group) by
gavage daily (5 days per week) for 90 days with 3-methylfuran at ﬁnal doses of 0.0 0.02, 0.075, 0.25,
1.0 and 4.0 mg/kg bw per day. Based on a severity score, statistically signiﬁcant differences were
found for some types of hepatic lesions (zone 1 hepatocytes with eosinophilic, i.e. altered cytoplasm
and hyperchromasia) in the 1.0 mg/kg bw male rats while in females, statistical differences appeared
at the 4.0 mg/kg bw dose. Furthermore, the authors reported a number of hepatic histopathological
observations which were not statistically signiﬁcant when based on a severity score. These included
very mild lesions characterised by hyperchromasia of chromatin with enlarged nucleoli and increased
cytoplasmic eosinophilia in the 0.25 mg/kg bw dose group, in the left and caudate lobes of the males.
Small numbers of cells were pale or had mild microvesicular steatosis. The numbers of hepatic mitoses
were slightly increased and slight proliferation of oval cells was noted in the left and caudate lobes. In
females at the same dose level (0.25 mg/kg bw), similar mild changes and slight oval cell proliferation
were observed. There was no statistical analysis or long-term comparison with controls. The extent
and severity of the alterations increased with increasing doses. In the 4.0 mg/kg bw group, massive
nodular changes of the liver were observed. Serum ALP and bilirubin were signiﬁcantly enhanced in
males at 1.0 mg/kg bw and in females et 4.0 mg/kg bw. In the highest dose group, serum parameters
indicative of diminished renal function, i.e. serum creatinine (at 4.0 mg/kg bw) and uric acid (at
1.0 mg/kg bw) were also increased in males. Based on these ﬁndings, including statistically non-
signiﬁcant histopathological observations in the liver, the authors suggested a NOAEL of 0.075 mg/kg
bw per day. Based on benchmark dose modelling, the authors also derived BMDL10 values of 0.08 mg/kg
bw for liver focal necrosis and oval cell hyperplasia in the left lobe in males, and of 0.05–0.17 mg/kg bw
for liver lesions (oval cell hyperplasia and karyocytomegaly in the left lobe) in females.
C. Observed effects for methylfurans compared to other alkylfurans
The CONTAM Panel reviewed the literature on the toxicity of several alkylated furans in order to
obtain more information on possible structure–activity relationships with respect to the pattern of
adverse effects. Appendix B gives an overview of the reported effects for different alkylfurans. Such
information was expected to be possibly instrumental in addressing the question if certain alkylated
furans could eventually be considered together with furan. For this purpose, also non-oral routes of
exposure were considered, since the number of oral studies with alkylated furans is very limited and it
was expected that such studies might provide more insight into MoAs of the compounds of interest.
For 2- and 3-methylfuran, pulmonary and hepatic toxicity was shown. Pulmonary toxicity was
observed upon inhalation but also upon i.p. application. There is also indication for kidney toxicity of
3-methylfuran after 90 days exposure. 2- and 3-Ethylfuran exhibited renal, pulmonary and hepatic
toxicity in different species. For 3-pentylfuran, adverse renal and hepatic but not pulmonary effects
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were reported (no inhalation studies). Thus, no clear structure–effect relationship for the alkylated
furans with respect to the pattern of adverse effects/the target organs could be derived.
D. Summary
Taken together, in experiments of a duration of up to 90 days, furan is strongly hepatotoxic and
moderately nephrotoxic in rodents when applied by oral gavage. Rats seem to be more sensitive
towards furan than mice. Furan leads to characteristic changes in serum markers related to
hepatotoxicity as well as severe histopathological damage in the liver. These effects are particularly
pronounced in centrilobular and subcapsular areas and can be attenuated by suppression of CYP
activity. After 90 days, distinct histopathological changes and signiﬁcant increases in serum thyroid
hormones were seen in male rats even after a daily dose of 0.12 mg/kg bw, given 5 days a week. For
effects of this type, a NOAEL of 0.03 mg/kg bw per day for furan was derived by the authors. The
observations in B6C3F1 mice were not considered sufﬁcient by the CONTAM Panel for dose–response
analysis since they were not quantiﬁed (histopathology).
2- and 3-Methylfuran exerted toxicity in the liver, kidney and lung in rodents. After oral application
to rats, furan, 2-methylfuran and 3-methylfuran led to a similar overall picture of liver toxicity.
Although the studies on methylfurans are not sufﬁciently robust to identify a speciﬁc reference point
for the individual compounds, they show that the toxic potencies are in the same order of magnitude,
whether expressed as dose or molarity.
3.1.2.3. Long-term toxicity (including carcinogenicity)
There have been two long-term toxicity studies carried out under the NTP, one in 1993 and a
follow-up study in 2015. The ﬁndings of these studies are described below and the details are shown
in Tables 3–6. The ﬁrst NTP study was carried out on male and female Fischer 344/N rats and B6C3F1
mice. Furan was given by gavage in corn oil 5 days per week for 104 weeks. The doses in rats were 0,
2, 4 and 8 and in mice were 0, 8 and 15 mg/kg bw. There was clear evidence of carcinogenicity and
survival decreasing with increasing dose.
In the rat study, cholangiocarcinomas were found in both males and females at all doses of furan
(NTP, 1993). Hepatocellular carcinomas were observed at 4 and 8 mg/kg bw in the males but none
occurred in the female rats (Maronpot et al., 1991). Male rats developed hepatocellular adenomas at 4
and 8 mg/kg bw but these only occurred in the females at the highest dose (Maronpot et al., 1991).
When combined (hepatocellular adenoma/carcinoma), the results were signiﬁcant for males at the two
higher doses and for females at the highest dose only (Table 3). Mononuclear cell leukaemia was
observed in both males and females at the two higher doses. A high incidence of mesothelioma of the
tunica vaginalis (including in the control) was also reported.26 Overall, males are more sensitive than
female rats. Other non-malignant effects were observed as shown in Tables 3 and 6.
Histologically, it is difﬁcult to distinguish between cholangiocarcinoma and cholangioﬁbrosis and a
consensus report by Thoolen et al. (2010) provided clear guidelines for a standardised nomenclature
and differential diagnosis of microscopic lesions in the hepatobiliary system of commonly used
laboratory rodents. Samples (23 from 2 mg/kg bw and 6 from 8 mg/kg bw) from the NTP study
(1993) were re-examined following the guidelines described by Thoolen et al. (2010) and it is now
clear that cholangiocarcinomas were only observed at the highest dose (NCTR, 2015; Von Tungeln
et al., 2017) while cholangioﬁbrosis was observed at the lower doses.
As the ﬁrst study used exposure to furan that induced effects at all doses, a second study was
undertaken to determine the dose–response relationship in male rats using a signiﬁcantly lower dose
range, 0, 0.02, 0.044, 0.092, 0.2, 0.44, 0.92 and 2 mg/kg bw per day, 5 days per week for
104 weeks. Interim analyses were carried out at 36 and 60 weeks. The doses were chosen to ensure
a range of concentrations that would give a lower tumour incidence in order to establish the dose
response relationship. The group sizes in this study were not equal with higher numbers of animals in
the lower dose groups to maximise the chance of detecting tumours in these low exposed groups.
There was a dose-related decrease in survival but this did not reach signiﬁcance.
In the NCTR study, mononuclear cell leukaemia was observed in all groups, including the control.
There was a statistically signiﬁcant increase at doses of 0.092 mg/kg bw and above. However, the
incidence was within the historical control range for this endpoint and rat strain within the same
laboratory (NCTR, 2015). The Fischer 344 rat is known to develop a high incidence of mononuclear cell
leukaemia (Caldwell, 1999). This tumour type is unique to the rat and occurs in aged, untreated F-344
26 In the paper, this was noted as interstitial cell adenoma of testes but is in fact mesothelioma of the tunica vaginalis.
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rats at a high and variable rate. It is common only to the Fischer 344 strain. Signiﬁcant increases in C-
cell adenoma or carcinoma, and malignant mesothelioma of the tunica vaginalis were noted at the top
dose of 2 mg/kg bw. Bearing in mind the high spontaneous incidence of mesotheliomas, C-cell
adenoma and carcinoma and of the observed leukaemias in the Fischer 344 rat speciﬁcally the
relevance of these tumours to human risk assessment is questionable. There were no treatment-related
neoplastic changes at 36 or 60 weeks. There were no signiﬁcant increases in hepatocellular adenoma or
carcinoma observed in the NCTR study (Von Tungeln et al., 2017). The cholangiocarcinomas, observed
at the highest dose (8 mg/kg bw per day) in the NTP (1993) study after reclassiﬁcation, were not seen
in the NCTR study with dose levels up to 2 mg/kg bw per day (2015; Von Tungeln et al., 2017).
Of the non-neoplastic effects, the most sensitive endpoint was cholangioﬁbrosis with increases
observed from 0.2 mg/kg bw and above. The dose response was non-linear showing a low incidence
(1%) at 0.092 mg/kg bw and a high incidence (≥ 76%) from 0.2 mg/kg bw and above.
Cholangioﬁbrosis was also noted at 36 and 60 weeks with the severity increasing with time from
minimal (36 weeks) to minimal to mild (60 weeks). Other signiﬁcant changes observed were biliary
tract hyperplasia, cytoplasmic vacuolisation of oval cells and regenerative hypertrophy (Table 3).
Interim analyses at 36 and 60 weeks showed similar responses with the signiﬁcance at lower doses
increasing with the time (NCTR, 2015; Von Tungeln et al., 2017).
In a separate study, male rats were exposed to 30 mg/kg bw furan by gavage (n = 50) in corn oil
5 days per week for 13 weeks and then followed up for 9, 15 and 24 months (NTP, 1993).
Cholangiocarcinomas were observed in all rats at all time points. Hepatocellular carcinoma was ﬁrst
noted at 15 months.
In the equivalent mouse studies, both male and female mice developed hepatocellular adenomas
and adenomas/carcinomas at both doses tested (8 and 15 mg/kg bw; Table 4). Male mice also
showed hepatocellular carcinomas at both doses (Table 4; NTP, 1993). Carcinomas were only observed
in female mice at the higher dose. In a later study, female mice were treated by gavage with 0, 0.5,
1.0, 2.0, 4.0 and 8 mg/kg bw per day furan in corn oil 5 days per week for 104 weeks. Hepatocellular
adenomas were observed at the two highest doses and hepatocellular carcinomas only at 8 mg/kg bw.
The combined hepatocellular adenoma/carcinoma incidence was signiﬁcant at 4 and 8 mg/kg bw
(Moser et al., 2009).
Johansson et al. (1997) undertook a study in preweaning B6C3F1 mice to investigate the dose–
response relationship to furan over 95 weeks. In this study, they compared single (400 mg/kg bw on
post-natal day (PND) 15) vs multiple (6 doses of 200 mg/kg bw administered on PND 3, 6, 9, 12, 15
and 18) exposures to furan. The single exposure group showed an overall increase in multiplicity of
liver tumours but not in prevalence. Neither of these observations was signiﬁcant. In the multiple
dosed group, a statistically signiﬁcant increase in both multiplicity and prevalence of liver tumours was
noted. PCR analysis of the tumours revealed mutations on codon 61 of the Ha-ras1 gene in 82% of
the single dose group while only 32% of the multiple does group had the Ha-ras1 mutation. Their
ﬁndings conﬁrm the hepatocarcinogenicity of furan in mice and suggest that the dose of carcinogen
may inﬂuence the activation of Ha-ras1 that results in liver tumours.
Morton et al. (2002) used furan as an exemplar chemical to evaluate the Eker rat as a model for
short-term exposure to nephrotoxins and carcinogens. Rats were exposed to 8 mg/kg bw furan in olive
oil for 5 days/week for 4 or 6 months. Furan treatment did not result in any increase in the number or
incidence of preneoplastic or neoplastic lesions at all sites and at either time.
Høie et al. (2016) investigated the tumourigenic potential of 2,5-dimethylfuran administered orally
to the C57BL/6J-ApcMin/+ mouse (Min). The study included Min mouse and Min mouse expressing the
human sulfotransferase 1A1 and 1A2 (Min/hSULT mice). In untreated Min/hSULT mice, the
spontaneous tumours in the small intestine were smaller, but not fewer, compared to the Min mouse.
Colonic tumour incidence and tumour load were also decreased in the untreated Min/hSULT mice. Mice
were exposed to 5, 25 and 50 mg/kg bw by gavage in corn oil three times per week for 6 weeks (a
total of 18 doses), no consistent signiﬁcant changes in intestinal or colon tumours or in aberrant crypt
foci were seen in male or female Min mice exposed to 2,5-dimethylfuran. There was a signiﬁcant
increase in the incidence of colonic tumours in the female, but not the male, mice expressing hSULT at
the medium dose but this was not signiﬁcant at either the low or high doses. Exposure to 2,5-
dimethylfuran increased the tumour number in the middle to distal part of the small intestine and
colon, the area where the majority of the spontaneous tumours are found. These effects of 2,5-
dimethylfuran in Min/hSULT females were suggested to be due to the low background level of tumours
in the untreated females. There were no effects of 2,5-dimethylfuran in the Min mice. Overall the data
for the tumourigenicity of 2,5-dimethylfuran in metabolically competent mice were not convincing.
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In summary, most of the cholangiocarcinomas in rats reported in the NTP study were later
reclassiﬁed as cholangioﬁbrosis and only at the top dose of 8 mg/kg bw, cholangiocarcinomas were
conﬁrmed. In the NCTR study where a lower dose range was used, cholangioﬁbrosis was observed at
doses of 0.2 mg/kg bw and above and no neoplastic ﬁndings of relevance to human risk assessment
were observed. In the mouse studies, hepatocellular adenomas and carcinomas were observed. The
male rats and mice appear more sensitive to furan exposure for hepatocellular adenoma and
carcinoma development. In a short-term tumour model system, 2,5-dimethylfuran did not enhance
colorectal tumour formation.
Table 3: Incidence of neoplastic lesions and statistical analysis results derived from male and
female F344/N rats and male F344/N Nctr(e) rats from 2-year carcinogenicity assays with
furan
Lesion(a)
Dosage (mg/kg
bw per day)
Incidence(b)
Reference
Male Female
Cholangiocarcinoma
before re-evaluation(c)
0
2
4
8
0/50
43/50***
48/50***
49/50***
0/50
49/50***
50/50***
48/50***
NTP (1993),
Maronpot et al. (1991)
Hepatocellular
adenoma/carcinoma
0
2
4
8
1/50
5/50
22/50***
35/50***
0/50
2/50
4/50
8/50**
NTP (1993)
Interstitial cell adenoma
of testes(d)
0
2
4
8
41/50
36/50
39/50
43/50
NTP (1993)
Hepatocellular
carcinoma
0
2
4
8
0/50
1/50
6/50*
18/50***
0/50
0/50
0/50
1/50
Maronpot et al. (1991)
Hepatocellular adenoma 0
2
4
8
1/50
4/50
18/50***
27/50***
0/50
2/50
4/50
7/50**
Maronpot et al. (1991)
Mononuclear cell
leukaemia
0
2
4
8
8/50
11/50
17/50*
25/50***
8/50
9/50
17/50*
21/50**
NTP (1993)
Malignant
mesothelioma
0
2
4
8
1/50
1/50
3/50
3/50
– NTP (1993)
Mononuclear cell
leukaemia
0
0.02
0.044
0.092
0.2
0.44
0.92
2
47/150
56/150
36/100
44/100*
29/50***
18/50
27/50***
28/50***
– NCTR (2015)
Malignant
mesothelioma of the
tunica vaginalis
0
0.02
0.044
0.092
0.2
0.44
0.92
2
6/150
8/150
1/100
2/100
0/50
2/50
2/50
6/50*
– NCTR (2015)
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Lesion(a)
Dosage (mg/kg
bw per day)
Incidence(b)
Reference
Male Female
Follicular cell adenoma 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/150
2/150
5/99
0/100
1/50
1/49
0/50
0/50
– NCTR (2015)
C-cell adenoma 0
0.02
0.044
0.092
0.2
0.44
0.92
2
11/150
15/150
9/99
13/100
7/50
8/49
1/50
8/50*
– NCTR (2015)
C-cell adenoma or
carcinoma
0
0.02
0.044
0.092
0.2
0.44
0.92
2
12/150
21/150
11/99
14/100
8/50
9/49
1/50
9/50*
– NCTR (2015)
bw: body weight.
(a): Only the major tumour sites and/or those showing signiﬁcant effects at the lower dose are listed.
(b): *Equals signiﬁcant at > 0.05; **equals signiﬁcant at > 0.01; ***equals signiﬁcant at > 0.001.
(c): Re-examination of 23 of these samples at a later date revealed that only in the highest dose cholangiocarcinomas were
present.
(d): This was the terminology used in the paper, however, this is equivalent to mesotheliomas of the tunica vaginalis
(e): Von Tungeln et al. (2017) speciﬁed that the F344/N NCTR substrain differs from the Charles River substrain used in the
previous furan bioassay (NTP, 1993). However, the NCTR F344/N sub-strain has tumourigenic responses that are comparable
to those of other F344/N substrains used in previously reported carcinogenicity bioassays such as acrylamide.
Table 4: Tumour incidence and statistical analysis results derived from B6C3F1 mice from 2-year
carcinogenicity assays with furan
Tumour(a)
Dosage (mg/kg
bw per day)
Incidence(b)
Reference
Male Female
Hepatocellular adenoma 0
0.5
1.0
2.0
4.0
8.0
– 3/36
4/72
4/53
4/41
11/36*
25/39***
Moser et al. (2009)
Hepatocellular
carcinoma
0
0.5
1.0
2.0
4.0
8.0
– 0/36
4/72
2/53
1/41
2/36
11/39***
Moser et al. (2009)
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Tumour(a)
Dosage (mg/kg
bw per day)
Incidence(b)
Reference
Male Female
Hepatocellular adenoma
or carcinoma
0
0.5
1.0
2.0
4.0
8.0
– 3/36
8/72
6/53
5/41
12/36*
29/39***
Moser et al. (2009)
Hepatocellular
carcinoma
0
8
15
7/50
32/50***
34/50***
2/50
7/50
27/50***
NTP (1993)
Hepatocellular adenoma 0
8
15
20/50
33/50**
42/50***
5/50
31/50***
48/50***
NTP (1993)
Benign
Pheochromocytoma
0
8
15
1/49
6/50
10/50***
2/50
1/50
6/50
NTP (1993)
Hepatocellular
adenoma/carcinoma
0
8
15
26/50
44/50***
50/50***
7/50
34/50***
50/50***
NTP (1993)
bw: body weight.
(a): Only the major tumour sites and/or those showing signiﬁcant effects at the lower dose are listed.
(b): *Equals signiﬁcant at > 0.05; **equals signiﬁcant at > 0.01; ***equals signiﬁcant at > 0.001.
Table 5: Summary of non-neoplastic lesions in rats and mice taken from NTP (1993)
Lesion Dosage (mg/kg
bw per day)
Incidence(a)
Rats Male Female
Biliary tract cysts 0
2
4
8
0/50
44/50**
47/50**
49/50**
0/50
49/50**
50/50**
46/50**
Biliary tract ﬁbrosis, multifocal 0
2
4
8
0/50
44/50**
48/50**
49/50**
0/50
49/50**
50/50**
49/50**
Biliary tract hyperplasia 0
2
4
8
0/50
44/50**
48/50**
49/50**
0/50
49/50**
48/50**
49/50**
Biliary tract inﬂammation chronic multifocal 0
2
4
8
0/50
44/50**
48/50**
49/50**
0/50
49/50**
50/50**
49/50**
Biliary tract metaplasia 0
2
4
8
0/50
44/50***
48/50***
49/50***
0/50
49/50***
50/50***
49/50***
Hepatocyte cytomegaly 0
2
4
8
0/50
35/50**
46/50**
49/50**
0/50
44/50**
50/50**
49/50**
Hepatocyte degeneration 0
2
4
8
0/50
33/50**
46/50**
49/50**
0/50
35/50**
49/50**
47/50**
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Lesion Dosage (mg/kg
bw per day)
Incidence(a)
Rats Male Female
Hepatocyte hyperplasia, multifocal 0
2
4
8
0/50
33/50
46/50**
49/50**
0/50
32/50
47/50**
46/50**
Hepatocyte necrosis, multifocal 0
2
4
8
0/50
32/50**
46/50**
49/50**
0/50
18/50**
46/50**
47/50**
Hepatocyte vacuolisation, cytoplasmic 0
2
4
8
0/50
39/50**
45/50**
49/50**
0/50
43/50**
49/50**
47/50**
Kupffer cell pigmentation, multifocal 0
2
4
8
0/50
44/50**
48/50**
49/50**
0/50
49/50**
50/50**
48/50**
Mice
Multifocal hyperplasia liver 0
8
15
1/50
44/50**
49/50**
0/50
7/50
11/50
Biliary tract ﬁbrosis 0
8
15
0/50
45/50**
49/50**
0/50
47/50**
50/50**
Biliary tract hyperplasia 0
8
15
0/50
46/50**
49/50**
0/50
47/50**
50/50**
Biliary tract inﬂammation 0
8
15
0/50
44/50**
49/50**
2/50
48/50**
50/50**
Hepatocyte hepatomegaly 0
8
15
8/50
45/50**
50/50**
0/50
48/50**
50/50**
Hepatocyte degeneration 0
8
15
0/50
43/50**
43/50**
0/50
47/50**
48/50**
Hepatocyte necrosis 0
8
15
2/50
39/50**
41/50**
0/50
44/50**
47/50**
Kupffer cell pigmentation 0
8
15
2/50
43/50**
50/50**
5/50
48/50**
50/50**
bw: body weight.
(a): **equals signiﬁcant at > 0.01; ***equals signiﬁcant at > 0.001.
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Table 6: Summary of non-neoplastic lesions in male rats taken from NCTR (2015)
Lesion
Dosage (mg/kg
bw per day)
Incidence/time of assessment(a)
36 weeks 60 weeks 104 weeks
Cholangioﬁbrosis 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
0/20
6/20***
17/20***
19/20***
0/20
0/10
0/10
0/10
0/10
10/10***
10/10***
8/10***
0/149
0/150
0/99
1/100
38/50***
49/49***
47/50***
49/49***
Oval cell hyperplasia 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
0/20
0/20
1/20
16/20***
0/20
0/10
0/10
0/10
0/10
0/10
3/10*
7/10***
14/149
15/150
10/99
8/100
7/50
6/49
14/50***
33/49***
Mixed cell foci 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
1/20
0/20
1/20
5/20*
1/20
0/10
1/10
0/10
1/10
1/10
3/10
6/10**
7/149
7/150
6/99
3/100
5/50
3/49
6/50
13/49***
Biliary tract hyperplasia 0
0.02
0.044
0.092
0.2
0.44
0.92
2
1/20
1/20
0/20
1/20
0/20
0/20
6/20*
19/20***
7/20
3/10
1/10
2/10
1/10
2/10
3/10
8/10*
89/149
86/150
5,999
56/100
29/50
25/49
32/50
43/49***
Bile duct subcapsular
hyperplasia
0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
1/20
12/20***
19/20***
20/20***
0/20
0/10
0/10
0/10
1/10
9/10***
10/10***
7/10***
–
Hepatocyte hypertrophy 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
1/20
0/20
2/20
12/20***
0/20
0/10
0/10
0/10
0/10
5/10**
4/10**
8/10***
–
Periportal cytoplasmic alteration 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
0/20
0/20
7/20**
19/20***
0/20
0/10
0/10
1/10
0/10
1/10
7/10***
8/10***
–
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Lesion
Dosage (mg/kg
bw per day)
Incidence/time of assessment(a)
36 weeks 60 weeks 104 weeks
Subcapsular ﬁbrosis 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
3/20
14/20***
20/20***
20/20***
0/20
0/10
0/10
0/10
4/10**
9/10**
10/10**
7/10***
–
Subcapsular chronic inﬂammation 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
2/20
14/20***
20/20***
20/20***
0/20
0/10
0/10
0/10
8/10***
9/10**
10/10**
7/10***
–
Subcapsular pigmentation 0
0.02
0.044
0.092
0.2
0.44
0.92
2
0/20
0/20
0/20
0/20
2/20
14/20***
20/20***
20/20***
0/20
0/10
0/10
0/10
8/10***
9/10**
10/10**
7/10***
–
Basophilic foci 0
0.02
0.044
0.092
0.2
0.44
0.92
2
– – 28/149
16/150
19/99
18/100
11/50
13/49
10/50
21/49***
Regenerative hyperplasia 0
0.02
0.044
0.092
0.2
0.44
0.92
2
– – 0/149
1/150
1/99
2/100
1/50
1/49
7/50***
12/49***
Cytoplasmic vacuolisation 0
0.02
0.044
0.092
0.2
0.44
0.92
2
– – 23/149
23/150
14/99
19/100
12/50
18/49***
23/50***
37/49***
bw: body weight.
(a): *Equals signiﬁcant at > 0.05; **equals signiﬁcant at > 0.01; ***equals signiﬁcant at > 0.001.
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3.1.2.4. Genotoxicity
A. Furan
The genotoxicity of furan has been studied in bacteria, and mammalian cells in vitro, and in vivo.
The available studies are summarised below and further details are given in Table 7.
The CONTAM Panel noted that in vitro studies with furan are often hampered by the properties of
the compound. First, the high volatility of the furan exhibiting a boiling temperature of 31.4°C leads to
its rapid evaporation from the test vessels under open conditions. In closed systems that used to
prevent evaporation of furan, however, an equilibrium between the liquid and the gas phase is rapidly
achieved, thus markedly decreasing the initial concentration of furan in the liquid phase. Finally,
reducing the headspace in order to avoid this effect may cause a lack of oxygen which is required for
CYP-catalysed metabolic activation of furan. Thus, quantitative considerations based on in vitro
experiments with furan must be made with caution.
Bacteria
Furan did not induce gene mutations in S. Typhimurium strains TA100, TA1535, TA1537 and TA98
in the presence or absence of exogenous metabolic activation (S9) (Mortelmans et al., 1986; NTP,
1993). In another report, positive results were reported only in strain TA98 (but not in strain TA100) in
the presence of S9 (Shinohara et al., 1986). Finally, a weak positive effect was reported only in strain
TA100 both in the presence and absence of S9 fraction (Lee et al., 1994).
In vitro genotoxicity in mammalian cells
In vitro tests for genotoxicity in mammalian cells were generally positive. In the NTP study (1993),
furan induced triﬂuorothymidine resistance in mouse L5178Y lymphoma cells in the absence of S9
(McGregor et al., 1988), sister chromatid exchanges (SCEs) and chromosomal aberrations (CA) in
Chinese hamster ovary (CHO) cells, with and without S9 (NTP, 1993).
In another report, an increase in CA (chromatid breaks and chromatid exchanges) was observed in
CHO cells exposed to furan (up to 200 mM) only in the presence of S9 (Stich et al., 1981).
Furan induced SCEs in a modiﬁed V79 cell line that stably expressed human CYP2E1 and SULT1A1.
No information on the activity of CYP2E1 was reported. The increment in the number of SCEs was
small and showed no clear dose response, with only a marginal increase in the hCYP2E1-SULT1A1-
expressing cells in comparison to the parental cell line (Glatt et al., 2005).
In the presence or absence of metabolic activation, no signiﬁcant increase in the frequency of
micronuclei was observed in human lymphocytes derived from two non-smoking women (Durling
et al., 2007).
The genotoxicity of furan was also investigated in L5178Y tk+/- mouse lymphoma cells. Furan did
not induce mutations at the tk locus, micronuclei, and DNA strand breaks as measured by Comet
assays (Kellert et al., 2008a). The CONTAM Panel noted that all the assays were performed at furan
concentrations devoid of any cytotoxic effects.
In vivo studies
Furan did not induce sex-linked recessive lethal mutations in germ cells of male Drosophila
melanogaster when administered either by feeding or by injection (NTP, 1993; Foureman et al., 1994).
Furan did not induce unscheduled DNA synthesis (UDS) in hepatocytes isolated after single gavage
treatment of male F344 rats or male B6C3F1 mice (Wilson et al., 1992).
In male B6C3F1 mice, furan administered by i.p. induced CA but not SCEs in bone marrow cells.
The CONTAM Panel noted that the signiﬁcant increase in the frequency of CA was observed only at the
highest tested dose and required the use of an extended harvesting protocol to maximise the
detection of these effects (NTP, 1993).
Furan administered by i.p or subcutaneous injection to BALB/c and CBA mice did not induce
micronuclei in peripheral blood (a single sampling time of 42 h was used; Durling et al., 2007).
Furan was administered by gavage to Sprague–Dawley rats from 8 h up to 20 days and for 1, 2
and 3 months. Increased DNA 8-oxodeoxyguanosine levels as measured by immunoﬂuorescence were
observed in the liver. This increase was associated with inﬂammation in areas adjacent to, as well as
within, necrotic regions. Persistence of DNA oxidation was also observed in cholangioﬁbrotic lesions,
biliary epithelia, metaplastic ducts and hepatocytes in proximity of inﬂamed areas in animals sampled
at the end of 3-month treatment or after 1-month recovery (Hickling et al., 2010a).
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Furan induced micronuclei and double-strand breaks (DSBs) as measured by c-H2AX foci (a known
biomarker for DNA-strand breaks) in mitogen-stimulated splenocytes from B6C3F1 mice treated by
gavage for 4 weeks. Negative results were obtained in quiescent spleen lymphocytes. No induction of
single strand breaks (SSBs) or DNA crosslinks as measured by Comet assays were observed (Leopardi
et al., 2010). The CONTAM Panel noted that this study represents evidence of genotoxicity of orally
administered furan in mice. It also indicates that for primary DNA damage in the spleen to be
converted into frank DSBs and chromosomal damage requires DNA replication.
Furan-induced DNA damage was investigated in the liver of B6C3F1 mice following a 28-day
repeated exposure by gavage. No induction of DSBs (as measured by c-H2AX induction) or SSBs and
DNA crosslinks was observed in liver cells following the 28-day treatment. In contrast, an increase of
SSBs and DNA crosslinks, as measured by Comet assays, was observed in the liver of mice receiving a
single very high oral dose of 250 mg/kg bw. Increased expression of DNA repair genes following the
28-day treatment was also observed (Cordelli et al., 2010).
Following a 2 h administration by gavage of a single dose of [3,4-14C]-furan to F344 rats, a dose-
dependent increase of 14C was found by mass spectrometry in liver and kidney DNA, suggesting that
furan metabolites were able to bind covalently to DNA (Neuwirth et al., 2012). The number of DNA
adducts induced in the liver were 1.6 and 32.5 adducts/108 nucleotides at 0.1 and 2.0 mg/kg bw of
furan. However, individual DNA adducts could not be identiﬁed and it was demonstrated that these
adducts are not identical to those induced in chemical model systems by the reactive BDA metabolite.
Metabolic incorporation of furan into DNA bases during DNA synthesis occurred only to a minor extent.
In a parallel oral 28-day study, furan induced an increase in CA in proliferating splenocytes. No
increase in micronuclei, CA, SCEs or strand breaks by Comet assays were observed in bone marrow
and peripheral blood (Neuwirth et al., 2012). At 2 mg/kg bw, furan produced an increase in DNA
strand breaks in the liver as measured in the Comet assay. This occurred, however, after a 14-day
recovery period following a 28-day exposure (Neuwirth et al., 2012). The CONTAM Panel recognises
that this study provides some evidence of the ability of furan to covalently bind to DNA in vivo.
However, in view of the low number of furan-induced DNA adducts their biological signiﬁcance remains
to be clariﬁed. Finally, this study conﬁrms in splenocytes from furan-treated rats the previously
observed increase in chromosomal damage in proliferating mouse splenocytes (Leopardi et al., 2010).
DNA-protein crosslinks were studied by injecting furan into turkey eggs at 23 days of incubation.
Hepatocytes were prepared from the embryos 24 h later and analysed by alkaline Comet assays (tail
length and moment) for the presence of strand breaks and DNA protein crosslinks. Furan treatment
produced a reduction in DNA migration suggesting the formation of DNA crosslinks. Comet tail length
was increased following treatment with proteinase K indicating that these were due to DNA-protein
crosslinks (Jeffrey et al., 2012).
Furan administered to F344 rats by gavage for 4 days increased DNA strand breaks (as measured
by Comet assays) in the liver but not in the bone marrow (Ding et al., 2012). Maximal DNA damage
was observed 1 h after the last furan treatment and decreased with time (3, 6 and 8 h) to reach
control levels by 16 h. Comet assays were performed also in the presence of Fpg and EndoIII
(enzymes involved in the repair of oxidised bases). In both cases, the number of SSBs increased (in
the range 12–16 and 4–16 mg/kg bw for Fpg and EndoIII, respectively) indicating the presence of
oxidised purines and pyrimidines. No induction of micronuclei was observed in the peripheral blood
(although signs of toxicity were present in the bone marrow). The CONTAM Panel noted that furan-
induced DNA strand breaks, identiﬁed by Comet assays, in the liver show a relatively short half-life.
The potential of furan to produce systemic genotoxicity was evaluated by treating female Big Blue
transgenic F344 rats by gavage for 1 and 8 weeks (ﬁve times a week) with doses of furan used in the
cancer bioassay (2 and 8 mg/kg bw) and two higher doses (16 and 30 mg/kg bw). No increases of
micronuclei in peripheral blood, Hprt mutations in lymphocytes, Pig-A mutations in spleen lymphocytes
and peripheral red blood cells, and transgene cII mutations in the liver were observed. In line with the
Ding et al. (2012) study, liver DNA damage as measured by Comet assay was increased at the two
highest doses (McDaniel et al., 2012).
Furan was administered to female Big Blue cII transgenic B6C3F1 mice by gavage either for 6 weeks
with 5 daily doses or for 3 weeks with a single weekly dose (15 mg/kg bw). Furan did not increase
mutation frequency under either treatment regimen. However, in the 6-week protocol, there was a
change in the liver cII mutational spectrum (a signiﬁcant reduction in GC>AT transitions and an increase
in CG>GC transversions). A much larger furan-dependent shift in mutational spectra was observed in
the liver of mice receiving three weekly doses of furan (a signiﬁcant increase in transversions including
GC>TA, GC>CG and AT>TA). The mutagenic potential of BDA in the same target gene was also
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investigated by in vitro treatment of mouse embryo ﬁbroblasts derived from this transgenic mouse
strain. Again, no increase in mutation frequency was observed, but BDA treatment induced a shift in
mutational spectrum with a signiﬁcant increase in AT>CG transversions (Terrell et al., 2014).
Gpt and Spi- mutations were measured in the liver of gpt delta rats treated with furan at doses of 2
and 8 mg/kg bw for 13 weeks. No increase in mutation frequencies was observed and mutational
spectra did not identify furan-speciﬁc gpt mutations. In the high dose group, the number and areas of
glutathione S-transferase placental form (GST-P)-positive foci, the number of PCNA-positive
hepatocytes and the mRNA levels of cyclin d1 and cyclin e1 were increased. Cholangioﬁbrosis was only
observed in the caudate lobe. The authors conclude that cell proliferation, but not genotoxic
mechanisms, contribute to the early stages of furan-induced hepatocarcinogenesis (Hibi et al., 2017).
Analysis of liver neoplasms (hepatocellular adenomas/carcinomas) induced by furan in B6C3F1 mice
(from the NTP 1993 study) showed the presence of dominant transforming oncogenes (13/29, 45%).
Activating Ha-ras mutations were found both in codon 61 and in codon 117, the majority being GC>TA
transversions. The authors concluded that the spectrum of furan-induced mutations in the Ha-ras
oncogene differs from that of untreated animals, mostly because the localisation of mutations in
untreated animals occurs only at codon 61 (Reynolds et al., 1987).
The presence of Ha-ras mutations was also analysed in DNA from liver tumours induced in
preweaning B6C3F1 mice administered a single or multiple (6x) doses of furan. Mutations in codon 61
of the Ha-ras gene were present in 82% of liver neoplasms (adenoma + carcinoma) occurring in mice
treated with a single dose, while in the concomitant controls these occurred in 33% of the animals and
in the historical ones in 54% of the animals. In contrast, in mice treated with multiple doses only 32%
of the tumours had codon 61 Ha-ras1 mutations. The majority of mutations associated with furan
exposure in codon 61 were G>T transversions (74%) followed by A>G transitions (22%). A single G>T
transversion in codon 117 was also identiﬁed in an adenoma induced by this multiple treatment. In
historical controls, the majority of codon 61 Ha-ras1 mutations were transversions followed by
transitions (58% and 30%, respectively) (Johansson et al., 1997).
To verify whether furan treatment caused an early expansion of pre-existing spontaneous Ha-ras
mutations, allele-speciﬁc competitive blocker polymerase chain reaction (ACB-PCR) was used to
quantify CAA>CTA and CAA>AAA mutations in codon 61 of the Ha-ras gene. Mutation analyses were
performed in liver DNA from female B6C3F1 mice treated by gavage with furan over a 3-week period.
No difference in mutation frequencies at codon 61 was identiﬁed between controls and furan-treated
groups (Banda et al., 2013). The CONTAM Panel noted the limitations of the study including the low
sensitivity of the technique.
Treatment of Sprague–Dawley rats by gavage with furan for 30 days resulted in large increases
(10-fold) in serum levels of 8-oxodeoxyguanosine as measured by enzyme-linked immunosorbent
assay (ELISA) (Alam et al., 2017).
Treatment (i.p.) of BALB/c mice with furan for 7 days resulted in increased serum levels of reactive
oxygen species (ROS) and 8-oxodeoxyguanosine as measured by ELISA (Wang et al., 2014a).
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Table 7: Genotoxicity of furan
Test system Cells/animals
Concentration/
treatment
Result Comments Reference
In vitro (bacteria)
Bacterial reverse
mutation assay (Ames
test)
S. Typhimurium TA98,
TA100, TA1535, TA1537
33–10,000 lg/plate Negative Aroclor 1,254-induced male Sprague–
Dawley rat and Syrian hamster liver S9
NTP (1993);
Mortelmans et al. (1986)
Ames test S. Typhimurium TA98,
TA100
56–225,000 lg/plate
+/ S9
Positive: only in TA98
(+S9)
Positive only at the lowest dose in TA98
Clear effect only + S9
Shinohara et al. (1986)
Ames test S. Typhimurium TA98,
TA100
54, 272, 1,361,
6,807 lg/ plate
Positive: only in
TA100 (+/ S9)
Weak effects Lee et al. (1994)
In vitro (mammalian cells)
Forward mutation
assay
L5178Y tk+/tk mouse
lymphoma cell line
125–3,800 lg/mL (S9) Positive:
≥ 1,139 lg/mL
Relative total growth was about 77%
Not tested: + S9
McGregor et al. (1988)
SCEs CHO cells 1.6, 5, 16, 50, 160,
500 lg/mL
Positive –S9:
1.6–160 lg/mL
+S9: only at
500 lg/mL
S9 from Aroclor 1,254-induced Sprague–
Dawley rat liver
NTP (1993)
CA CHO cells 100, 160, 300, 500,
1,000 lg/mL
Positive S9:
100–500 lg/mL
+S9: ≥ 500 lg/mL
S9 from Aroclor 1,254-induced Sprague–
Dawley rat liver
NTP (1993)
CA CHO cells 3 h exposures, up to
13,614 lg/mL +/ S9
from Aroclor 1,254-
induced rat liver
Positive: Chromatid
breaks and chromatid
exchanges only in the
presence of S9
No information on toxicity Stich et al. (1981)
SCEs V79-Mz-hCYP2E1-SULT1
cell line
0.2–1,089 lg/mL Positive: both V79-
hCYP2E1-SULT1 and
parental V79-Mz cell
line
Unusual constant increase over the
whole dose range. Marginal increase in
comparison to the parental V79-Mz cell
line
Glatt et al. (2005)
Micronucleus assay Lymphocytes from two
non-smoking women
136, 340, 511, 681,
1021, 1,361, 6,807
lg/mL +/ rat liver
homogenate.
Negative Aroclor 1,254-induced rat liver might
contain low CYP2E1 activity. Cytotoxicity:
1,361 and 6,807 lg/mL
Durling et al. (2007)
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Test system Cells/animals
Concentration/
treatment
Result Comments Reference
Micronucleus assay,
tk+/tk mutation assay
and DNA breaks by
Comet assays
L5178Y tk+/tk mouse
lymphoma cell line
15–211 lg/mL (~ 225–
3,100 lM)
Negative Only assayed in the absence of S9. No
cytotoxicity was observed at any of the
tested doses
Kellert et al. (2008a)
In vivo
Sex-linked recessive
lethal assay
Drosophila
melanogaster
Feeding (10,000 mg/kg)
and injection (25,000
mg/kg)
Negative – NTP (1993), Foureman et al.
(1994)
Unscheduled DNA
synthesis in
hepatocytes
Hepatocytes from furan-
treated male F344 rats
or B6C3F1 mice
Single gavage treatment:
5, 30, 100 mg/kg bw
(rats) and 10, 50, 100,
200 mg/kg bw (mice)
Negative – Wilson et al. (1992)
SCEs in bone marrow Male B6C3F1 mice i.p.: 87.5, 175, 350 mg/kg
bw (23 h sampling) and
25, 50,100 mg/kg bw
(42 h sampling)
Negative – NTP (1993)
CA in bone marrow Male B6C3F1 mice i.p.: 87.5, 175, 350 mg/kg
bw (17 h harvest); 62.5,
125, 250 mg/kg bw (36 h
harvest)
Positive: only at
250 mg/kg furan with
36 h sampling time (2
experiments)
– NTP (1993)
Micronucleus assay in
peripheral erythrocytes
(ﬂow cytometer-based)
BALB/c and CBA mice BALB/c mice: i.p. (0, 50,
75, 90, 110, 125, 150,
175, 200, 250, 300 mg/
kg bw) and s.c. (0, 150
and 275 mg/kg bw)
CBA mice: i.p. (0 and
225 mg/kg bw)
Negative No signiﬁcant depression of cell
proliferation in any of the experiments.
A single sampling time (42 h) was used
Durling et al. (2007)
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Test system Cells/animals
Concentration/
treatment
Result Comments Reference
Measurements of DNA
8-oxodeoxyguanosine
in liver by immune
ﬂuorescence
Sprague–Dawley rats Gavage (30 mg/kg bw
per day, 5 daily doses per
week). Time points: 1, 3,
7, 10, 12, 20 days and 1,
2 and 3 months
In addition, a 3-month
treatment + 1-month off
was included
Positive: Increased
DNA 8-
oxodeoxyguanosine
levels in areas of
centrilobular necrosis.
Persistence of DNA
oxidation after
recovery time in areas
affected by
cholangioﬁbrosis
– Hickling et al. (2010a)
Micronuclei, SSBs and
DNA cross-links by
Comet assays, DSBs
by c-H2AX foci in the
spleen.
B6C3F1 mice Gavage for 4 weeks with
2, 4, 8 and 15 mg/kg bw
per day
Positive: micronuclei
in mitogen-stimulated
splenocytes (4–15
mg/kg)
Positive: c-H2AX foci
(8 and 15 mg/kg)
Negative: Comet
assays
All assays gave negative results in
quiescent spleen lymphocytes
Leopardi et al. (2010)
DSBs by c-H2AX foci;
SSBs and DNA
crosslinks by Comet
assays in the liver.
B6C3F1 mice Gavage for 28 days (2, 4,
8, 15 mg/kg bw per day,
5 days per week)
Single oral dose (15, 100,
250 mg/kg bw)
Negative: c-H2AX
foci and Comet assays
(28-day exposure)
Positive: DNA breaks
and crosslinks (acute
exposure at 250
mg/kg bw)
28-day exposure: Increased polyploidy in
liver cells
Increased expression of several DNA
repair genes
Cordelli et al. (2010)
DNA adducts,
micronuclei, CAs, SCEs
and SSBs and DNA
crosslinks by Comet
assays
F344 rats Adducts determination:
[3,4 14C]-furan (0.1 and
2 mg/kg bw) for 2 h by
gavage. Genotoxicity:
Oral administration of 0.1,
0.5 and 2 mg/kg bw per
day for 5 and 28 days
Positive: some
evidence of DNA
adducts in the liver
and kidney
Positive: CAs in
proliferating
splenocytes
Negative:
micronuclei, CAs, SCEs
and Comet assays in
bone marrow and
peripheral blood
DNA adducts apparent in 14 C-furan
treated rats are not the same of those
induced by BDA (MS peaks are not
identical). Some indication of DNA
damage in the liver by Comet assay (a
reduction of tail moment and tail
intensity after 28 days of furan
treatment and increased DNA strand
breaks after two weeks recovery)
Neuwirth et al. (2012)
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Test system Cells/animals
Concentration/
treatment
Result Comments Reference
DNA-protein crosslinks
by Comet assays
Turkey eggs Furan injection in eggs at
23 days incubation (136–
1,360 lg). Hepatocytes
preparation 24 h later
Positive: Formation
of DNA protein
crosslinks
– Jeffrey et al. (2012)
Micronucleus and
Comet assay +/-Fpg
and EndoIII in liver
and bone marrow.
F344 rats Gavage for 4 days (2, 4,
8, 12, 16 mg/kg bw per
day)
Positive: Comet
assays in the liver (8–
16 mg/kg bw per day)
Negative: Comet
assays in the bone
marrow and
micronuclei in
peripheral blood
Increased proliferation in the liver. Up-
and down-regulation of several DNA
repair, apoptotic and cell cycle genes
Ding et al. (2012)
Micronuclei in
normochromatic
erythrocytes and
reticulocytes, mutation
assays at Pig-A and
Hprt, liver cII
transgene mutation
assay, liver Comet
assay.
Transgenic Big Blue rats Gavage for 1 and
8 weeks (2, 8, 16,
30 mg/kg bw per day;
5 days per week) and
sampling time 24 h after
the end of the treatment
Positive: Comet
assay in the liver (16
and 30 mg/kg bw per
day)
Negative: micronuclei
and mutation assays
Measurements of mutations at Hprt,
Pig-A and cII transgene and micronuclei
were performed after 1 or 8 weeks of
treatment
McDaniel et al. (2012)
Mutations in the cII
transgene in the liver
Transgenic Big Blue
B6C3F1 mice
Gavage for 6 weeks
(15 mg/kg bw per day;
5 days per week, 24 h
sampling time) and for
3 weeks (once weekly,
1 week sampling time)
Negative: no increase
in mutation frequency
under either treatment
condition
Positive: changes in
mutational spectra
Small increase in GC>CG transversions
(6-week treatment); a larger shift with
increases in GC>TA, GC>CG, AT>TA
transversions in the 3-week protocol
Terrell et al. (2014)
Mutations in the gpt
transgene and Spi- in
the liver
Transgenic gpt F344
male and female rats
Gavage for 13 weeks (0,
2, 8 mg/kg bw per day)
Negative: no increase
in mutation
frequencies. No
changes in mutational
spectra at the gpt
gene
Increased number of GST-P foci, PCNA+
hepatocytes and cyclin d1 and cyclin e1
at 8 mg/kg bw per day. Cholangioﬁbrosis
observed in the caudate lobe
Hibi et al. (2017)
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Test system Cells/animals
Concentration/
treatment
Result Comments Reference
Analysis of Ha-ras
mutations
Liver of furan-treated
B6C3F1 mice
Samples from NTP study
(1993)
Positive: 9 Ha-ras
mutations: 4/5 GC>TA
transversions at codon
61 and 2 GC>CG + 2
GC>TA transversions
at codon 117
The localisation of Ha-ras mutations in
furan-treated livers differs from that of
untreated animals (100% vs 60%
mutations at codon 61 in untreated and
furan-treated animals, respectively).
Reynolds et al. (1987)
Analysis of Ha-ras
mutations
Liver tumours induced
in infant B6C3F1 mice
(adenomas +
carcinomas)
Treatment in preweaning
mice (day 15): i.p. 400
mg/kg bw (single dose)
or 6 doses of 200 mg/kg
bw (at day 15).
Positive: only in
single dose exp: codon
61 mutations were
23/28 (82%) (vs 1/3
(33%) in parallel
controls) (mostly C>A
transversions)
Statistically signiﬁcant increased
incidence and multiplicity of
hepatocellular neoplasms in the multiple
treatment group and only increased
multiplicity in the single dose group
Johansson et al. (1997)
Analysis of Ha-ras
mutations by ACB-PCR
Liver of furan-treated
B6C3F1 mice
Gavage: 0, 1, 2, 4 and 8
mg/kg bw per day (5
days per week) over a 3-
week period
Negative: No
increase in mutations
frequency at codon 61
(CAA>AAA and
CAA>CTA)
Relatively insensitive assay Banda et al. (2013)
DNA adduct formation
(BDA-dC adduct)
Serum and liver of
furan-treated Fischer
344 rats
Gavage: 0.92–9.2 mg/kg
bw (single dose) and 4.4
mg/kg bw per day
(multiple doses, 45–360
days)
Negative: No
increase over
background levels
Background levels in untreated rats:
1.2–2.4 adducts 9108 nucleotides
Churchwell et al. (2015)
8-Oxodeoxyguanosine Serum of furan-treated
Sprague–Dawley rats
Gavage. 16 mg/kg bw per
day over 30 days
Positive: large
increases in 8-
oxodeoxyguanosine
levels
Method: ELISA kit Alam et al. (2017)
ROS and 8-
oxodeoxyguanosine
Serum of furan-treated
BALB/c mice
i.p. 8 mg/kg bw per day
over 7 days
Positive: increased
ROS levels; threefold
increase in 8-
oxodeoxyguanosine
Method: ELISA kit Wang et al. (2014a)
A: adenosine; ACB-PCR: Allele-speciﬁc competitive blocker-polymerase chain reaction; BDA: cis-but-2-ene-1,4-dialdehyde; bw: body weight; C: cytidine; CA: chromosomal aberrations;
CHO: Chinese hamster ovary; dC: 2’-deoxycytidine; DSB: double strand break; ELISA: enzyme-linked immunosorbent assay; G: guanosine; i.p.: intraperitoneal; ROS: reactive oxygen species;
s.c.: subcutaneous; SCE: sister chromatid exchange; SSB: single strand break; T: thymidine.
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B. cis-2-Butene-1,4-dial (BDA)
The genotoxicity of BDA has been studied in bacteria and mammalian cells in vitro and the
available studies are summarised below and further details are given in Table 8. The reactivity of BDA
with DNA is discussed in Section 3.1.1.4.
In the absence of exogenous metabolic activation, BDA induced a dose-dependent increase of
mutations in S. Typhimurium TA104. Pre-incubation of BDA with GSH inhibited the toxic and mutagenic
effects of the compound. In contrast, BDA was not mutagenic in S. Typhimurium strains TA97, TA98,
TA100 and TA102 (Peterson et al., 2000).
dC and dA adducts were detected in calf thymus DNA treated in vitro with BDA. These adducts
were also present in DNA isolated from S. Typhimurium strain TA104 treated with BDA (Byrns et al.,
2006).
The DNA damaging capacity of BDA was investigated by alkaline elution in CHO-K1 cells. Both SSBs
and DNA crosslinks were observed at non-toxic doses (Marinari et al., 1984). The ability to form DNA-
protein crosslinks observed in CHO cells was not conﬁrmed by Kellert et al. (2008a) in a Comet assay.
Genotoxicity of BDA was investigated in L5178Y tk+/ mouse lymphoma cells. A concentration-
dependent increase in mutation frequency at the tk locus and in the number of DNA breaks as
measured by Comet assays was observed. No concentration related increases were observed for
micronuclei (Kellert et al., 2008a).
No increase in mutation frequency at the cII locus was observed in BDA-treated mouse embryo
ﬁbroblasts derived from Big Blue B6C3F1 mice. However, BDA treatment induced a shift in mutational
spectrum with a concentration-dependent increase in AT > CG transversions only (Terrell et al., 2014).
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Table 8: Genotoxicity of cis-2-Butene-1,4-dial (BDA) in vitro
Test system Experimental system
Concentration/
treatment
Result Comments Reference
Formation of ICLs In situ oxidation of furan
containing oligonucleotide
Positive: formation of DNA
interstrand cross-link in duplex
oligonucleotides
– Halila et al. (2005)
Formation of dC and dA
adducts
Calf thymus DNA and DNA
from BDA-treated
S. Typhimurium TA104
Positive: formation of DNA
adducts in both systems
– Byrns et al. (2006)
Bacterial reverse mutation
assay (Ames test)
S. Typhimurium TA104 118, 143, 177, 244,
362 lg/plate
Positive Toxic at doses
> 177 lg/plate
BDA mutagenic
potential revealed in a
speciﬁc strain sensitive
to aldehydes
Peterson et al. (2000)
SSBs and crosslinks by
alkaline elution
CHO-K1 14, 42, 126 lg/mL Positive: both end-points High concentrations
(in the mM range) but
no apparent toxicity
Marinari et al. (1984)
Forward mutation
Comet and micronucleus
assays
L5178Y tk+/ mouse
lymphoma cells
0.5, 1.1, 2.1,
4.2 lg/mL
Positive: Comet and mutation
(at ≥ 70% survival)
Negative: micronucleus assays
and crosslinks
– Kellert et al. (2008a)
Mutation induction at the cII
transgene
In vitro treatment of mouse
embryo ﬁbroblasts from Big
Blue B6C3F1 mice
0.2 and 0.4 lg/mL Negative: no increase in mutation
frequency
Positive::change in mutational
spectrum
Increase in AT > CG
transversions
Terrell et al. (2014)
BDA: cis-but-2-ene-1,4-dialdehyde; CHO: Chinese hamster ovary; dA: 2’-deoxyadenosine; dC: 2’-deoxycytidine; dG: 2’-deoxyguanosine; SSB: single strand break; ICL: inter-strand crosslink.
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C. 2-Methylfuran
The genotoxicity of 2-methylfuran has been studied in bacteria and mammalian cells in vitro and
the available studies are summarised below and further details are given in Table 9.
2-Methylfuran was negative for induction of gene mutations in S. Typhimurium strains TA100,
TA102 and TA98 in the presence or absence of exogenous metabolic activation. A pre-incubation assay
in closed vials was used to prevent the loss of 2-methylfuran (Aeschbacher et al., 1989). Negative
results were also reported by Shinohara et al. (1986) in strains TA100 and TA98 and by Zeiger et al.
(1992) in strains TA100, TA98, TA97 and TA1535. Equivocal results were reported for strain TA104
(Zeiger et al., 1992).
CHO cells exposed to 2-methylfuran showed an increased number of CA (chromatid breaks and
chromatid exchanges) in the absence of S9 (Stich et al., 1981). The CONTAM Panel noticed the lack of
requirement of metabolic activation of 2-methylfuran clastogenicity which is remarkable because of the
lack of chemical reactivity of unmetabolised 2-methylfuran.
D. 2,5-Dimethylfuran
The genotoxicity of 2,5-dimethylfuran has been studied in bacteria, mammalian cells in vitro, and
in vivo. The available studies are summarised below and further details are given in Table 9.
2,5-Dimethylfuran was negative for induction of gene mutations in S. Typhimurium strains TA100,
TA1535, TA97 and TA98 in the presence or absence of exogenous metabolic activation. A
pre-incubation assay in closed vials was used to prevent the loss of 2,5-dimethylfuran (Zeiger et al.,
1992). These negative results were conﬁrmed in another study with S. Typhimurium strains TA100 and
TA98 (Shinohara et al., 1986).
CHO cells exposed to 2,5-dimethylfuran (up to 1,922 lg/mL) showed an increased number of CA
(chromatid breaks and chromatid exchanges). The clastogenic activity was signiﬁcantly decreased in
the presence of S9 (Stich et al., 1981). The CONTAM Panel noticed that, similarly to 2-methylfuran,
2,5-dimethylfuran clastogenicity does not seem to require S9-mediated metabolic activation.
The ability of 2,5-dimethylfuran to induce micronuclei was investigated in in vitro cultures of murine
erythropoietic cells. Exposure to 2,5-dimethylfuran induced an increase in micronuclei frequency both
in the absence and presence of S9 (Fromowitz et al., 2012).
2,5-Dimethylfuran induced a concentration-dependent increase in DNA breaks as measured by
Comet assays in V79 cells, irrespective of the co-expression in these cells of the human CYP2E1 and
SULT1A1 sulfotransferase (Huffman et al., 2016).
A single oral dose of 2,5-dimethylfuran was administered by gavage to wild-type and FVBN mice
expressing the human SULT1A1/A2 (hSULT mice). Induction of DNA damage was evaluated in vivo by
alkaline single cell gel electrophoresis (Comet assays) 2 h after the end of treatment. No genotoxicity
is associated with 2,5-dimethylfuran exposure of wild-type mice, while increased levels of DNA damage
were observed in the kidney and colon, but not in the liver, of 2,5-dimethylfuran treated hSULT mice.
These increases were modest and occurred at a single 2,5-dimethylfuran dose (150 mg/kg bw). No
evidence of interstrand crosslinks formation was observed (Høie et al., 2015). The authors anticipated
that 2,5-dimethylfuran can be hydroxylated at the methyl groups and subsequently conjugated with
sulfate involving SULT1A1 which may lead to genotoxic breakdown products.
2,5-Dimethylfuran has been shown to act as a scavenger of singlet oxygen (Noguchi et al., 1977;
Mongin et al., 2016) and hydroxyl radicals (Okada and Okajima, 1998). In a limited in vitro study, DNA
adducts induced by benzo [A] pyrene were decreased in the presence of 2,5 dimethylfuran used as
scavenger of singlet oxygen (Bryla and Weyand, 1991). The CONTAM Panel noted that the possible
role of 2,5-dimethylfuran as a scavenger of singlet oxygen in vivo remains to be determined.
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Table 9: Genotoxicity of 2-methylfuran and, 2,5-dimethylfuran
Compound Test system Cells/animals
Concentration/
treatment
Result Comments Reference
2-Methylfuran Bacterial reverse
mutation assay
(Ames test)
S. Typhimurium TA98,
TA100, TA102
0.9–90,000 lg
(+/S9)
Negative Use of a pre-incubation assay to
maximise the reaction of volatile
compounds with bacteria
Pre-incubation assay
Aeschbacher et al. (1989)
2-Methylfuran Ames test S. Typhimurium TA98,
TA100, TA1535, TA102
TA104
33–6,666 lg/plate
(+/S9)
Negative: TA98,
TA100, TA1535,
TA102
Questionable response in strain
TA104
Pre-incubation assay
Zeiger et al. (1992)
2-Methylfuran Ames test S. Typhimurium TA98,
TA100
14–55 lg (+/S9) Negative – Shinohara et al. (1986)
2-Methylfuran Chromosome
aberrations
CHO cells 4,105–12,315 lg/mL Positive (+/S9): Increased chromatid breaks and
chromatid exchanges. Decreased
clastogenicity in the presence of
S9. No information on toxicity
Stich et al. (1981)
2,5-Dimethylfuran Ames test S. Typhimurium TA97,
TA98, TA100, TA1535
10–3,333 lg/plate
(+/S9)
Negative Pre-incubation assay Zeiger et al. (1992)
2,5-Methylfuran Ames test S. Typhimurium TA98,
TA100,
16–64 lg (+/S9) Negative – Shinohara et al. (1986)
2,5-Dimethylfuran Chromosome
aberrations
CHO cells 2,5-Dimethylfuran
(up to 1,922 lg/mL)
Positive (+/S9): Increased chromatid breaks and
chromatid exchanges. Decreased
clastogenicity in the presence of
S9. No information on toxicity
Stich et al. (1981)
2,5-Dimethylfuran In vitro
micronucleus
assay
BM cells prepared from
C57BL/6J mice
48 and 96 lg/mL (1 h
exposure)
Positive (+/S9) Same increase in micronuclei both
in the absence and presence of S9
Fromowitz et al. (2012)
2,5-Dimethylfuran Single strand
breaks by Comet
assays
Wild-type and human
hSULT /CYP2E1-co-
expressing V79 cells
48, 96, 144 and
192 lg/mL (30 min
exposure)
Positive: both
wild-type and
hSULT/CYP2E1-co-
expressing V79
Increase in breaks at > 50%
survival
Huffman et al. (2016)
2,5-Dimethylfuran Comet assays in
kidney, colon
and liver
hSULT and wild-type
FVBN mice
Gavage: 75, 150,
300 mg/kg bw
Negative: wild-
type mice
Positive: hSULT
mice
Positive at a single dose in kidney
and colon but not in the liver
No evidence of interstrand
crosslinks formation
Høie et al. (2015)
CHO: Chinese hamster ovary.
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Summary of genotoxicity studies on furan and methylated derivatives.
Furan was unable to induce gene mutations in bacteria (with the exception of a single report
showing a weak mutagenic effect). When furan genotoxic potential was investigated in mammalian
cells in vitro, both negative and positive results were reported. In the majority of the studies, furan
was able to induce chromosomal aberrations and sister chromatid exchanges. However, the role of
metabolic activation in these studies is unclear, with one study showing positive results only in the
presence of S9 and several others where furan genotoxicity was decreased by the presence of S9. In
view of the volatility, quantitative considerations based on in vitro experiments with furan must be
made with caution.
The primary microsomal metabolite of furan, via CYP2E1, is BDA. This can form DNA adducts at the
exocyclic N atom of the dC, dG and dA nucleosides. In vitro studies indicate that BDA-induced adducts
on dG and dA are unstable, with the initial ethano adduct decomposing into substituted etheno-
acetaldehyde adducts. These secondary adducts retain a reactive aldehyde with the potential to form
DNA inter-strand crosslinks (ICLs). BDA is directly mutagenic in S. Typhimurium TA104, in which BDA-
induced DNA adducts were also identiﬁed. It also induces strand breaks and mutations in mammalian
cells in vitro. One in vitro study suggests that BDA can induce ICLs in mammalian cells.
In vivo studies suggested that furan was able to bind covalently to DNA in the liver and kidney of
repeatedly exposed rats. Although in one study a speciﬁc DNA adduct was not detected, in a separate
study DNA adducts were detected but their molecular nature was not identiﬁed. It was demonstrated
that these adducts are not identical to those induced in chemical model systems by the reactive BDA
metabolite. In addition, in view of the low number of furan-induced DNA adducts their biological
signiﬁcance remains to be clariﬁed.
In several in vivo studies, no increase in chromosomal damage was observed either in the bone
marrow or in peripheral blood of mice and rats exposed to furan. The single exception was the NTP
study (1993) in which a dose-related increase in chromosome aberrations in the bone marrow was
found in mice following an acute treatment with unusually high doses of furan.
In rodent liver, the genotoxic potential of furan was mainly investigated by measuring strand breaks
by Comet assays. This assay measures strand breaks and alkali-labile sites, including apurinic/
apyrimidinic (AP) sites, which might arise from the loss of a damaged base or as intermediates during
base excision repair. In general, negative results have been reported. Two studies showed that DNA
breaks/AP sites induced by repeated exposure to furan appear rapidly and disappear within a few hours
post-treatment. This observation might explain the negative results observed in several studies in which
liver cells were analysed at late time points post-treatment. Thus, observations based on Comet assays at
late post-treatment times are likely to be of limited relevance. The CONTAM Panel recognises that
disappearance of strand breaks measured by the Comet assay does not necessarily indicate error-free,
non-mutagenic DNA repair.
Evidence of chromosomal damage (micronuclei, chromosome aberrations and DSBs) was observed
in proliferating, but not in resting, splenocytes of mice and rats repeatedly exposed to furan at the
same doses used in the NTP carcinogenicity assay reported in 1993. These data indicate that cell
proliferation is required to convert the primary furan-induced DNA damage to detectable DNA lesions.
This premutagenic DNA damage could be due to ICLs that require replication to be converted into
frank lesions or secondary events associated with oxidative stress-induced DNA damage.
Studies investigating the formation of ICLs following in vivo furan exposure were generally negative.
Limited evidence comes from Comet assays in the liver of mice exposed to unusual high furan doses. DNA-
protein crosslinks were induced in hepatocytes from embryos following furan injection in turkey eggs.
It is possible that some of the genotoxic effects of furan are secondary to oxidative stress caused
by repeated furan administration. Increased levels of ROS and 8-oxodeoxyguanosine were indeed
observed in sera of furan-treated rats and mice. The sensitivity of DNA from the liver of treated
animals to digestion by EndoIII and Fpg, enzymes that, respectively, act on oxidised purines and
pyrimidines, conﬁrms the presence of oxidatively damaged DNA after relatively short exposures to
furan. Finally, DNA 8-oxodeoxyguanosine persists in areas of furan-induced rat cholangioﬁbrosis long
after furan exposure had been discontinued.
However, furan-induced oxidative stress is not associated with a clear induction of base substitutions
in transgenic models. Furan is weakly mutagenic in the liver of a mouse transgenic model, with the
mutational spectrum differing from that induced by BDA in cultured mouse cells. In contrast, consistent
negative results, either in reporter or endogenous genes, were observed in transgenic rats. Moreover
(GST-P)-positive foci, a marker of a preneoplastic phenotype in hepatocellular tumours, were increased
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in the liver of rats treated with carcinogenic doses of furan in the absence of any furan-speciﬁc
mutation. These data indicate that mutagenicity is not likely to contribute to the early stages of furan-
induced hepatocarcinogenesis.
Analysis of activating mutations in the Ha-ras oncogene in liver tumours from furan-treated B6C3F1
mice show a strong selective bias, with the vast majority being GC > TA transversions at codon 61.
Since this type of transversion is also the major mutational class in control animals, it cannot be
excluded that this result simply reﬂects an expansion of pre-existing spontaneous Ha-ras mutations.
Information on the genotoxic properties of methylated furans is limited. Both 2-methylfuran and 2,5-
dimethylfuran showed negative results in bacteria. There is some evidence that both compounds can
induce chromosomal damage in mammalian cells in vitro and a limited evidence that 2,5-dimethylfuran
can induce DNA breaks, but not ICLs, in vivo.
Concluding remarks
In vitro tests have provided contradictory indications as to the genotoxicity of furan. It is possible
that these studies may be hampered by technical difﬁculties arising from the speciﬁc physicochemical
properties of this compound.
In contrast, the CYP2E1-mediated metabolite of furan, i.e. BDA, can form DNA adducts, and possibly
crosslinks, in in vitro assays and is able to directly induce mutations in bacteria and mammalian cells
in vitro.
In vivo, furan can induce the formation of low levels of covalent DNA adducts in liver and kidney.
However, the precise nature of these DNA adducts has not been established. Conﬂicting data were
reported for the induction of DNA breaks in the liver. These discrepancies may be related to the timing
of measurements, dosing and assays sensitivities. These breaks, likely reﬂecting oxidative stress-
induced DNA damage, occurred at doses showing limited liver cytotoxicity. A role for oxidative stress in
furan-induced liver carcinogenesis is suggested by molecular analysis of Ha-ras mutations in furan-
induced liver tumours indicating an excess of GC > TA transversions at codon 61 in mice. This is a
mutational class commonly associated with oxidatively damaged DNA which is also present in
spontaneous liver tumours. However, furan-induced oxidative stress is not associated with a clear
induction of base substitutions in transgenic rodent models. A single study suggests a weak mutagenic
activity in a transgenic mouse model, while negative results were consistently reported in transgenic
rat models. Finally, there is convincing evidence that chronic exposure to furan induces chromosomal
damage in proliferating splenocytes from mice and rats, but the DNA lesions responsible for these
effects remain undeﬁned. In particular, it is unclear whether the observed chromosomal instability is
due to direct damage to DNA (formation of ICLs or DNA adducts) or is the consequence of secondary
events associated with oxidative stress-induced DNA damage.
3.1.2.5. Developmental and reproductive toxicity
In F344 rats treated up to 8 mg/kg bw per day by gavage, no effect was observed in testes,
epididymis, prostate, seminal vesicles, ovaries, uterus or vagina (Gill et al., 2010).
In contrast, Wistar rats with similar exposure but during weaning and post-puberty (3–4 weeks old
treated for 90 days) exhibited a signiﬁcant increase in the weight of prostate glands and decreased
weight of seminal vesicles at 8 but not at 4 mg/kg bw per day or below. Dose-dependent histological
changes (including some at the lowest dose tested of 2 mg/kg bw per day) were recorded in the
testes, prostate gland, seminal vesicles and Leydig cells with an increase in apoptotic cells in the testes
(Karacaoglu and Selmanoglu, 2010). No effects on sperm counts or sperm morphology were observed.
Steroidogenic acute regulating protein (stAR) mRNA was increased at all dose levels studied in
F344 rats (0.03 mg/kg bw and above given daily for 90 days) while the mRNA for the cholesterol side-
chain cleavage enzyme (CYP11A1) was increased by furan at 8 mg/kg bw per day along with an
increase in intratesticular testosterone suggesting an ability of furan to interfere with testicular
steroidogenesis (Cooke et al., 2014).
Gill et al. (2011) found no effect of furan on testes or ovaries in B6C3F1 mice when examined
microscopically following doses up to 8 mg/kg bw per day by gavage, 5 days per week for 90 days.
Furan was studied in embryos of Xenopus laevis and found to be non-teratogenic having 96 h LC50
and EC50 values that were very similar (approximately 44 and 40 mM, respectively Williams et al., 2014).
Kara et al. (2016) used male Wistar rats, made diabetic through treatment with streptozotoxin, and
exposed them to 40 mg/kg bw furan by gavage daily for 28 days. Testicular malondialdehyde levels,
and the activities of CAT, GPx, SOD and GST were found to be higher than in the control and diabetic
control animals and the effects were inhibited by treatment of animals with the antioxidant lycopene
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suggesting oxidative stress in testes. This was associated with a lowering of plasma FSH, LH and
testosterone levels in animals treated with furan.
Male Sprague–Dawley rats (3–4 weeks old) were administered furan by gavage in corn oil at 4 mg/kg
per day for 5 days per week for 90 days. This treatment also produced oxidative stress in testes as
evidenced by an increase in malondialdehyde and decreased activity of antioxidant enzymes. These effects
were associated with decreased plasma testosterone concentrations (El-Akabawy and El-Sherif, 2016).
In conclusion, histological changes in the testes, prostate gland, Leydig cells and seminal vesicles
were observed in Wistar rats at 2 mg/kg bw (lowest dose of furan tested) and above given during
weaning and post-puberty. No histological effects in reproductive organs were observed in adult rats
and mice up to 8 mg/kg bw.
3.1.3. Observations in humans
In a study in Korea, blood (Lee et al., 2009) and urine (Jun et al., 2008) samples were collected
from 100 volunteers (49% males, 51% males age ranging from 30 to 70 years; see also
Section 3.1.1.6). The authors in the two study reports stated that the participants consumed a regular
Korean diet and avoided large amounts of furan-rich foods. However, they also stated that: ‘Since a
database on amounts of furan in the typical foods is not available so far, an actual intake of furan per
individual was not shown in this study. Also, other factors such as smoking were not considered for
actual intake of furan’. Furan could be detected in 56 urine samples out of 100 samples collected with
average values of 0.5–1.3 lg/L, with a concentration above the LOQ (1.0 lg/L) in 15 volunteers. The
highest concentration found was 3.14 lg/L. In 21 volunteers, furan could be detected in the plasma
(LOD: 0.3 lg/L) with 17 samples above the LOQ (1.0 lg/L) ranging from 1.2 to 17.9 lg/L. From the
data provided, it is not possible to correlate the outcome of plasma and urine analysis for the
individual volunteers. No information is provided on the handling of non-detects or on the handling of
levels < LOQ. It was not stated how much time elapsed between the last consumption of food and the
collection of urine, and whether 24 h urines were collected or spot samples. However, in the paper Jun
et al. (2008), it was stated that that blood samples were collected after a 12 h fasting period.
Jun et al. (2008) further investigated correlations between average urinary furan levels (above
LOD) and plasma ALT, aspartate amino transferase (AST) and c-glutamyl transpeptidase (c-GT) as
markers of liver toxicity. There were good correlations between ALT, AST and c-GT, but for urinary
furan only a signiﬁcant correlation with plasma c-GT activity was found, which remained signiﬁcant
when covariates like age, sex, body weight, triglyceride and diastolic blood pressure were taken into
account. The study authors further mentioned that mean urinary furan levels in males were higher
than in females and that a similar trend was observed for plasma furan levels. However, elsewhere in
the paper, they mention that quantiﬁable levels of furan in plasma were not found in any of the
volunteers, which invalidates this comparison. The study did not investigate correlations between
plasma furan levels and plasma indicators of liver toxicity. Residual confounding cannot be excluded
and no graphical representation was given of the regression observed. In addition, for only 15
individuals, quantiﬁable urinary furan levels were observed, which puts doubts to the validity of the
observed correlation. From these two studies (Lee et al., 2009; Jun et al., 2008), it is impossible to
conclude that at the reported levels of blood and urinary furan, there is an effect of furan on the liver.
These two studies (Jun et al. 2008; Lee et al., 2009) show many inconsistencies and are therefore
of limited value for this opinion.
3.1.4. Mode of action
Mode of action in hepatocellular toxicity
Furan depletes GSH and is cytotoxic to rodent hepatocytes both in vitro and in vivo evidently
through CYP2E1-mediated conversion to BDA (see Section 3.1.1.3). Likewise, the corresponding
unsaturated aldehydes, acetylacrolein and methylbutenedial, were found to be reactive intermediates
of 2- and 3-methylfurans (Ravindranath et al., 1984).
Chen et al. (1997) also concluded that reactions between BDA and amino acids may be involved in
the toxicity of furan. Nunes et al. (2016) provided evidence that a reactive BDA-GSH adduct can bind
to lysine 107 of histone H2B in male F344 rats treated with 0.92 mg/kg bw per day for 90 days.
In vitro, the EC50 has been estimated at 27.2 lg/mL in rat hepatocytes using an oxygen controlled
closed system to avoid loss of furan by evaporation (Brueck et al., 2009). Hepatic toxicity associated
with oxidative stress produced in mice by daily i.p. injection of furan (8 mg/kg bw) was inhibited by
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treatment with the antioxidant, salidroside, suggesting a role of ROS in hepatotoxicity (Yuan et al.,
2013). Following a single dose of radiolabelled furan (2 mg/kg bw) in rats, protein binding analyses
suggested particular disturbance of pathways related to mitochondrial energy production, redox
regulation and protein folding that are likely to combine to alter cellular homeostasis leading to
hepatotoxicity (Hamberger et al., 2010; Moro et al., 2012a). This is in accordance with the ability of
furan to uncouple oxidative phosphorylation (Mugford et al., 1997). Twenty-four hours after a single
oral dose of 30 mg/kg bw to rats, a signiﬁcant inhibition of activities of glyceraldehyde-3-phosphate
dehydrogenase and succinate dehydrogenase, increased activity of enoyl-CoA hydratase and enhanced
production of ketone bodies, was indicative of inhibited glycolysis, enhanced fatty acid oxidation and
mitochondrial dysfunction (Ramm et al., 2016).
Furan was found to signiﬁcantly alter the level of thyroxine-T4 and triiodothyronine-T3 in rats at
0.12 mg/kg bw and above (Section 3.1.2.2) leading Gill et al. (2010) to conclude on a NOAEL of
0.03 mg/kg bw in rats (90 day study). The elevation of triiodothyronine-T3 and thyroxine-T4 reported
at 0.12 mg/kg bw and above may relate to altered hepatic metabolism relating to these hormones.
However, no direct evidence is available.
Furan induced cholangioﬁbrosis which was extensive following 2 mg/kg bw per day but no
signiﬁcant incidence was found at 0.02, 0.04 or 0.092 mg/kg bw per day in rats (NCTR, 2015; Von
Tungeln et al., 2017). Cholangioﬁbrosis is only observed in rodents. However, it is an adverse outcome,
which has to be taken seriously with regard to risk assessment (Weber, 2017).
In conclusion, furan induces oxidative stress. BDA binds covalently to a range of target molecules,
including proteins and GSH. These features lead ultimately to cell and tissue damage, mitochondrial
dysfunction and ﬁbrosis, primarily in the liver.
Mode of action in carcinogenesis
The observation that furan is also occurring in food has generated a number of new studies that try to
explain the MoA underlying the observed carcinogenicity in animals (see Section 3.1.2.3). These studies
have demonstrated the production of hepatocellular carcinomas, adenomas and cholangiocarcinomas
in rodents. The formation of diagnosed cholangiocarcinoma appears to be a feature of a high dose
(8 mg/kg bw) and secondary to hepatotoxicity.
Findings suggest that both genotoxic and non-genotoxic modes contribute to furan carcinogenesis
depending upon the level of exposure (dose and route), the tumour type, species and gender.
Furan can be metabolised by CYP2E1 to BDA and this represents a mechanism leading to hepatic
cytotoxicity and possibly to genotoxicity in mammalian cells. The mechanism and potency of
genotoxicity of furan in vivo is, however, uncertain (see Section 3.1.2.4). The dial metabolite (BDA)
has been found to produce substituted 1,N4-etheno-20-dC; 1,N6-etheno-20-dA and 1,N2-etheno-20-dG
adducts in chemical reactions (Byrns et al., 2002, 2004, 2006). The dC and dA adducts were also
detected in S. Typhimurium strain TA104 treated with a mutagenic concentration of the dial metabolite
(Byrns et al., 2006). Churchwell et al. (2015) could not detect an elevation of the adduct BDA-dC in
furan-treated rat liver DNA using LC–MS/MS after single doses up to 9.2 mg/kg bw or repeated dosing
with 4.4 mg/kg bw (5 days per week) for up to 360 days. However, furan has been found to produce
DNA adducts in rat tissues albeit at very low levels, suggesting a low potency (Neuwirth et al., 2012).
There is some evidence of chromosomal damage observed in vivo, but the underlying mechanism
(s) has not been clariﬁed at the molecular level (see Section 3.1.2.4). Since DNA crosslinking, DNA
adducts or DNA oxidation are each potential mechanisms, it is not possible to determine if the
chromosomal damage is direct or indirect.
Furan can also induce a range of cellular responses potentially relevant to cancer in rat and mouse
liver. In rats, the most sensitive pathological endpoint following 2-year exposure by gavage was
cholangioﬁbrosis seen markedly at 0.2 mg/kg and above (NCTR, 2015; Von Tungeln et al., 2017).
Increased BrdU-labelling of hepatocytes, indicative of cell proliferation, also showed a lowest-observed-
effect-level (LOAEL) (statistically signiﬁcant) of 2 mg/kg bw in rats administered furan by gavage
5 days per week for 5 and 28 days (Mally et al., 2010).
In mice, there was an increase in BrdU-labelling in hepatocytes following treatment with 8 mg/kg bw
but not 4 mg/kg bw furan for 28 days, 5 days per week (Cordelli et al., 2010). Subcapsular inﬂammation
was seen in the mouse liver at the lowest dose level employed (0.5 mg/kg bw) when given 5 days per week
for 3 weeks (Moser et al., 2009). In addition, after 90 days dosing (5 days per week) of mice hepatocyte
apoptosis was observed with a NOAEL of 0.12 mg/kg bw (Gill et al., 2011). From their short- and long-term
toxicity studies in mice, Moser et al. (2009) concluded that there was an association between furan-induced
hepatotoxicity, compensatory cell replication and liver tumour formation at 4 mg/kg bw furan.
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Gene expression changes in the liver following furan doses of 4 and 40 mg/kg bw for up to 14 days
in Sprague–Dawley rats were in accord with ﬁbrosis (Hamadeh et al., 2004). Statistically signiﬁcant
changes in the expression of a number of genes involved in oxidative stress, apoptosis and cell-cycle
were seen in rats after 2 mg/kg bw per day furan over 90 days (Curran et al., 2014; Yauk et al., 2014;
Dong et al., 2016) or following 4 weeks of treatment with 0.1 and 2 mg/kg bw furan (Chen et al.,
2010). Male rats responded more than female rats. Genes associated with DNA repair, cell cycle and
apoptosis were also altered in expression at 2 mg/kg and above in rats exposed by gavage daily up to
3 days (Ding et al., 2012). Following a single gavage dose of 30 mg/kg bw to male rats, a wave of
compensatory hepatocyte proliferation following necrosis was associated with a transient increase in
the expression of c-myc, c-fos and Ha-ras genes. However, a later, sustained increase in expression of
c-myc was seen and suggested to be independent of cell proliferation (Butterworth et al., 1994).
Gpt delta rats were given furan at 0, 2 or 8 mg/kg bw per day by gavage for 13 weeks (assumed
daily) and the frequency of hepatic mutations in gpt or Spi were not altered despite an increase in
PCNA-positive hepatocytes, cyclin d1 and cyclin e1 mRNA levels and in the number and area of GST-P-
positive foci at 8 mg/kg bw. These results do not support a role of genotoxicity in the production of
the observed GST-P- positive foci (Hibi et al., 2017).
Furan doses of 0.92, 2.0 or 4.4 mg/kg bw per day for 360 days in F344 rats also caused a dose-
dependent hepatic global DNA demethylation and a sustained decrease in the levels of histone
methylation (de Conti et al., 2014). Reduction of histone lysine acetylation following treatment of F344
rats with 8 mg/kg bw of furan 5 days per week up to 90 days persisted after removal of the treatment
(de Conti et al., 2015). The p53 target microRNA, miR-34a, was signiﬁcantly increased at 2 mg/kg bw
per day (Dong et al., 2016). de Conti et al. (2016) showed that treatment of rats with furan at 0.92 or
2.0 mg/ kg bw per day for 90, 180 and 360 days led to increased expression of various microRNAs
(miR-34a, miR-93, miR-200a, miR-200b and miR-224) which was reversible following cessation of the
dosing. In contrast, there was a sustained, reduced expression of miR-375 in morphologically normal
and in cholangioﬁbrotic liver tissue. This is a tumour suppressing microRNA involved in the regulation
of Yes-associated protein 1 which is a feature of hepatic carcinogenesis and the effects were seen in
conjunction with increased methylation, both of cytosine in DNA and of lysine in histone H3K9 and
H3K27 at the miR-375 gene. BDA-GSH binding to lysine 107 of histone H2B (see above, Nunes et al.,
2016) may contribute to epigenetic interference.
In liver lesions of F344 male rats treated with furan (0.92 or 2 mg/kg bw daily for 104 weeks),
1,336 and 1,541 genes were found to be differentially expressed compared to control rat liver at the
two doses, respectively. Of 1,001 transcripts mutually altered in expression at both doses, the
expression level of a total of 42 of these was found to be negatively correlated with the methylation of
their associated CpG Islands (Tryndyak et al., 2017). Thus, changes in DNA methylation appear to be
involved in some of the gene expression changes induced by furan.
With regard to the induction of cholangiocarcinoma in rats, which is only seen at the top dose
studied (8 mg/kg bw), evidence has been provided for an apparent sustained biliary cell and
hepatocellular proliferation that persisted without recovery provided that the dosage is sufﬁcient to
cause extensive centrilobular hepatocellular toxicity (see Table 2; Hickling et al., 2010a,b). Indeed a
biliary epithelial cell origin has been proposed for cholangiocarcinomas produced by furan (Sirica,
1996; Sirica et al., 1994a,b, 1997). Aberrant expression of HGF/SF expression in both furan–induced
cholangiocarcinoma epithelium and in intestinal metaplastic epithelium, suggested that the latter are
putative precancerous lesions (Lai et al., 2000). At a high dose of 30 mg/kg bw, this is associated with
metaplasia in the liver and an inﬂammatory response involving excessive production of ROS, epigenetic
changes and irreversible enhanced expression of DNA-damage responsive genes, cytokines and
microRNAs (Elmore and Sirica, 1991, 1992, 1993; Hickling et al., 2010a,b; Chen et al., 2012).
Changes in hepatic gene expression were also observed in mouse liver following furan exposure.
Thus, in mice treated with a carcinogenic dose of 4 and 8 mg/kg bw per day, similar changes in
hepatic gene expression were observed and the proﬁle of expression changes differed from that at
2 mg/kg bw in which a more adaptive response was considered by the authors. Changes in the
expression of NF-kappaB and c-Jun were suggestive of liver regeneration and oxidative stress-
mediated NRF2 activity. Chronic inﬂammation was suggested as a critical event in the transition
between the adaptive changes and adversity (Jackson et al., 2014). Moreover, in mice treated for
3 weeks, long-non-coding RNA was differentially expressed at carcinogenic doses of 4 and 8 mg/kg bw
but not at 1 or 2 mg/kg bw (Recio et al., 2013; Webster et al., 2014a,b). Cordelli et al. (2010) found
altered expression of genes involved in the DNA damage response in mice treated with 15 mg/kg bw
per day furan for 28 days although this was not associated with a change in DNA methylation.
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Yauk et al. (2016) assessed the proﬁle of gene expression produced by furan (68, 136 and 390 lg/mL,
4 h exposure) in human TK6 cells with rat liver S9 (induced by 5% ethanol to elevate CYP2E1). By
comparing gene expression proﬁles for both genotoxic and non-genotoxic chemicals, they concluded
that the proﬁle of furan matched that of a genotoxic chemical for 28 selected gene (TGx-28.65)
biomarkers. However, principal component analysis and dendrogram indicated that the proﬁle of gene
expression, albeit with a limited set of reporter genes for oxidative stress, was similar to
acetaminophen that induces oxidative stress (Jaeschke et al., 2012) under the conditions of the study.
Their analysis of micronuclei induction supported their conclusion that furan is clastogenic at high
concentrations associated with oxidative stress. Furihata et al. (2016) were able to discriminate furan
from 8 genotoxic carcinogens based on the hepatic gene expression proﬁle of 100 candidate marker
genes at 4 and 48 h after an i.p. dosage (30 mg/kg bw) in B6C3F1 male mice. These two studies do
not support a direct genotoxicity of furan.
A computational analysis sought signiﬁcant disease associations with either furan or 2,5-dimethylfuran
using data from the Comparative Toxicogenomics Database. There were inferred associations between
furan and lung neoplasms, liver injury and cirrhosis based on 21 gene interactions. There were no
detected direct associations between 2,5-dimethylfuran and disease (Phuong et al., 2012).
In human lung alveolar epithelial cells, 2,5-dimethylfuran at concentrations up to 2 mM showed no
effect on viability or changes in gene expression as assessed using a human microarray platform
(Cheah et al., 2013).
In conclusion, when considering MoAs, the contributing factors are likely to vary according to dose,
length of exposure and degree of severity of liver cellular damage, inﬂammation and regenerative
hyperplasia.
It is possible that, based on the potential for genotoxicity (evidenced in some but not all studies
in vitro, and limited evidence in vivo of some chromosomal damage of unknown origin), the mode of
carcinogenic action of furan, in rats and mice, may involve genotoxicity. However, there is clear
evidence for the involvement of indirect mechanisms in the carcinogenic MoA of furan. These include
epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all of these effects
being accompanied by tissue damage. Extensive protein binding of the reactive metabolite BDA
restricts access to DNA. On the other hand, protein binding may contribute to the epigenetic changes
(histone binding). Theoretically inactivation of proteins involved in DNA processing may also contribute
to genomic instability, however, no studies were conducted with furan.
In particular, oxidative stress with associated production of DNA 8-oxodeoxyguanosine in liver and
8-oxodeoxyguanosine in blood, gene expression alteration and epigenetic changes are evidently
involved along with an inﬂammatory and cell proliferative component to the MoA. This is particularly
evident in the liver of rodents at 2 mg/kg bw and above accompanied by toxicity.
3.1.5. Considerations of critical effects and dose–response analysis
3.1.5.1. Considerations of critical effects
In rodents, furan was shown to be hepatotoxic and nephrotoxic when applied by oral gavage. The
liver is the most sensitive organ. Furan leads to characteristic changes in markers related to
hepatotoxicity as well as severe histopathological damage in the liver. The observed changes in blood
parameters, including the effect on thyroid hormones, are considered secondary to changes in liver
function. Hepatic toxicity is thought to be due to conversion of furan into the highly reactive metabolite,
BDA. In long-term experiments hepatic necrosis, cholangioﬁbrosis, regenerative hyperplasia, metaplasia
and adenomas/carcinomas are observed. The CONTAM Panel noted that non-neoplastic effects have
been observed at low doses, i.e. cholangioﬁbrosis in a 2-year study in male rats at doses as low as
0.2 mg/kg bw per day (NCTR, 2015) and an increase in serum T4 levels in a 90-day study in male rats
at doses of 0.12 mg/kg bw per day (Gill et al., 2010).
Neoplastic lesions comprise hepatocellular adenomas/carcinoma, mononuclear cell leukaemia, C-cell
adenoma/carcinoma and mesothelioma of the tunica vaginalis. The mononuclear cell leukaemia, C-cell
adenoma/carcinoma and mesothelioma of the tunica vaginalis were not considered critical for the risk
assessment for reasons discussed in Section 3.1.2.3. The CONTAM Panel selected the incidence of
hepatocellular adenomas/carcinoma as critical effect for the neoplastic changes.
There is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of
furan. These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with
all of these effects being accompanied by tissue damage. In addition, extensive protein binding of the
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reactive furan-metabolite BDA restricts access to DNA, and binding to histones may also contribute to
the reported epigenetic changes.
There is limited evidence of a direct mechanism (i.e. direct interaction with DNA) in the
carcinogenic action of furan. A very low level (see Section 3.1.1.4) of altered DNA bases was observed
in vivo but their chemical structures could not be identiﬁed. These altered DNA bases are not identical
to the adducts formed by reaction of the furan metabolite, BDA, with isolated DNA and DNA in
bacteria. Nevertheless, there is evidence of chromosomal damage in vivo, but it is unknown whether
this is caused by a direct or indirect mechanism.
The CONTAM Panel selected the incidence of cholangioﬁbrosis in male rats, increase in serum T4 in
male and female rats and the incidence of hepatocellular adenoma and carcinoma in mice and male
rats for the dose–response analysis of furan, but considered that there was insufﬁcient information for
the methylfurans.
3.1.5.2. Dose–response analysis (including benchmark dose analysis)
The BMD analysis performed followed the updated guidance of the Scientiﬁc Committee on BMD
modelling (EFSA Scientiﬁc Committee, 2017) and a detailed description of the BMD analysis performed
by the Panel can be found in Appendix C. The reported BMD10, BMDL10 and BMDU10 have not been
corrected for the applied dose regimen (i.e. 5 days per week), unless indicated.
As described in Section 3.1.5.1, the CONTAM Panel considered the induction of cholangioﬁbrosis in
rats as a critical effect following oral exposure to furan. The CONTAM Panel selected the most recent
chronic study with male rats for dose–response modelling of the incidence of cholangioﬁbrosis after
36 weeks and after 2 years (NCTR, 2015; Von Tungeln et al., 2017). This study is particularly suitable
for dose–response modelling as 8 dose levels (0, 0.02, 0.044, 0.092, 0.2, 0.44, 0.92 and 2 mg/kg bw
per day, 5 days per week for 104 weeks) were tested with a higher number of animals per dose group
in the lower dose range (see Table 6). A benchmark dose analysis was performed using the EFSA web-
tool, which is based on the R-package PROAST 61.3 (see Appendix C). The default benchmark
response (BMR) for quantal data was selected, i.e. an extra risk of 10% compared with the
background risk. Using model averaging, the resulting BMDL10 for cholangioﬁbrosis after 36 weeks was
0.22 mg/kg bw and after 2 years 0.09 mg/kg bw (see Table 10).
Although the effects on thyroid hormones are considered as secondary to changes in liver function,
the CONTAM Panel performed a dose–response analysis of the increase of the serum T4 levels in a
90-day study in male and female rats (Gill et al., 2010). The BMD analysis showed that there was
insufﬁcient information in these data on the dose–response to calculate a BMDL (i.e. the BMDL–BMDU
interval ranged from 0 to inﬁnite). Since the effects are observed in the same dose range as
cholangioﬁbrosis, the changes in thyroid hormones were not used further in the risk assessment.
The induction of hepatocellular adenomas or carcinomas following furan exposure has been
reported in male rats and male and female mice. The CONTAM Panel selected the incidence of
hepatocellular adenomas or carcinomas (combined) and hepatocellular carcinomas (only) in female
mice after 2 years reported in two independent studies (NTP, 1993; Moser et al., 2009) for BMD
analysis, since this was a more robust data set covering the low dose-range compared to the male
mice and rats. A BMD analysis of the combined data from both studies (Moser et al. (2009) and NTP
(1993); see Appendix C, Table C.8), using the studies as a covariate, was performed. Model averaging
was used. The resulting BMDL10 for hepatocellular adenomas or carcinomas was 1.84 mg/kg bw per
day for both studies combined. For hepatocellular carcinomas alone, the shape of the dose–response
curves of the two studies differed and the resulting BMDL10 were 4.18 and 4.82 mg/kg bw for the
Moser et al. and the NTP study, respectively. When analysing the Moser et al. study alone, the BMDL10
values were 1.45 and 3.45 mg/kg bw per day for hepatocellular adenomas or carcinomas and
hepatocellular carcinomas, respectively.
Table 10: Summary of the BMD analysis, using model averaging
Response variable
Species
and sex
BMD10
(mg/kg bw
per day)(a)
BMDL10
(mg/kg bw
per day)(a)
BMDU10
(mg/kg bw
per day)(a)
Cholangioﬁbrosis after 36 weeks Male rats 0.3 0.22 0.41
Cholangioﬁbrosis after 2 years Male rats 0.11 0.09 0.12
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From this analysis, the CONTAM Panel selected the BMDL10 of 0.09 mg/kg bw per day (5 days per
week dosing regimen) for the induction of cholangioﬁbrosis in male rats after 2 years as a reference
point for non-neoplastic effects. This corresponds to 0.064 mg/kg bw per day (correcting for the applied
dose regimen of 5 days per week). For neoplastic effects, the CONTAM Panel considered that the
combined data set from NTP (1993) and Moser et al. (2009) on the incidence of hepatocellular
adenomas and carcinomas in female mice after 2 years is the most robust data set to derive a reference
point and selected the BMDL10 of 1.84 mg/kg bw per day (5 days per week dosing regimen). This
corresponds to 1.31 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week).
3.1.6. Possibilities for derivation of a health-based guidance value (HBGV)
Based on the available information, the CONTAM Panel concluded that there is clear evidence for
the involvement of indirect mechanisms in the carcinogenic MoA of furan. However, there are also
some indications for a direct genotoxic mechanism. Therefore, the CONTAM Panel considered it
inappropriate to establish a tolerable daily intake (TDI). The CONTAM Panel selected a BMDL10 of
0.064 mg/kg bw per day for the incidence of cholangioﬁbrosis and a BMDL10 of 1.31 mg/kg bw per
day for the incidence of hepatocellular adenomas or carcinomas as reference points and to use an
MOE approach for the risk characterisation.
3.2. Occurrence data
3.2.1. Factors inﬂuencing furan and methylfurans levels in food
Both the food matrix and the process variables will have an impact on the formation and loss of
furan and methylfurans in foods. Currently, most of the information is related to furan. In view of its
chemical properties, it is supposed that the formed furan is chemically stable during storage of foods,
although limited studies examining stability are available (Guenther et al., 2010). Losses for furan are
typically linked to its high volatility (evaporation). First, the factors impacting furan formation in foods
and model systems will be summarised, followed by reviewing the factors inﬂuencing the evaporative
losses of furan. Similarly, the available information on methylfurans will be discussed.
Factors inﬂuencing furan formation in food and model systems
As outlined in Section 1.3.5, several precursors and formation mechanisms have been suggested.
Most of these precursors have been identiﬁed in simpliﬁed model systems in which the complexity of a
real food matrix cannot be mimicked. Indeed, it should be realised that in foods, multiple precursors
can be present, and that their formation pathways may interfere with each other. It also seems that
interaction with non-precursor matrix components (e.g. starch) may impact the furan formation (e.g.
Owczarek-Fendor et al., 2010a).
Only a limited number of studies have tried to corroborate the speciﬁc role of particular precursors
in real food systems for which stable isotope labelled precursors are necessary. Such studies revealed
that the role of some precursors can be largely overestimated. Limacher et al. (2008) reported that
Response variable
Species
and sex
BMD10
(mg/kg bw
per day)(a)
BMDL10
(mg/kg bw
per day)(a)
BMDU10
(mg/kg bw
per day)(a)
Hepatocellular adenoma or carcinoma;
combined data set from Moser et al. (2009)
and NTP (1993)
Female mice 2.6 1.84 4.00
Hepatocellular carcinoma; combined data
set from Moser et al. (2009) and NTP (1993)
• Moser et al. (2009)
• NTP (1993)
Female mice
Female mice
5.72
7.21
4.18
4.82
7.24
9.10
Hepatocellular adenoma or carcinoma;
data set from Moser et al. (2009) only
Female mice 2.4 1.45 3.59
Hepatocellular carcinoma; data set from
Moser et al. (2009) only
Female mice 5.34 3.45 7.55
(a): For a 5 days per week dosing regimen.
Furan and methylfurans in food
www.efsa.europa.eu/efsajournal 65 EFSA Journal 2017;15(10):5005
only 21% of the formed furan originated from the available sugars in the pumpkin puree studied, while
the remaining 79% was suggested to result from lipids, although this reaction pathway was not
considered or investigated.
In an acidic environment, it has been shown that sugars are less efﬁcient precursors in model
systems compared to neutral or alkaline conditions (e.g. Limacher et al., 2008; Owczarek-Fendor et al.,
2012). For ascorbic acid, an acidic pH favours the conversion to furan (e.g. Limacher et al., 2007;
Owczarek-Fendor et al., 2010a). Care needs to be taken in the interpretation of these observations as
the pH of a model system is sometimes difﬁcult to control, it varies as a function of the temperature, and
some buffers, like phosphate, are supposed to enhance furan formation as well (e.g. Fan et al., 2008).
The redox potential is another matrix-relevant parameter. The use of antioxidants in model systems
reduces lipid peroxidation and furan formation (Becalski and Seaman, 2005). Metal ions, as pro-
oxidants have the opposite effect (Becalski and Seaman, 2005). It should be noticed that the different
reports are not always consistent (M€ark et al., 2006). Reduction of the available amount of oxygen in
food products (in potato purees supplemented with, respectively, ascorbic acid, fructose and poly-
unsaturated fatty acids; Palmers et al., 2016) or model systems (M€ark et al., 2006) resulted in a
variable decrease in the furan formation.
The process variables time and temperature have an impact on furan levels in food. Sterilisation
treatments typically result in higher furan levels compared to pasteurisation treatments (Fan et al.,
2008). Dry heating, generally more intense than sterilisation or pasteurisation treatments, typically
results in higher furan levels (Limacher et al., 2007, 2008). This is consistent with the observation that
the highest concentrations of furan are reported in roasted coffee (EFSA, 2010c). Furan levels in coffee
increase with the degree of roasting (Guenther et al., 2010; Altaki et al., 2011; Arisseto et al., 2011)
and this effect is attributed to the increase in roasting temperature. Coffees with the same degree of
roasting but roasted using different time–temperature conditions show different levels, with the
highest levels observed after quick roasting at high temperature (Altaki et al., 2011). Also, during
deep-frying the applied time-temperature combination inﬂuences the furan level. DTU (2009) studied
the levels of furan in chips and crisps during deep-frying as a function of different time-temperature
combinations. No difference was observed in the level of furan in chips fried at 160°C for 6 mins or
175°C for 4 mins. However, higher levels were found in chips fried for 3 mins at 190°C. For crisps, the
authors observed an increase in furan level with increased frying temperature and decreased frying
time (7 mins at 150°C vs 3.5 mins at 190°C). In toast, on the other hand, the inﬂuence of increasing
toasting time, without changing the toasting temperature, was studied. The level of furan increased
with toasting time and consequently with the degree of browning.
In aqueous solutions, it was initially accepted that temperatures of 90–100°C resulted in a limited
amount of furan formation and that typically higher temperatures were necessary (e.g. Fan et al., 2008;
Owczarek-Fendor et al., 2010a). Subsequently, it was shown that during storage at 35°C, thermally
treated fruit juices were able to generate furan, while the same authors observed limited additional furan
formation during storage of vegetable purees at 4°C (Palmers et al., 2015a,c). Presumably, precursors
formed during thermal treatment or storage are further converted to furan during long-term storage,
without the need for additional thermal input. In comparison, conventional sterilisation techniques, high-
pressure high-temperature sterilisation or alternative heat treatments (e.g. dielectric heating) resulted in
a lower furan formation due to a lower time-temperature impact (Palmers et al., 2015b).
In addition, the inﬂuence of ionising and UV-C radiation on furan formation has been studied (Fan,
2005, 2015; Fan and Sokorai, 2008; Hu et al., 2016), but given the limited application of these
techniques at EU level the Panel did not consider this for this opinion.
Factors inﬂuencing furan losses in food
Van Lancker et al. (2009) showed that the evaporation of furan is highly inﬂuenced by the
composition of foods (e.g. lipids, starch). In foods such as coffee, although coffee is roasted at
temperatures above 200°C, furan is still present. The retention of furan in this matrix can be explained
by the interaction of furan with matrix components, such as the lipids and the low molecular weight
extractables (Van Lancker et al., 2009).
Given the volatility of furan, various studies considered the evaporation of furan from samples
before consumption, typically during reheating and open storage conditions (e.g. Kim et al., 2009;
Fromberg et al., 2014; Palmers et al., 2015a). Appendix D, Table D.1 gives an overview of furan
concentrations in commercially processed foods, before and after heating by the consumer, reported in
the scientiﬁc literature. As shown in Appendix D, Table D.1, limited evaporation occurs and variable
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results are obtained, depending upon the particular experimental conditions (e.g. time, temperature,
stirring, type of container).
From the information available in scientiﬁc literature, the CONTAM Panel concluded that the
inﬂuence of reheating commercially processed foods on furan levels is limited and highly dependent on
the consumer behaviour which is not predictable. Moreover, it should be noted that some consumers
might consume these products without heating.
During beverage preparation however, furan levels decrease substantially due to a combination of
dilution, evaporation and partial extraction. Guenther et al. (2010) estimated losses regardless of the
dilution for each process/handling step of roasted coffee: grinding (40%), degassing (20%), shelf life
(0% as long as original package is closed, 25% when original package is opened), brewing (55%) and
standing time (10–35%). Several other studies investigated the effect of the brewing method in more
detail. An overview of furan levels in coffee before and after brewing retrieved from those studies is
provided in Appendix D, Table D.2. In this table, only the studies that provided sufﬁcient information
on any of the following parameters were retained: brewing method, amount of solid coffee used for
brewing, volume of brew obtained and concentrations of furan before and after brewing. These data
allowed the CONTAM Panel to calculate for each sample an overall reduction factor by dividing the
furan concentration in the food as purchased by the furan concentration in the food as consumed. This
reduction factor comprises a dilution and a loss factor. The loss factor is considered as an indicator for
the amount of furan lost during the brewing process, regardless of the dilution effects. The higher the
loss factor, the higher the amount of furan lost during the brewing process.
Although highly variable results are obtained, some trends were identiﬁed when merging the
individual loss factors obtained throughout the different studies (Appendix D, Table D.2). The highest
losses of furan were observed when whole coffee beans are used as a starting material, indicating that
loss of furan does not only occur during the brewing process itself, but also during the grinding. When
ground coffee was used as a starting material, the highest loss factors were obtained for boiled/
Turkish coffee (Median = 11.6; P25 = 5.9; P75 = 18.5). Loss factors for ﬁlter coffees (Median = 4.2;
P25 = 2.3; P75 = 5.9) were also found to be higher compared to espresso coffees (Median = 2.8;
P25 = 2.3; P75 = 4.4). Altaki et al. (2011) explained the higher transfer of furan to espresso brews by
the higher pressure applied in the espresso machine which increases the furan extraction compared to
a ﬁlter coffee maker. Also, the time difference between both brewing methods to prepare a cup of
coffee may explain the higher levels of furan in espresso ( 30 s for espresso vs  100 s for ﬁlter
coffee). For instant coffees, the loss of furan during beverage preparation is considered negligible as
the median loss factor amounted to 1.1 (P25 = 1.0; P75 = 1.4).
Several researchers studied the impact of stirring and the standing-time (time between preparation
and consumption) on furan levels. In general, stirring the sample results in a decrease of furan, while
variable effects have been observed during standing. Mesias and Morales (2014) studied the effect of
standing and stirring on the furan level in brewed coffee: Standing at room temperature for 5 min
resulted in a loss of 74%, while standing at room temperature for 5 min in combination with 30 s
stirring resulted in a loss of 64%. Stirring on the other hand for 5 min resulted in losses of 94% and
coffee that was kept for 8 h in a sealed thermo had furan levels that were 98% lower. Also, Kim et al.
(2009) and Becalski et al. (2016) observed a decrease of the furan in brewed coffee during standing.
Roberts et al. (2008) on the other hand demonstrated that furan levels in composite foods that were
left to stand without stirring did not change signiﬁcantly, while stirring the foods resulted in lower
furan levels. Altaki et al. (2017) on the other hand observed losses between 22% and 47% when baby
food was standing for 5 min. For methylfurans, few studies are available. Palmers et al. (2014)
conﬁrmed the susceptibility of heat-treated tomato based products for 2-methylfuran and 3-
methylfuran formation as reported in a survey of Becalski et al. (2010), while for other vegetable
products (broccoli, carrot, pumpkin, potato) formation was restricted (up to 127 lg/kg in tomato
product for the sum of 2- and 3-methylfuran, others < 20 lg/kg). It is, however, not clear which
factors are responsible for these remarkable differences.
Factors inﬂuencing methylfurans levels in food
Although amino acid degradation is considered as an important pathway in the 2-methylfuran
formation, addition of supplementary glucose to a pumpkin puree (stimulating the Maillard reaction)
did not result in a signiﬁcant increase of 2-methylfuran (Limacher et al., 2008). From the methylfuran
survey data, however, it is obvious that various factors should have an impact on the formation of
methylfurans in foods (Becalski et al., 2010).
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In contrast to furan, methylfurans seem to be prone to degradation or loss in some foods during
storage. Palmers et al. (2015a) observed that during the storage of pasteurised tomato puree at 35°C,
a reduction was seen from 127 lg/kg to 13 lg/kg, while in other vegetable puree or fruit juices, this
was not observed or at least not to this extent. The decrease observed at 4°C was lower (24%). The
cause of the decrease is not known.
Summary
The food characteristics, processing and cooking conditions, and the losses which occur mainly due
to evaporation in the preparation of the food at the level of the consumer, affect the ﬁnal
concentration in the food as consumed.
3.2.2. Occurrence data submitted to EFSA
Although the call for data requested the submission of chemical occurrence data on furan, 2-
methylfuran and 3-methylfuran, only data for furan were made available within this framework. The
data for the present assessment were provided by national authorities from Austria, Belgium, China,
Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy,
Lithuania, Luxembourg, the Netherlands, Norway, Poland, Slovakia, Slovenia, Spain and United
Kingdom, and by the European Breakfast Cereal Association (CEEREAL), the European Coffee
Federation (ECF) and Specialised Nutrition Europe (SNE).
An initial number of 18,141 analytical results on furan in food were available. This data set also
included the 5,500 records included in the latest report on furan in food (EFSA, 2011d). These
5,500 records were previously validated by EFSA and incorporated in the current assessment without
further involvement of the data providers. The remaining data were subject to the validation processes
described in Section 2.3.2, and data providers were invited to clarify possible inconsistencies identiﬁed
by EFSA’s DATA Unit. Where such a clariﬁcation was not received from the data provider, the CONTAM
Panel was required to apply certain assumptions. These assumptions, and the number of records
impacted are summarised in Annex A, Table A.1.
Furthermore, the overall data set was carefully analysed before being used to estimate dietary
exposure and a total of 378 records were excluded from the ﬁnal data set. Criteria for exclusion of
these analytical results are also detailed in Annex A, Table A.1.
3.2.2.1. Governmental data
The data set retained for assessment included 10,370 analytical results from governmental
organisations. As requested through the call for data, Member States reported analytical results for
commercial foodstuffs as purchased, disregarding any further preparation, and commercial foodstuffs
analysed as consumed after further preparation in the laboratory. Since the data set also included
samples analysed both as purchased and as consumed, the number of analytical results reported
above actually corresponds to a total of 9,663 samples. Samples were taken in 21 Member States
(Figure 8) throughout the years 2004–2016 (Figure 9).
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Apart from the above-mentioned samples that were analysed both as purchased and as consumed
(n = 707), available samples were analysed only once, either as purchased (n = 8,531) or as
consumed (n = 237). For some remaining samples (n = 188), data providers did not clearly specify
whether the samples were analysed as purchased or as consumed, but on the basis of the observed
levels these samples were assumed to be analysed as purchased.
In view of the exposure assessment, the data were grouped at different FoodEx levels taking into
consideration several factors including the similarities between food categories, the number of samples
and the concentrations observed (Annex A, Table A.2). The CONTAM Panel agreed that where a
sample was analysed both as purchased and as consumed, only the analytical result for the sample
analysed as consumed would be retained for assessment because this is the most representative for
the consumer exposure. Furthermore, in order to assess the impact of food and beverage preparation
Figure 8: Number of governmental samples reported by Member State
Figure 9: Number of governmental samples reported by year
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on the concentration levels of furan, reduction factors were calculated for each sample that was
analysed both as purchased and as consumed (samples with left-censored results were excluded). For
those food categories where no dilution occurs during food preparation (i.e. heating of commercially
processed foods), the median reduction factors are reported in Table 11.
These data indicate that heating of commercially available foods (where no dilution occurs) has a
limited impact on the levels of furan with median reduction factors generally ranging from 1 to 1.2.
Median reduction factors in legumes, fruit and fruit products, and meat and meat products were
higher (amounting to 1.3, 3.2 and 1.6, respectively), but the number of samples in these food groups
was not considered sufﬁcient to demonstrate that a signiﬁcant loss of furan is expected during
preparation of such food items. These ﬁndings are consistent with ﬁndings in scientiﬁc literature (see
Section 3.2.1) and it was agreed that for these food categories further distinction between foods
analysed as purchased or consumed would not be meaningful.
A similar analysis was attempted for foods and beverages where furan concentrations are expected
to decline, not only due to the possible loss of furan during preparation, but also through the effect of
dilution (i.e. cereal-based products for infants and young children, infant and follow-on formulae, and
cocoa, tea, coffee and coffee imitate beverages). However, in most of these samples, the preparation
method applied by the laboratories was not reported and it could not be assessed to what extent the
decline of furan concentrations in these samples was driven by the effect of dilution or by the loss of
furan during preparation. For these reasons, the information on coffee retrieved from scientiﬁc
literature was considered more useful (Appendix D, Table D.2). Meanwhile, it was agreed that for
these food categories furan concentrations in the food as purchased are not comparable to the furan
concentrations in the food as consumed. Samples analysed as purchased were reported under the
corresponding solid or powder, while the samples analysed as consumed were reported under the
corresponding beverage or food.
The Panel also noted that the food category ‘Coffee beans, roasted’ may have been used by some
Member States to report any unspeciﬁed roasted coffee sample (regardless whether it was ground or
not). In order to allow for a better comparison between ground and unground roasted coffee, only the
samples where the product description explicitly refers to grains or beans were retained in this food
category. All other samples were reported as unspeciﬁed coffee beans and coffee products. A similar
analysis was made for coffee imitates, in order to make a distinction between instant coffee imitates
and coffee imitates for brewing.
Based on this classiﬁcation, the highest number of samples was reported for ‘Foods for infants and
small children’ with a particular attention to ready-to-eat meals for infants and young children
(n = 2,090), and ‘Vegetables and vegetable products (including fungi)’, which includes the coffee
beans and solid coffee products (n = 1,547) as well as the solid coffee imitates (n = 136). Other well-
represented food groups are composite foods (n = 1,292) and grains and grain-based products
(n = 1,207). These also correspond to the most relevant food categories in terms of furan levels.
The highest concentrations of furan were found in whole roasted coffee beans, with a mean value
of 3,956 lg/kg and the highest individual value of 12,810 lg/kg. The mean values in ground roasted
coffee (2,446 lg/kg) and unspeciﬁed coffee solids (2,186 lg/kg) were signiﬁcantly lower, suggesting a
Table 11: Reduction of furan levels during heating of commercially processed foods for which no
dilution occurs
Food group
Number of
samples
Median reduction
factor(a)
Grains and grain-based products 3 1.1
Vegetables and vegetable products (including fungi) 13 1.1
Legumes, nuts and oilseeds 4 1.3
Fruit and fruit products 1 3.2
Meat and meat products (including edible offal) 1 1.6
Herbs, spices and condiments 18 1.1
Food for infants and small children 157 1.1
Composite food (including frozen products) 130 1.2
Snacks, desserts and other foods 2 1
(a): Note that in this speciﬁc case the reduction factor is equal to the loss factor.
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loss of furan during the process of grinding, while the mean concentration in instant coffee powder
was found to be even lower (429 lg/kg). A similar observation was made for coffee imitates where
concentrations in solids for brewing (1,922 lg/kg) were higher compared to the instant powders
(127 lg/kg). Due to the low number of left-censored data within these food categories, the difference
between lower bound and higher bound estimations was negligible.
In prepared salads and cereal- and vegetable-based composite foods, mean furan concentrations
ranged from 10 to 20 lg/kg, while in other composite foods (including the unspeciﬁed ones) mean
levels ranged between 20 and 34 lg/kg. On average, levels in ready-to-eat meals for infants and
young children were similar (31 lg/kg), but in this case, the quality of the data was not sufﬁcient to
allow for further disaggregation on the basis of the meal content. Comparable mean levels were also
found in bread and rolls, raw pasta, breakfast cereals and ﬁne bakery wares (16–30 lg/kg).
All remaining samples included a wide range of other foods, most of which are also expected to be
commercially prepared foods (including canned and jarred products). Nevertheless, mean levels of
furan in these food categories were generally found to be below 20 lg/kg, with the exception of soy
sauce (32 lg/kg) and spirits (57 lg/kg).
Almost 90% of the samples were taken through objective, selective or convenient sampling while
for the majority of the remaining samples the sampling strategy was not speciﬁed. Suspect sampling
was reported for only 0.4% of the samples. However, the CONTAM Panel noted that there are no legal
limits or indicative values for furan, and that the compound is present due to processing and not due
to intentional use or environmental contamination. Therefore, the Panel considered it would be difﬁcult
in practice to identify suspect samples and that it cannot be excluded that the product was placed on
the market. It was therefore decided to retain those samples in the data set.
The majority of the samples were analysed by means of different GC–MS techniques, except for
approximately 27% of the samples where Member States did not provide a detailed classiﬁcation of
the method. LOQs were reported for more than 97% of the samples (Figure 10). Samples where the
LOQ value was omitted either referred to a sample with quantiﬁable levels or to a sample with
residues below the LOD.
Vertical line represent the median value, box outline represent 25th and 75th percentiles and whiskers represent
5th and 95th percentiles.
Figure 10: Distribution of reported limits of quantiﬁcation in lg/kg, presented by food group
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Furan may also be a constituent of the food additive caramel colours and the food ﬂavouring rum
ether. Caramel colours were re-evaluated by the ANS Panel (EFSA ANS Panel, 2011) and according to a
reﬁned exposure assessment combining all caramel colours (EFSA, 2012), the main contributors to the
mean exposure of toddlers and children to caramel colours were identiﬁed as ‘Dairy products and
analogues’, ‘Salts, spices, soups, sauces, salads and protein products’, ‘Non-alcoholic beverages’, ‘Edible
ices’ and ‘Bakery wares’. For adults, elderly and very elderly, the main contributors to the mean
exposure were ‘Salts, spices, soups, sauces, salads and protein products’, ‘Non-alcoholic beverages’
and ‘Alcoholic beverages, including alcohol-free and low-alcohol counterparts’. Rum ether was recently
evaluated by the CEF Panel (EFSA CEF Panel, 2017). For this ﬂavouring, a reﬁned exposure
assessment was not carried out, but use levels were reported for ‘Edible ices’, ‘Confectionery’, ‘Chewing
gum’, Cereal and cereal products derived from cereal grains, roots and tubers, and pulses and
legumes, excluding bakery wares of food category 7.0’, ‘Bakery wares’, ‘Meat and meat products’,
‘Salts, spices, soups, sauces, salads, protein products (including soya bean protein products) and
fermented soya bean products’, ‘Non-alcoholic beverages’ and ‘Alcoholic beverages’.
Although slightly different food classiﬁcations are applied in the area of food additives and ﬂavourings,
it can be concluded that the above reported food categories are covered by the available occurrence data
on furan. It is therefore expected that most of the furan levels resulting from the use of caramel colours
and rum ether have been captured in the ﬁnal data set, possibly contributing to the relatively high levels
of furan observed in certain food items (e.g. ﬁne bakery wares, soy sauce and spirits).
Occurrence of 2-methylfuran and 2,5-dimethylfuran resulting from their use as a food ﬂavouring is
no longer expected since both substances were removed from the Union list of ﬂavourings (see
Section 1.3.4).
3.2.2.2. Commercial data
A total number of 7,393 analytical results reported by commercial organisations were retained.
Samples analysed both as purchased and as consumed were in this case not reported; hence the
available data set refers to the same number of samples. The highest number of samples was reported
by ECF, mainly covering the years 2010–2016. From 2012 onwards, samples were also reported by
CEEREAL and SNE (Figure 11).
In view of a possible comparison, the commercial data were grouped in the same way as for the
governmental data (Annex A, Table A.2). Reported samples mainly referred to coffee beans and coffee
products (n = 6,796), coffee beverages (n = 131), ready-to-eat meals for infants and young children
(n = 348), and breakfast cereals (n = 67). All samples were analysed as purchased, except for the
samples in coffee beverage which were assumed to be solid coffee samples analysed as consumed.
However, as the corresponding solid samples could not be identiﬁed, a detailed impact assessment of
coffee preparation on the levels of furan was not possible.
CEEREAL: European Breakfast Cereal Association, ECF: European Coffee Federation, SNE: Specialised Nutrition
Europe.
Figure 11: Number of samples reported by commercial organisations, presented by year
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For most commercial data (over 99%), the sampling strategy remained unspeciﬁed but, as for the
governmental data, this is not expected to have a major impact on the assessment.
Most samples were analysed using a GC–MS method, while for 114 samples in coffee beverage the
data provider was not able to retrieve the adequate classiﬁcation for the method. LOQs were reported
for approximately 17% of the samples, ranging from 3 to 10 lg/kg. For the remaining samples LOQs
were not reported, but all these samples referred to quantiﬁable levels of furan in roasted coffee
beans (incl. ground coffee), instant coffee and coffee beverages.
In view of comparing the governmental and commercial data, several statistical tests were
considered but they were not adequate, in particular, for those food categories with a high percentage
of left-censored data. Nevertheless, looking at the most predominant food categories (coffee beans
and coffee products, coffee beverages, ready-to-eat meals for infants and young children, and
breakfast cereals), commercial data were generally found to be higher or within the same range as the
governmental data. One exception was identiﬁed for instant coffee powder where the mean of the
governmental data is approximately 50% higher compared to the commercial data. Due to the high
number of commercial samples, inclusion of the commercial data in the assessment would signiﬁcantly
lower the estimated mean for instant coffee powder. On the other hand, the CONTAM Panel also noted
that furan levels in instant coffee liquid are relatively low and that contribution of instant coffee to the
overall exposure is expected to be low, as already indicated in a previous assessment by EFSA
(2011d). The Panel therefore concluded that it would be appropriate to merge both data sets in view
of the exposure assessment.
3.2.3. Previously reported occurrence data in the open literature
EFSA and JECFA reviewed occurrence data on furan in foods up to 2010 (EFSA, 2011d; FAO/WHO,
2011). A literature search for recent reviews was conducted. However, since the occurrence of
methylfurans was not addressed in the identiﬁed reviews, a separate search to identify papers regarding
the occurrence of 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran was conducted. In addition, the
VCF database20 on volatile compounds in food was consulted to identify papers on methylfurans.
There are numerous citations reporting the occurrence of furan and methylfurans in the aroma
proﬁles of foods, of which some examples are presented below. These studies refer mainly to
commercially heat-processed foods, however, some report the natural occurrence of furan and
methylfurans in unprocessed foods.
It should be noted that some of the reviews described in this Section considered data that are
included in the EFSA occurrence data set described in Section 3.3.2.
A. Furan
Several papers reviewing the occurrence of furan in food were published after 2010 (Moro et al.,
2012b; Stadler, 2012; Mariotti et al., 2013; Seok et al., 2015; Santonicola and Mercogliano, 2016).
These reviews conclude that the highest levels of furan occur in roasted coffee (powder and beans).
High furan levels are also observed in foods that received a heat treatment in sealed containers such
as baby foods, soups, baked beans and meat products. However, furan also occurs in low moisture
foods that were not heated in a closed container, such as cereals, crackers, cookies (biscuits).
These conclusions are in accordance with JECFA review of furan including over 3,300 food samples
from 14 EU countries and Switzerland. Additionally, data from 6 other countries were considered. The
report of the review stated, ‘The range of national mean levels of furan for foods with the highest
contamination levels were as follows: roasted coffee (powder) (814–4,590 lg/kg), instant coffee
(powder) (90–783 lg/kg), brewed roasted coffee (34–113 lg/kg), baby food (19–96 lg/kg), soya
sauce (16–52 lg/kg), canned ﬁsh (6–76 lg/kg) and baked beans (27–581 lg/kg)’ (FAO/WHO, 2011).
Besides the presence in commercially heat-processed foods, furan has also been reported to occur
in home-cooked foods. Appendix E, Table E.1 gives an overview of furan concentrations in home-
cooked foods reported in scientiﬁc literature. The reported levels are in general low (< 10 lg/kg)
except for home-made toast, pizza, chips, candied potatoes, apple cake, caramel and crisps.
No furan (concentration < LOQ of 2.4 lg/kg) was quantiﬁed in home-made oatmeal porridge,
home-made soups, sweet and sour pork, meat sauce (Bolognese), omelette, mashed potatoes,
marinated potato salad, syrup cake, cookies, caramel sauce, lemon cream, fruit compote, white bread
and tea buns. Also, in meat balls, no furan was detected; however, in the crust of heavily fried meat
balls, a level of 2.4 lg/kg was quantiﬁed (DTU, 2009; Fromberg et al., 2014). Arisseto et al. (2012,
2013) studied the formation of furan during pressure cooking of beans, whole rice, soy beans, beef,
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pork, potato and cassava but no quantiﬁable results were measured (LOQ = 2.4 lg/kg). Furan was
also not detected (LOD = 3 lg/kg) in microwaved chips (Crews, 2009) and freshly home-cooked
vegetable, cereal, potato and fruit-based baby foods (LOD = 0.15 lg/kg) (Lachenmeier et al., 2009).
Juaniz et al. (2016) studied the formation of furan in frozen precooked bread-coated foods during
frying at 190°C in fresh or reheated oil. The data are reported in a ﬁgure and therefore not included in
Appendix E, Table E.1. Using fresh oil, the furan levels ranged from 16 lg/kg (ﬁsh ﬁngers) to 115 lg/
kg (onion rings). With the exception of ham croquettes and tuna pasties, furan levels were higher
when reheated oil was used (ranging from 12 lg/kg in tuna pasties to 172 lg/kg in onion rings).
Furan was not quantiﬁed (< LOQ of 2.3 lg/kg) in chopped vegetables (yellow onion, green peper,
cardoon, cabbage and chicory) that were fried (115/108°C) or griddled (150/110°C) with the exception
of griddled onion (3.5  0.3 lg/kg; mean  standard deviation; n = 3).
B. Co-occurrence of furan with methylfurans
Several studies have investigated the co-occurrence of furan, 2-methylfuran, 3-methylfuran and
2,5-dimethylfuran. Appendix E Table E.2 gives an overview of the concentrations reported in studies in
which furan and at least one methylfuran was analysed.
Health Canada published levels of furan, 2-methylfuran and 3-methylfuran for a wide range of
different foods mainly packaged in cans or jars (n = 176; fruit products, vegetable products, mixed
products, meat products, coffee and baby foods). The highest concentrations of 2-methylfuran were
reported for coffee. In all coffee samples (n = 3), 2-methylfuran occurred at higher concentrations
compared to furan, while 3-methylfuran concentrations were well below the concentrations of furan. In
all 17 samples of baby food, the levels of 2-methylfuran and 3-methylfuran were well below the levels
of furan. For the other foods, the highest 2-methylfuran concentrations ( 150 lg/kg) were found in a
sample of baked beans, ﬂakes of chicken and whole smoked oysters. In general, the 2-methylfuran
concentration was below the concentration of furan, but the CONTAM Panel noted that, particularly for
canned/jarred tomatoes (including sauces and drinks), some meat products, salmon and tuna, higher or
similar concentrations of 2-methylfuran compared to furan were reported. As for 2-methylfuran, the
3-methylfuran concentration was generally below the concentration of furan, but the CONTAM
Panel noted that, particularly for canned/jarred corn and tomatoes (including drinks), the concentration
of 3-methylfuran was higher than the concentrations reported for furan and 2-methylfuran (Becalski
et al., 2010).
The conclusions regarding the co-occurrence of furan, 2-methylfuran and 3-methylfuran in coffee
observed by Becalski et al. (2010) were conﬁrmed by the same authors in 2016. Commercially brewed
coffee (n = 40) and non-brewed coffee (n = 48) samples were collected in Canada and analysed for the
presence of furan, 2-methylfuran and 3-methylfuran. In all samples analysed, 2-methylfuran was
present at the highest concentrations and 3-methylfuran at the lowest concentrations. In non-brewed
coffee, the highest 2-methylfuran concentrations were reported for regular ground coffee, decaffeinated
ground coffee and cartridge ground coffee (mean: 9,470, 10,400, 10,700 lg/kg, respectively). In
comparison, the mean levels of furan in these coffees were 2,200, 2,450 and 2,360 lg/kg, respectively.
Lower levels of furan, 2-methylfuran and 3-methylfuran were reported for instant coffee powder; the
mean concentrations of 2-methylfuran were 1,595 and 1,800 lg/kg in regular and decaffeinated instant
coffee power, respectively, while the mean concentrations of furan were 233 and 329 lg/kg,
respectively. For non-brewed coffee, the authors reported mean 2-methylfuran/furan proportions
ranging from 4.24 to 6.84 and mean 3-methylfuran/furan proportions ranging from 0.19 to 0.31. For
commercially brewed coffee, the highest mean 2-methylfuran concentration was reported for espresso
(583 lg/kg), while lower mean concentrations were reported for medium roast or bold roast coffee
(172 lg/kg) and decaffeinated coffee (184 lg/kg). The mean concentrations of furan in these coffees
were 157, 38.7 and 53.1 lg/kg, respectively. For commercially brewed coffee, the authors reported
mean 2-methylfuran/furan proportions ranging from 3.5 to 4.4 and mean 3-methylfuran/furan
proportions ranging from 0.12 to 0.17 (Becalski et al., 2016).
Shen et al. (2016) analysed heat-processed Chinese foods samples for the presence of furan,
2-methylfuran, 2,5-dimethylfuran and other alkylfurans not in the scope of this Scientiﬁc Opinion. The
study included soy sauce, vinegars, fruit juices, beer and other alcoholic beverages, milk and milk
beverages, infant formula, coffee, salad sauce, tomato ketchup, baby-food purees, chocolates and
meat products. The information on the coffee samples was not included in this Scientiﬁc Opinion due
to uncertainty regarding the coffee type and the representiveness for coffee on the EU market.
2,5-Dimethylfuran was detected less frequently and at lower concentrations than furan and
2-methylfuran in soy sauce and vinegar. In fruit juices, beer and other alcoholic drinks, 2-methylfuran
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was most frequently detected; however, all three furans (i.e. furan, 2-methylfuran, 2,5-dimethylfuran)
only occurred at low concentrations (≤ 2.4 lg/kg). 2,5-Dimethylfuran was detected in 2 samples of
raw milk at relatively high concentrations (34.5 and 88.8 lg/kg), while furan and 2-methylfuran were
not detected in these samples. Both compounds on the other hand occurred in one condensed
milk sample and ﬁve milk powder samples at low but similar concentrations (≤ 8 lg/kg), while
2,5-dimethylfuran was not detected. In infant formula, 2,5-dimethylfuran was detected more
frequently compared to 2-methylfuran but in general at concentrations below the furan concentrations.
2,5-Dimethylfuran was not detected in any of the samples of meat products (n = 11), chocolates
(n = 6), tomato ketchup (n = 2), baby food purees (n = 11) and salad sauce (n = 1). In these food
groups, furan and 2-methylfuran were also not detected or at low levels (< 3 lg/kg), with the
exception of baby food purees, in which furan was detected at concentrations up to 16.2 lg/kg and
2-methylfuran up to 13.5 lg/kg.
Chaichi et al. (2013) analysed three coffee samples (ground, instant and a coffee-mix) to evaluate
the reliability of a newly developed a headspace liquid-phase microextraction GC/MS method for the
analysis of furan, 2-methylfuran and 2,5-dimethylfuran. 2-methylfuran was in all three samples present
at the highest concentration. Chaichi et al. (2015) used the same method to analyse 67 coffee
samples collected in supermarkets and hypermarkets in Tehran, Iran and the results conﬁrm the
occurrence of 2-methylfuran at high levels in coffee. However, the CONTAM Panel noted that only for
furan a labelled standard is used in this method and only to correct for the variation in injection
volume. Therefore, these studies are not further considered in the assessment.
The co-occurrence of furan, 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran in the headspace
of brewed coffee has also been reported in several other studies (e.g. Kallio et al., 1990; Shimoda and
Shibamoto, 1990; Leino et al., 1992).
Fromberg et al. (2014) analysed furan, 2-methylfuran and 2,5-dimethylfuran in coffee samples
(n = 15) and canned food (n = 12). The mean concentration of 2-methylfuran in coffee (1,328 lg/kg)
was higher than the concentration of furan (885 lg/kg) and 2,5-dimethylfuran (217 lg/kg). In canned
food, the highest mean concentration was reported for 2,5-dimethylfuran (67 lg/kg), while the levels
of furan and 2-methylfuran were 20.5 and 4.7 lg/kg, respectively.
Habibi et al. (2013) analysed six commercial baby food samples based on ﬂour or cereals for the
presence of furan, 2-methylfuran and 2,5-dimethylfuran. 2,5-Dimethylfuran was the dominant component
and furan was present at the lowest concentrations in all except one sample. Levels of 2,5-dimethylfuran
ranged from 69.42 to 230.25 lg/kg. These results are in contradiction with Shen et al. (2016) that
reported that 2,5-dimethylfuran was below the LOQ (1 lg/kg) in all analysed commercial baby food
purees (n = 11). However, it should be noted that these samples were fruit or vegetable based.
Bouseta et al. (1992) analysed 84 honey samples to determine their aroma proﬁles using dynamic
headspace GC–MS. Furan was reported to occur at concentrations up to 256 lg/kg (% of left-censored
data not reported). 2-Methylfuran was detected in 15 samples (18%) at concentrations up to 29 lg/kg.
The co-occurrence of furan and the methylfurans has also been reported in cooked meat. Galt and
MacLeod (1984) cooked beef for 1 or 4 h in an oven at 205°C and analysed the volatiles in the aroma.
3-Methylfuran and traces of furan and 2-methylfuran were present after 4 h but none of the
compounds was present after 1 h. Also, in the volatiles from cooked mutton, the co-occurrence of
furan and 2-methylfuran was reported (Nixon et al., 1979). Macleod and Ames (1986b) studied the
effect of heat on beef aroma in steak cooked at 104°C or 171°C for 1, 2 or 6 min. Traces of furan and
2-methylfuran were detected but not in the same aroma isolates. The same authors reported the
occurrence of 2-methylfuran in ground beef that had been cooked at 104°C for 2 min followed by
171°C for 6 min (Macleod and Ames, 1986a). The occurrence of 2,5-dimethylfuran was reported in
roasted chicken at a concentration of 1 lg/kg (250°C for 75 min) (Noleau and Toulemonde, 1986)
and in roast beef heated to internal temperatures of 85°C and 95°C at a concentration of 6.9 and
1.2 lg/kg, respectively (Vercellotti et al., 1987), while the other furan compounds studied in this
opinion were not reported to be present.
In addition, EFSA received data from FoodDrinkEurope, representing the European food and drink
industry, on the occurrence of furan, 2-methylfuran and 3-methylfuran in jarred baby foods, cereal
ﬂakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce. A few datapoints
on 2,5-dimethylfuran were also received; however, since no furan levels were reported for these
samples, the data could not be used for the evaluation of the co-occurrence of furan and the
methylfurans. In all baby food samples (n = 35), the highest concentration was observed for furan. In
infant cereals, on the other hand, the highest concentration was reported in general for 2-methylfuran
(mean: 15.4 lg/kg vs 7.3 and 1.6 lg/kg for furan and 3-methylfuran, respectively). In cereal ﬂakes,
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similar levels were reported for furan and 2-methylfuran (mean: 22 and 24 lg/kg, respectively) while
3-methylfuran was present at concentrations below or close to the reporting limit (5 lg/kg). A large
data set on roasted and grounded coffee (n = 117) and soluble coffee (n = 64) conﬁrmed the
conclusion from the scientiﬁc literature that 2-methylfuran occurs in coffee at concentrations higher
than furan. In tomato sauce (n = 3), furan occurred at concentrations below the reporting limit, while
both 2-methylfuran and 3-methylfuran were quantiﬁed although at low levels (≤ 10 lg/kg).
From the available data on the co-occurrence of furan and methylfurans, the CONTAM
Panel concluded that only for coffee, infant cereals, jarred baby-food and cereal ﬂakes a 2-methylfuran/
furan and 3-methylfuran/furan ratio can be calculated (Appendix E, Table E.3). The reported ratios are
calculated from the samples for which both furans were quantiﬁed. These food groups are also important
contributors to furan exposure as shown in previous exposure assessments (see Section 3.3.3). For the
other food groups, only limited data were available that does not allow drawing ﬁrm conclusions.
The CONTAM Panel noted the higher ratios for solid coffee compared to brewed coffee. This
difference might be explained by the fact that 2- and 3-methylfuran are more apolar compared to
furan and consequently the extraction to the liquid phase might be lower. Since coffee is consumed in
the liquid form, only data on brewed coffee were considered. From the available data, a median
2-methylfuran/furan ratio of 4.0 was calculated (average 2-methylfuran/furan ratio = 4.0) (Table 12).
The overall median 3-methylfuran/furan ratio for brewed coffee was 0.15 (average 3-methylfuran/
furan ratio = 0.15).
Based on a small data set (n = 18), the CONTAM Panel noted that similar concentrations of furan
and 2-methylfuran occur in cereal ﬂakes and calculated a median 2-methylfuran/furan ratio of 1.1.
3-Methylfuran on the other hand occurred at lower concentrations and was only quantiﬁed in 5 out of
the 18 samples with a median 3-methylfuran/furan ratio of 0.15. Also, in infant cereals (n = 28),
2-methylfuran was an important contributor to the total concentration of furans with a median
2-methylfuran/furan ratio of 1.4 (average = 1.7) (ratio calculated from 15 samples). 3-Methylfuran was
only a minor contributor and the % of left-censored data was high. The median 3-methylfuran/furan
ratio was 0.26 (ratio calculated from 5 samples).
Several data sources were identiﬁed reporting the co-occurrence of furan and methylfurans in
jarred baby foods (see Appendix E, Table E.2). The CONTAM Panel noted the differences in furan
levels among different data sets. For example, Shen et al. (2016) reported a mean furan concentration
for Chinese baby food purees of 5.1 lg/kg (range: < 1.0–16.2 lg/kg; n = 11) while higher levels were
reported by FoodDrinkEurope (mean: 35.6 lg/kg; range: 20–67 lg/kg; n = 35). The CONTAM
Panel noted that this mean value is close to the mean MB furan level of 31 lg/kg calculated from the
data set used for dietary exposure (see Section 3.2.2). In addition, the proﬁle of the furans was
different, showing higher methylfuran/furan ratios for the Chinese data compared to the European
data. Considering these differences and the uncertainty regarding the representativeness of samples
collected outside Europe for the jarred baby foods available on the European market, the CONTAM
Panel decided to use only the data on co-occurrence submitted by FoodDrinkEurope. From these data
a median 2-methylfuran/furan ratio of 0.23 (ratio calculated from 22 samples) and a 3-methylfuran/
furan ratio of 0.17 (ratio calculated from 19 samples) were calculated.
The CONTAM Panel noted that in canned/jarred tomatoes, 2-methylfuran and 3-methylfuran are
important contributors to the total level of furans. This has also been observed in other canned/jarred
tomato products such as tomato juices and tomato sauce. However, this observation is made on a
small data set and the data are too limited to calculate ratios.
Table 12: Overview of calculated median methylfuran/furan ratios
Food
Corresponding FoodEx
categories
Median 2-methylfuran/
furan ratio
Median 3-methylfuran/
furan ratio
Coffee Coffee beverage 4.0 0.15
Cereal ﬂakes Breakfast cereals 1.1 0.15
Infant cereals Cereal-based food for infants
and young children
1.4 0.26
Jarred baby foods Ready-to-eat meals for infants
and young children
0.23 0.17
Furan and methylfurans in food
www.efsa.europa.eu/efsajournal 76 EFSA Journal 2017;15(10):5005
C. 2-methylfuran
In addition to the studies on co-occurrence described above, the occurrence of 2-methylfuran has
been reported by several authors. However, it should be noted that in most studies the volatile
constituents were analysed.
2-Methylfuran has been reported to occur in the volatile constituents of milk (Coppa et al., 2011),
creams used as ﬁllers of bakery products (Ramos et al., 2009), okra (Ames and Macleod, 1990) and
roasted cocoa beans (Gill et al., 1984). Traces of 2-methylfuran have been detected during analysis of
volatile constituents in nectarines (Takeoka et al., 1988), acerola fruit (Pino and Marbot, 2001) and
peppers (Rodrıguez-Burruezo et al., 2010). Also, in a study on tomato volatiles, 2-methylfuran was
found in one of 10 samples of tomato juice, albeit at a low concentration (9% of the standard, not
quantiﬁed in the overall extractive). No 2-methylfuran was reported for fresh tomatoes, tomato paste,
tomato puree and canned diced tomatoes. Its presence was attributed to the heat processing of the
cooked tomato product analysed (Markovic et al., 2007).
Goldberg et al. (1999) analysed 2-methylfuran in 12 types of distilled spirits by HPLC-UV. The
highest concentrations were measured in bourbon (mean = 3,000 lg/L); however, it was also detected
in Armagnac, cognac, rye whiskey, blended scotch and rum (concentrations not reported). The
CONTAM Panel noted that the analysis was carried out using HPLC-UV which is not commonly used for
furan and methylfuran analysis (see Section 1.3.2). The occurrence of 2-methylfuran in distilled spirits
should therefore be conﬁrmed by another technique.
D. 3-methylfuran
The co-occurrence of furan and 3-methylfuran has been demonstrated in some studies as described
above. 3-methylfuran has also been reported to be present in the volatile compounds from wild rocket
(Diplotaxis tenuifolia L.) during storage (Luca et al., 2016).
E. 2,5-dimethylfuran
In addition to the studies on co-occurrence described above, the occurrence of 2,5-dimethylfuran
has been reported by some authors. However, it should be noted that in most studies the volatile
constituents were analysed.
Alasalvar et al. (2003, 2004) published two reports from studies examining volatiles in hazelnut
varieties. The average 2,5-dimethylfuran levels found in roasted nuts was 431 lg/kg and ranged from
14 to 75 lg/kg in different varieties of unroasted nuts. Traces of 2,5-dimethylfuran have been reported
to occur in Rooibos tea (Habu et al., 1985) and in the volatile components of okra (Ames and Macleod,
1990) and cooked eggs (Macleod and Cave, 1975).
3.3. Dietary exposure assessment for humans
3.3.1. Mean and high dietary exposure
Chronic dietary exposure was estimated across Europe following the methodology described in
Section 2.6. Hence a total of 35 dietary surveys, carried out in 19 different Member States, were
selected for this assessment. These dietary surveys and the number of subjects available per age class
are described in Annex A, Table A.3.
While the occurrence data for coffee and coffee imitates mainly referred to solid samples and a
limited number of samples was available for coffee and coffee imitate beverages, most of the selected
surveys reported consumption for coffee and coffee imitate beverages. Occurrence data from solid
coffee and coffee imitate samples were therefore converted to the corresponding beverages by
applying speciﬁc factors for dilution and loss of furan during brewing (see also Section 3.2.1).
Concentrations from all samples (i.e. liquid samples and converted solid samples) were subsequently
pooled to obtain a mean furan concentration for each beverage. Possible losses of furan during
standing of coffee and coffee imitate beverages after brewing were not considered because this
standing time is highly dependent on consumer behaviour and therefore not predictable. The adjusted
concentrations for coffee and coffee imitate beverages obtained through this conversion are
summarised in Table 13. On average, estimations for the major coffee types were consistent with the
mean furan concentrations observed in the limited number of samples reported for those beverages.
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For those consumption events referring to the solid coffee or coffee imitate rather than the
prepared beverage, only a loss factor was applied assuming that all these solids were consumed as a
beverage and loss of furan occurred during the preparation of those beverages. An overview of all
furan concentrations used for the chronic dietary exposure calculations (including the adjusted
concentrations for coffee and coffee imitates) is provided in Annex A, Table A.4.
Furthermore, EFSA identiﬁed a number of speciﬁc food categories where a consumption event may
refer either to fresh produce or commercially processed products (Annex A, Table A.5). As the
occurrence data for furan mainly refer to commercially processed products and furan is not expected
to occur in fresh produce, exposure through these food categories would be overestimated. In view of
reducing the uncertainty, consumption events reported for these food categories were analysed,
identifying those that referred to a canned, jarred, brined, pickled, smoked or cured product. This
analysis was performed by applying a text search to the original food description or by searching for
the corresponding facet descriptor when a dietary survey was already coded according to the FoodEx2
classiﬁcation. The overall contribution of commercially processed products was then calculated for each
food category and each dietary survey. Considering that such products have been under-reported in a
number of surveys, only the highest contribution of commercially processed products among dietary
surveys was retained for each food category (expressed in % in Annex A, Table A.5), and
subsequently applied to all consumers, regardless of the dietary survey. Any food item that is not listed
in Annex A, Table A.5 was assumed to be commercially processed.
Table 14 summarises the chronic dietary exposure estimates for furan across the 35 dietary
surveys. Detailed summary statistics on the exposure estimates calculated for each dietary survey are
presented in Annex A, Table A.6.
Table 13: Summary of the adjusted occurrence data for coffee and coffee imitate beverages
Coffee beverage DF(a) LF(b)
Liquid samples Solid samples(c) Pooled samples(d)
N
Mean
(lg/kg)
N
Mean
(lg/kg)
N
Mean
(lg/kg)
Coffee, Americano 18 2.3 164 51.2 4,605 2,361.2 4,769 56.8
Coffee, macchiato 7 2.3 0 – 4,605 2,361.2 4,605 146.7
Coffee, cappuccino 18 2.3 1 31 4,605 2,361.2 4,606 57
Coffee, espresso 7 2.3 17 81.6 4,605 2,361.2 4,622 146.4
Coffee, unspeciﬁed 18 2.3 179 59.7 4,605 2,361.2 4,784 57.1
Coffee, with milk 18 2.3 0 – 4,605 2,361.2 4,605 57
Imitates, brewed 18 2.3 0 – 28 1,921.9 28 46.4
Imitates, instant 50 1 18 1 108 126.5 126 2.3
Coffee, instant 63 1 54 4.9 1,457 309.5 1,511 4.9
DF: dilution factor; LF: loss factor; N: number of samples.
(a): The dilution factors usually applied by EFSA for Americano, cappuccino, espresso and instant coffee were extrapolated to the
other coffee (imitate) beverages, except for instant coffee imitates where (compared to the dilution factor for instant coffee)
a more conservative dilution factor was suggested during the consultation of stakeholders.
(b): For each brewing method, the loss factor selected by EFSA corresponds to the lowest reliable percentile (25th percentile) of
the loss factors reported in Section 3.2.1.
(c): All coffee drinks were assumed to be prepared from roasted and ground coffee beans, except for instant coffee and coffee
imitates where a speciﬁc category of solid samples is available.
(d): Prior to the pooling of liquid and solid samples, occurrence values for the solid samples were divided by the corresponding
dilution and loss factors to obtain an estimate for the corresponding beverages as consumed.
Table 14: Summary statistics of chronic dietary exposure assessments to furan across European
dietary surveys (baseline scenario)
Age class(a) N
Mean dietary exposure (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 6 0.14 0.21 0.40 0.49 0.87 0.99
Toddlers 10 0.22 0.31 0.36 0.46 0.52 0.65
Other children 18 0.19 0.27 0.28 0.36 0.45 0.52
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The difference between LB and UB estimates was found to be small, indicating that the uncertainty
due to left-censored data is limited. The highest chronic exposures were estimated in the youngest
population group, i.e. infants. Among the mean dietary exposures calculated for infants, the highest LB
estimate amounted to 0.87 lg/kg bw per day while the highest UB estimated amounted to 0.99 lg/kg
bw per day. Regarding the 95th percentile exposures, which refer to highly exposed consumers within
a given dietary survey and age class, the highest estimates were also observed for infants ranging
from 1.60 to 1.82 lg/kg bw per day (LB/UB). Dietary exposure in speciﬁc groups of the population,
namely pregnant and lactating women, were within the range of exposure estimates in the adult
population.
3.3.2. Contributions of different food groups
Contribution of the different food groups across dietary surveys is summarised by age class in
Annex A, Table A.7. These contributions were calculated on the basis of the middle bound (MB)
exposure estimates.
Food for infants and small children is the main contributor to the dietary exposure of infants to
furan. At the MB exposure, ready-to-eat meals for infants and small children accounted for up to 70%
of the exposure (median = 53%). One dietary survey did not report consumption of ready-to-eat
meals for infants and small children, which resulted in the lowest exposure estimate among infant
dietary surveys (see also Table 14). In this speciﬁc survey, where exposure is most likely
underestimated, the main contributors to the exposure were infant and follow-on formula liquid
(48%). The contribution of food for infants and small children in toddlers is still important, but much
lower compared to infants (max = 31%; median = 7%). In other age classes, contribution of this food
group to the exposure is negligible.
The group of non-alcoholic beverages was found to be the main contributor in adults, elderly and
very elderly. For all three age classes, the median contribution among surveys exceeds 50% and
contributions up to 85% were observed for speciﬁc surveys. Depending on the survey, these high
contributions are driven by either Americano coffee, espresso coffee or unspeciﬁed coffee, which is
consistent with the high concentrations of furan observed in coffee (see Section 3.2.2). Although high
concentrations of furan were estimated for other coffee beverages, consumption of these beverages is
less frequently reported and their contribution to the exposure is much lower. While non-alcoholic
Age class(a) N
Mean dietary exposure (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Adolescents 17 0.11 0.14 0.17 0.22 0.26 0.31
Adults 17 0.11 0.14 0.32 0.35 0.50 0.54
Elderly 14 0.12 0.15 0.32 0.36 0.58 0.61
Very elderly 12 0.13 0.16 0.28 0.32 0.71 0.75
Age class(a) N
95th percentile dietary exposure(c) (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 5 0.27 0.42 1.11 1.27 1.60 1.82
Toddlers 7 0.34 0.46 0.59 0.75 0.96 1.08
Other children 18 0.29 0.40 0.47 0.60 0.75 0.86
Adolescents 17 0.19 0.25 0.31 0.39 0.50 0.58
Adults 17 0.20 0.25 0.63 0.69 1.18 1.22
Elderly 14 0.24 0.28 0.66 0.70 1.25 1.27
Very elderly 9 0.27 0.32 0.52 0.56 0.92 0.96
bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.
(a): Section 2.4 describes the age range within each age class.
(b): Estimates were rounded to two decimal places.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011a). Those estimates were not included in this table.
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beverages may still contribute signiﬁcantly to the exposure of adolescents (max = 24%;
median = 12%, also driven by coffee beverages), their contribution to younger age classes is low. It is
also worth mentioning that in some surveys consumption of coffee was not reported as a beverage
but as a solid, which is included in the FoodEx category of vegetables and vegetable products. This
explains the high contribution of vegetables and vegetable products observed for certain surveys (21–
47%). Excluding these surveys, however, contributions to furan exposure from vegetables and
vegetable products are all below 10%.
Grains and grain-based products is another important contributor throughout all age classes, in
particular, for toddlers, adolescents and other children where it is the main contributor. The median
contribution among surveys ranges from 14% for infants to 49% for adolescents, with contributions
reaching up to 65% for certain surveys. A speciﬁc subcategory driving the contributions of this food
group cannot be identiﬁed.
A last important contributor to the dietary exposure is the group of composite foods, accounting for
more than 25% in several surveys. The main subcategories driving the contribution of this food group
are ready-to-eat soups and, to a smaller extent, cereal-based dishes.
Apart from a few exceptions, food groups other than those mentioned above generally accounted
for less than 10% of the dietary exposure.
3.3.3. Additional dietary exposure scenarios
In addition to the exposure assessment for furan reported under Section 3.3.1, hereafter referred
to as the baseline scenario, speciﬁc scenarios were considered in order to assess the inﬂuence of
several parameters, such as the impact of household preparation of food and the contribution of
2- and 3-methylfuran to the dietary exposure. Each of these scenarios was based on the baseline
scenario, including some additional assumptions which are further detailed in the following sections.
Reheating of ready-to-eat meals for infants and small children
The inﬂuence of reheating commercially processed foods on furan concentrations is limited and
highly dependent on the consumer behaviour which is not predictable (see Section 3.2.1). It was
therefore decided in the baseline scenario not to consider losses during re-heating of ready-to-eat
meals for infants and small children. However, ready-to-eat meals being the main contributor to the
dietary exposure of infants, an additional scenario was considered where all ready-to-eat meals for
infants and small children were assumed to be reheated in a hot-water bath without lid. Among the
heating techniques summarised in Appendix D, Table D.1, this heating technique leads to the highest
losses of furan with a median reduction factor of 1.7. Hence, in view of this scenario, furan
concentrations in ready-to-eat meals for infants and small children were divided by the aforementioned
reduction factor.
Chronic dietary exposure estimates assuming that all ready-to-eat meals for infants and small
children are re-heated in a hot-water bath (without lid) are summarised in Table 15, across all surveys.
Detailed summary statistics on the exposure estimates calculated for each dietary survey are
presented in Annex A, Table A.8. Infants and toddlers being the only age classes affected by the
current scenario, other age classes are not presented in Table 15.
Table 15: Summary statistics of the speciﬁc scenario assessing chronic dietary exposure to furan
across European dietary surveys, assuming that all ready-to-eat meals for infants and
small children are re-heated in a hot-water bath (without lid)
Age class(a) N
Mean dietary exposure (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 6 0.14 0.21 0.29 0.37 0.61 0.72
Toddlers 10 0.22 0.31 0.34 0.44 0.52 0.65
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Results indicate that heating of ready-to-eat meals for infants and small children is mainly expected
to impact on the dietary exposure of infants. According to this scenario, the exposure estimates for
infants are now in the same range as the exposure estimates for the adult population groups.
Compared to the outcome of the baseline scenario for infants, the present scenario is expected to
reduce the MB dietary exposure by 16–33% depending on the dietary survey. Only one dietary survey
for infants was not impacted by the present scenario. However, as for the baseline scenario, this
survey did not report consumption of ready-to-eat meals for infants and small children, and resulted in
the lowest exposure estimate among all infant dietary surveys.
For toddlers, the impact on the mean dietary exposure is limited but for highly exposed consumers
(95th percentile exposure) a reduction by up to 18% may be expected (median = 2%).
Home-cooking: toasting bread
Furan has been reported in home-cooked foods. The highest furan concentrations for these foods
were reported for toasted bread and caramel (see Appendix E, Table E.1). Considering the importance
of toasted bread in some diets, a scenario assessing the impact of toasting bread on the dietary
exposure was considered by the CONTAM Panel.
For this scenario, a furan concentration of 260 lg/kg was assumed for all toasted bread, which
corresponds to the highest mean concentration reported for fully browned toast in Appendix E, Table E.1.
To identify consumption records referring to toasted bread, any consumption record containing ‘toast’ in
its original food description was selected, and where the consumption data were already coded according
to FoodEx2, consumption records containing the processing facet for toasting (A07HC) were also
considered. Furthermore, any consumption record reported as toast bread was assumed to be toasted.
Chronic dietary exposure estimates for this scenario are summarised in Table 16, across all surveys.
Detailed summary statistics on the exposure estimates calculated for each dietary survey are
presented in Annex A, Table A.9.
Age class(a) N
95th percentile dietary exposure(c) (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 5 0.27 0.42 0.70 0.84 1.15 1.32
Toddlers 7 0.34 0.46 0.57 0.74 0.77 0.91
bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.
(a): Section 2.4 describes the age range within each age class.
(b): Estimates were rounded to two decimal places.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011a). Those estimates were not included in this table.
Table 16: Summary statistics of the speciﬁc scenario assessing chronic dietary exposure to furan
across European dietary surveys, assuming that all toasted bread is fully browned
(home-cooking)
Age class(a) N
Mean dietary exposure (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 6 0.14 0.21 0.41 0.49 0.90 1.01
Toddlers 10 0.22 0.31 0.40 0.49 0.68 0.77
Other children 18 0.19 0.27 0.33 0.41 0.47 0.55
Adolescents 17 0.11 0.14 0.19 0.25 0.28 0.34
Adults 17 0.13 0.16 0.32 0.36 0.57 0.61
Elderly 14 0.14 0.17 0.33 0.37 0.63 0.66
Very elderly 12 0.13 0.16 0.31 0.35 0.76 0.80
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Based on these results, toasted bread is expected to have a limited impact on the exposure of
infants where the mean and the 95th percentile MB exposure estimates increased by up to 16% and
9%, respectively.
For all other age classes, the impact on the dietary exposure is very variable depending on the
dietary survey. While a high number of exposure estimates remained unchanged compared to the
baseline scenario, the highest increases were observed for the 95th percentile exposures (MB), ranging
from 65% to 116% depending on the age class. These differences may partially be explained by the
fact that some surveys did not clearly report consumption of toasted bread, but it is also expected that
dietary habits may be different among Member States.
Nevertheless, the high increases reported above did not necessarily refer to the surveys giving the
highest exposure estimates under the baseline scenario and, when comparing the maximum exposure
estimates from the current scenario (Table 16) with the maximum exposure estimates from the
baseline scenario (Table 14), the overall impact of toasting bread on the outcome of the exposure
assessment is limited.
Contribution of 2- and 3-methylfuran to the exposure
Due to the lack of occurrence data for 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran in food,
these compounds could not be considered in the baseline exposure assessment. While for coffee
beverages, breakfast cereals, cereal-based food for infants and young children, and ready-to-eat meals
for infants and young children, indicative ratios for 2- and 3-methylfuran over furan were reported (see
Section 3.2.3, Table 12), literature data were too limited to derive such ratios for 2,5-dimethylfuran.
Hence, in order to assess the possible contribution of 2- and 3-methylfuran to the exposure,
occurrence values for the food categories reported in Table 12 were adjusted according to the
following equation:
MeanTF = MeanF 9 (1 + Ratio2MF/F + Ratio3MF/F)
Where:
MeanTF: mean concentration for the sum of furan, 2-methylfuran and 3-methylfuran
MeanF: mean concentration for furan
Ratio2MF/F: ratio of 2-methylfuran over furan
Ratio3MF/F: ratio of 3-methylfuran over furan
For those consumption events referring to a solid coffee product, the ratios derived for coffee
beverage were applied assuming that these solids were consumed as a beverage.
The food categories adjusted for this scenario are expected to provide a good indication for the
contribution of 2- and 3-methylfuran to the overall exposure because these food categories were also
identiﬁed as the main contributors to the exposure calculated under the baseline scenario.
Chronic dietary exposure estimates for the sum of furan, 2-methylfuran and 3-methylfuran are
summarised in Table 17, across all surveys. Detailed summary statistics on the exposure estimates
calculated for each dietary survey are presented in Annex A, Table A.10.
Age class(a) N
95th percentile dietary exposure(c) (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 5 0.27 0.42 1.11 1.27 1.75 1.94
Toddlers 7 0.34 0.46 0.70 0.82 1.35 1.47
Other children 18 0.29 0.40 0.60 0.71 0.91 1.00
Adolescents 17 0.22 0.28 0.39 0.47 0.61 0.66
Adults 17 0.24 0.29 0.67 0.72 1.27 1.31
Elderly 14 0.30 0.33 0.73 0.76 1.32 1.36
Very elderly 9 0.28 0.32 0.56 0.59 0.92 0.96
bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.
(a): Section 2.4 describes the age range within each age class.
(b): Estimates were rounded to two decimal places.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011a). Those estimates were not included in this table.
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When considering the sum of furan, 2-methylfuran and 3-methylfuran, the highest chronic
exposures are estimated for adults, the elderly and the very elderly. In these cases, the highest mean
exposure was calculated for the very elderly, ranging from 3.27 to 3.31 lg/kg bw per day (LB and UB
estimates, respectively). Compared to the exposures calculated under the baseline scenario, the
median contribution of 2- and 3-methylfuran to the overall exposure amounted to 245%, going up to
317% for one survey. Looking at the highly exposed consumers (95th percentile exposure), the
highest exposure is calculated for the elderly ranging from 6.11 to 6.14 lg/kg bw per day (LB and UB
estimates, respectively). In this case, the median contribution of 2- and 3-methylfuran corresponded to
351%, going up to 387% for one survey.
The high exposures calculated under this scenario for adults, elderly and very elderly are mainly
driven by the high occurrence of 2-methylfuran in coffee (four times higher than furan), while coffee
was already the major contributor to the exposure of furan in these age classes (see also
Section 3.3.2). For the younger age groups (infants, toddlers, adolescents and other children), the
major contributors to the exposure were food for infants and small children, and grains and grain-
based products. The concentrations of 2- and 3-methylfuran were much lower in these food groups.
Therefore, in the younger age groups, the contribution of these two compounds to the overall
exposure is estimated to be much lower than in the adult age groups.
3.3.4. Previously reported dietary exposure
The occurrence of furan in food was reported annually by the EFSA (2009, 2010c, 2011d). The
report published in 2011 includes all data collected between 2004 and 2010. In addition, it presents
exposure estimates for different populations. The analysis included a total of 5,050 analytical results
for furan content in food submitted by 20 countries. Mean furan exposure across surveys was
estimated to range between 0.03 and 0.59 lg/kg bw per day for adults, between 0.02 and 0.13 lg/kg
bw per day for adolescents, between 0.04 and 0.22 lg/kg bw per day for other children, between
0.05 and 0.31 lg/kg bw per day for toddlers, and between 0.09 and 0.22 lg/kg bw per day for
Table 17: Summary statistics of the speciﬁc scenario assessing chronic dietary exposure to the sum
of furan, 2-methylfuran and 3-methylfuran across European dietary surveys
Age class(a) N
Mean dietary exposure (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 6 0.17 0.25 0.52 0.61 1.21 1.35
Toddlers 10 0.28 0.36 0.40 0.50 0.63 0.77
Other children 18 0.23 0.31 0.31 0.39 0.49 0.60
Adolescents 17 0.15 0.18 0.21 0.27 0.44 0.50
Adults 17 0.21 0.24 1.14 1.18 2.25 2.29
Elderly 14 0.27 0.30 1.15 1.19 2.64 2.68
Very elderly 12 0.26 0.30 1.02 1.05 3.27 3.31
Age class(a) N
95th percentile dietary exposure(c) (lg/kg bw per day)
Minimum(b) Median(b) Maximum(b)
LB UB LB UB LB UB
Infants 5 0.34 0.49 1.54 1.70 2.21 2.36
Toddlers 7 0.51 0.64 0.63 0.81 1.25 1.40
Other children 18 0.37 0.49 0.55 0.67 1.31 1.40
Adolescents 17 0.29 0.33 0.51 0.58 1.31 1.36
Adults 17 0.46 0.50 2.66 2.70 5.73 5.78
Elderly 14 0.96 0.98 2.92 2.96 6.11 6.14
Very elderly 9 0.78 0.84 2.34 2.37 4.00 4.02
bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.
(a): Section 2.4 describes the age range within each age class.
(b): Estimates were rounded to two decimal places.
(c): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011a). Those estimates were not included in this table.
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infants. A major contributor to exposure for adults was brewed coffee with an average of 85% of total
furan exposure. Major contributors to furan exposure in toddlers and other children were fruit juice,
milk-based products and cereal-based products, whereas in addition for toddlers jarred baby foods
were major contributors. Table 18 gives an overview of the reported exposure levels.
JECFA evaluated furan at its 72nd meeting in 2010 (FAO/WHO, 2011) and considered dietary
exposure estimates for furan submitted by the USA, EU and Brazil. In general, the mean dietary
exposure was between 0.25 and 1.17 lg/kg bw per day for adults, between 0.08 and 0.23 lg/kg bw
per day for children 1–6 years of age, and between 0.27 and 1.01 lg/kg bw per day for infants. The
high dietary exposure was between 0.6 and 2.22 lg/kg bw per day for adults and between 0.99 and
1.34 lg/kg bw per day for infants. Coffee was the main contributor to dietary furan exposure for
adults, and breakfast cereals was the main contributor for children. Based on these data, JECFA
decided to use for the risk characterisation a value of 1 lg/kg bw per day to represent mean dietary
exposure and 2 lg/kg bw per day to represent high dietary exposure (see also Section 1.3.3).
In 2012, the Norwegian Food Safety Authority assessed the dietary exposure to furan as part of a
full risk assessment (VKM, 2012; see also Section 1.3.3). The mean dietary exposure was the highest
in 12-month old infants; being 0.62 lg/kg bw per day (0.65 lg/kg bw per day in non-breastfed
infants). For adults (18–70 years old), the mean dietary furan exposure was 0.27 lg/kg bw per day.
The 95th percentile dietary exposure was 1.43 lg/kg bw per day for 12-month-old infants and
0.77 lg/kg bw per day for adults. Coffee was the most important contributor to dietary furan exposure
in adults. For the younger age groups, jarred baby food and breakfast cereals (especially sweet
breakfast cereals) were the highest contributors.
The French Agency for Food, Environmental and Occupational Health & Safety (anses; Agence
nationale de securite sanitaire alimentation, environment, travail) published in 2016 the outcome of a
total diet study (TDS) in children younger than 3 years of age. The mean dietary exposure to furan was
0.14, 0.60, 0.84 and 0.37 lg/kg bw per day (UB) for 1–4 months, 5–6 months, 7–12 months and
13–36 months old infants, respectively. High dietary exposure (90th percentile) was 0.28, 1.29, 1.52 and
0.78 lg/kg bw per day for these age groups, respectively. For the youngest age group (1–4 months),
jarred baby food (vegetables) and infant formula27 were the main contributors and for the older age
groups jarred baby food (vegetables/vegetables with meat/vegetables with ﬁsh) (anses, 2016).
Health Canada carried out a deterministic exposure assessment for furan and the sum of furan and
2-methylfuran in 2010 using occurrence data reported by Becalski et al. (2005, 2010). This exposure
assessment was updated in 2016 using a probabilistic approach and the same occurrence data but more
recent consumption data. The mean dietary exposure to furan and the sum of furan and 2-methylfuran
was the highest in infants (0.65 and 0.69 lg/kg bw per day, respectively) and toddlers (0.32 and
0.40 lg/kg bw per day, respectively). For adults (age groups greater than 18 years of age), the mean
dietary exposures to furan and the sum of furan and 2-methylfuran were 0.18 and 0.20 lg/kg bw per
day, respectively. However, it should be noted that the presence of 2-methylfuran in brewed coffee and
rehydrated instant coffee was not taken into account in this assessment. Consequently, the exposure to
furan and 2-methylfuran of the age groups that consume coffee are expected to be higher than the
estimated intakes. It should also be noted that foods such as toast, breakfast cereals and milk were not
included in the exposure assessment. The major contributors to the dietary exposure of children up to
13 years of age were canned baked beans, fruit juices and sauces and condiments, while coffee was the
most important contributor in all age classes greater than 18 years (Health Canada, 2016).
Table 18: Overview of previously reported dietary exposure levels
Age group(a) Location
Mean dietary
exposure
(lg/kg bw
per day
High dietary
exposure
(lg/kg bw
per day
Reference
Infants EU 0.09–0.22 0.89–0.97 EFSA (2011d)
Infants USA, EU and Brazil 0.27–1.01 0.99–1.34 FAO/WHO (2011)
Infants France 0.14–0.84 0.28–1.52 Anses (2016)
Infants Norway 0.62–0.65 1.43 VKM (2012)
27 Reported by the authors as ‘Preparations 1er a^ge’.
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3.3.5. Non-dietary sources of exposure
In addition to dietary exposure, exposure through inhalation during cooking occurs. Crews (2009)
measured furan in the air during cooking. Low and variable concentrations were detected when the
cooking activity was less than 10 mins, while higher levels were observed when the cooking took
longer than 10 mins. The authors calculated the amount of furan inhaled during cooking which varied
between 11 and 523 ng furan depending on the food, the duration of the processing and type of
processing technique. However, the authors indicated that these values should be considered as rough
estimates only.
There are numerous reports of furan exposure through cigarette smoke. Furan is listed as one of
the ‘Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke’ on the US
Food and Drug Administration’s website.28 The exposure to furan per ‘puff’ (40 mL inhalation) was
reported to be about 8.4 lg (Egle and Gochberg, 1979a). Pouli et al. (2003) reported a higher level of
furan in cigarette smoke than 2,5-dimethylfuran (37.3 vs 19.4 lg/cigarette). The same observation was
made by Hatzinikolaou et al. (2006), although lower levels were reported (20.2 vs 10.7 lg/cigarette).
Baek and Jenkins (2004) reported besides the presence of furan and 2,5-dimethylfuran in cigarette
smoke also the presence of 2-methylfuran at similar levels as furan.
Furan29 and methylfurans are also used in industrial settings (see also Section 1.3.6).
3.4. Risk characterisation
3.4.1. Furan
Non-neoplastic effects
The CONTAM Panel selected the BMDL10 of 0.064 mg/kg bw per day (corrected for the applied
dose regimen of 5 days per week) for the induction of cholangioﬁbrosis in male rats after 2 years as
reference point for the risk characterisation of the non-neoplastic effects.
Comparison of the chronic dietary exposure to furan across dietary surveys and age groups
reported above (Table 14) to this BMDL10 of 0.064 mg/kg bw per day, results in MOE values (Table 19)
that range from 584 (minimum LB) to 65 (maximum UB) for the mean exposure estimates, and from
338 (minimum LB) to 35 (maximum UB) for the 95th percentile exposure estimates across dietary
surveys and age groups.
Age group(a) Location
Mean dietary
exposure
(lg/kg bw
per day
High dietary
exposure
(lg/kg bw
per day
Reference
Infants Canada 0.65 1.76 Health Canada (2016)
Toddlers EU 0.05–0.31 0.15–1.38 EFSA (2011d)
Toddlers France 0.37 0.78 Anses (2016)
Toddlers Canada 0.32 0.70 Health Canada (2016)
Children 1–6 years USA, EU and Brazil 0.08–0.23 n.a. FAO/WHO (2011)
Other children EU 0.04–0.22 0.06–0.46 EFSA (2011d)
Adolescents EU 0.02–0.13 0.05–0.31 EFSA (2011d)
Adults (> 18 years) EU 0.03–0.59 0.08–1.29 EFSA (2011d)
Adults USA, EU and Brazil 0.25–1.17 0.6–2.22 FAO/WHO (2011)
Adults (18–70 years) Norway 0.27 0.77 VKM (2012)
Adults (> 18 years) Canada 0.14–0.21 0.33–0.48 Health Canada (2016)
n.a.: not available; bw: body weight.
(a): Data are organised according to age classes speciﬁed in Section 2.4 unless otherwise speciﬁed.
28 http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm
29 https://echa.europa.eu/nl/substance/information/-/substanceinfo/100.003.390
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The CONTAM Panel considered that based on the available toxicity data and taking inter- and intra-
species variations into account, a MOE of 100 or higher would be sufﬁcient to conclude a low health
concern for the non-neoplastic effects. The calculated MOEs for the incidence of cholangioﬁbrosis are
below 100 in a number of dietary surveys, particularly for the high percentile exposure estimates for
the younger age groups (infants and toddlers) and adults (including elderly). The CONTAM
Panel concluded that these MOEs indicate a health concern.
Neoplastic effects
The CONTAM Panel selected the BMDL10 of 1.31 mg/kg bw per day (corrected for the applied dose
regimen of 5 days per week) for the induction of hepatocellular adenomas and carcinomas in female
mice after 2 years as a reference point for the risk characterisation of the neoplastic effects.
Comparison of the chronic dietary exposure to furan across dietary surveys and age groups
reported above (Table 14) to this BMDL10 of 1.31 mg/kg bw per day, results in MOE values (Table 20)
that range from 11,948 (minimum LB) to 1,328 (maximum UB) for the mean exposure estimates, and
from 6,917 (minimum LB) to 722 (maximum UB) for the 95th percentile exposure estimates across
dietary surveys and age groups.
For substances that are both genotoxic and carcinogenic, the EFSA Scientiﬁc Committee stated that
an MOE of 10,000 or higher, if based on the BMDL10 from an animal carcinogenicity study, would be of
low concern from a public health point of view (EFSA, 2005). The CONTAM Panel noted that, with the
exception of some dietary surveys, the calculated MOEs are smaller than 10,000, which would indicate
Table 19: Margins of exposure (MOE) values for the incidence of cholangioﬁbrosis across dietary
surveys and age groups
Age group
MOE calculated from mean dietary
exposure
MOE calculated from P95 dietary
exposure
Minimum Median Maximum Minimum Median Maximum
LB UB LB UB LB UB LB UB LB UB LB UB
Infants 459 306 161 131 74 65 238 153 58 51 40 35
Toddlers 292 207 179 140 124 99 189 140 109 86 67 60
Other children 338 238 230 179 143 124 222 161 137 107 86 75
Adolescents 584 459 378 292 247 207 338 257 207 165 129 111
Adults 584 459 201 184 129 119 321 257 102 93 54 53
Elderly 536 429 201 179 111 105 268 230 97 92 51 51
Very elderly 495 402 230 201 91 86 238 201 124 115 70 67
N: number of dietary surveys; LB: lower bound; UB: upper bound; P95: 95th percentile.
Table 20: Margins of exposure (MOE) values for the incidence of hepatocellular adenomas and
carcinomas across dietary surveys and age groups
Age group
MOE calculated from mean dietary exposure
MOE calculated from P95 dietary
exposure
Minimum Median Maximum Minimum Median Maximum
LB UB LB UB LB UB LB UB LB UB LB UB
Infants 9,388 6,259 3,286 2,682 1,511 1,328 4,868 3,129 1,184 1,035 821 722
Toddlers 5,974 4,240 3,651 2,857 2,527 2,022 3,866 2,857 2,228 1,752 1,369 1,217
Other
children
6,917 4,868 4,694 3,651 2,921 2,527 4,532 3,286 2,796 2,190 1,752 1,528
Adolescents 11,948 9,388 7,731 5,974 5,055 4,240 6,917 5,257 4,240 3,370 2,629 2,266
Adults 11,948 9,388 4,107 3,755 2,629 2,434 6,571 5,257 2,086 1,905 1,114 1,077
Elderly 10,952 8,762 4,107 3,651 2,266 2,155 5,476 4,694 1,991 1,878 1,051 1,035
Very
elderly
10,110 8,214 4,694 4,107 1,851 1,752 4,868 4,107 2,527 2,347 1,429 1,369
N: number of dietary surveys; LB: lower bound; UB: upper bound; P95: 95th percentile.
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a health concern for substances that are both genotoxic and carcinogenic. However, there is
uncertainty regarding the carcinogenic MoA of furan.
As discussed in Section 3.1.5 on critical effects, there is clear evidence for the involvement of
indirect mechanisms in the carcinogenic MoA of furan. These include epigenetic changes, oxidative
damage to DNA and regenerative hyperplasia, with all these effects being accompanied by tissue
damage. In addition, extensive protein binding of BDA restricts access to DNA, and binding to histones
may also contribute to the reported epigenetic changes. There is limited evidence of a direct
mechanism (i.e. direct interaction with DNA) in the carcinogenic action of furan. A very low level of
altered DNA bases was observed in vivo but their chemical structures could not be identiﬁed. These
altered DNA bases are not identical to the adducts formed by reaction of BDA with DNA. Nevertheless,
there is evidence of chromosomal damage in vivo, but it is unknown whether this is caused by a direct
or indirect mechanism.
Although there is uncertainty regarding the role of a direct genotoxic mechanism in the
carcinogenic action of furan, the CONTAM Panel considered the resulting MOEs for hepatocellular
adenomas and carcinomas as supporting evidence for its conclusion, based on the hepatotoxicity of
furan, that the current exposure to furan indicates a health concern.
3.4.2. Additivity of furan and methylfurans
For the methylfurans, insufﬁcient information is available to identify a reference point. 2-
Methylfuran, 3-methylfuran and 2,5-dimethylfuran have all been shown to convert to reactive species
via ring opening evidently via CYP2E1 similar to the metabolic pathway of furan. Also, as with furan,
these methylfurans have been found to give rise to non-extractable binding to protein (and, with 2-
methylfuran, to DNA) in the liver. Only limited information is available on 2-methylfuran and 2,5-
dimethylfuran genotoxicity. There is possible involvement of alternative routes of metabolic activation
for 2,5-dimethylfuran. Finally, the hepatic toxicity of both 2- and 3-methylfuran in rodents exhibited a
potency of the same order of magnitude to that of furan. Based on the above comparisons, it was
considered appropriate for hepatotoxicity to assume dose additivity for furan, 2-methylfuran, 3-
methylfuran. However, since there is no information on hepatotoxicity of 2,5-dimethylfuran in vivo the
CONTAM Panel is unable to include this in the additivity assumption.
Due to the lack of occurrence data on methylfurans in the available data set, a scenario was
designed to estimate the chronic dietary exposure to the sum of furan, 2-methylfuran and 3-
methylfuran based on 2-methylfuran/furan and 3-methylfuran/furan ratios for some selected foods
(see Section 3.3.3). Comparison of the chronic dietary exposure calculated for this scenario (Table 17)
to the BMDL10 of 0.064 mg/kg bw per day for the incidence of cholangioﬁbrosis, results in MOE values
(Table 21) that range from approximately 430 (minimum LB) to 20 (maximum UB) for the mean
exposure estimates, and from 220 (minimum LB) to 10 (maximum UB) for the 95th percentile
exposure estimates across dietary surveys and age groups.
Table 21: Margins of exposure (MOE) values for the incidence of cholangioﬁbrosis based on a
scenario for chronic dietary exposure to the sum of furan, 2-methylfuran and 3-
methylfuran across dietary surveys and age groups
Age group
MOE calculated from mean dietary
exposure
MOE calculated from P95 dietary
exposure
Minimum Median Maximum Minimum Median Maximum
LB UB LB UB LB UB LB UB LB UB LB UB
Infants 378 257 124 105 53 48 189 131 42 38 29 27
Toddlers 230 179 161 129 102 83 126 100 102 79 51 46
Other children 280 207 207 165 131 107 174 131 117 96 49 46
Adolescents 429 357 306 238 146 129 222 195 126 111 49 47
Adults 306 268 56 54 29 28 140 129 24 24 11 11
Elderly 238 214 56 54 24 24 67 66 22 22 11 10
Very elderly 247 214 63 61 20 19 82 77 27 27 16 16
N: number of dietary surveys; LB: lower bound; UB: upper bound; P95: 95th percentile
Note: the additive exposure has been calculated as mg/kg bw per day and not on a molar basis.
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The CONTAM Panel noted that the calculated MOEs for the incidence of cholangioﬁbrosis are below
100 for more than 50% of the dietary surveys for the adult age groups (including elderly and very
elderly) for both mean and high percentile exposure estimates. Also, for the younger age groups,
MOEs below 100 were calculated for some dietary surveys. From these ﬁgures, it becomes clear that
methylfurans may add signiﬁcantly to the overall exposure and therefore increase the concern for
hepatotoxicity.
3.5. Uncertainty analysis
The evaluation of the inherent uncertainties in the assessment of exposure to furan and
methylfurans has been performed following the guidance of the Opinion of the Scientiﬁc Committee
related to Uncertainties in Dietary Exposure Assessment (EFSA, 2007). In addition, the report on
‘Characterizing and Communicating Uncertainty in Exposure Assessment’ has been considered (WHO/
IPCS, 2008).
3.5.1. Assessment objectives
The objectives of the assessment were clearly speciﬁed in the terms of reference.
3.5.2. Exposure scenario/exposure model
To estimate chronic dietary exposure to furan, EFSA used a ﬁnal data set containing 9,663 samples
provided by governmental organisations and 7,393 samples provided by commercial organisations. The
amount of occurrence data submitted differs considerably depending on food products and reporting
data provider, with most of the samples (~ 80%) collected in only ﬁve Member States (and ~ 60%
originating from one single Member State). There is therefore uncertainty on whether possible country-
based differences in the levels of furan in diverse food commodities are well represented. Likewise, the
lack of information on the analytical method used to analyse some food samples (~ 30% of the
governmental data) adds some uncertainty to the concentrations of furan reported for some food
commodities.
Another uncertainty regarding the occurrence data refers to the roasting degree of coffee, as the
available data did not allow differentiating furan concentrations in light, medium and dark roast coffee.
While a consumer’s preference for dark roast coffee is expected to increase the dietary exposure to
furan, the exposure estimate for light roast coffee consumers will most likely be lower. Furthermore, in
order to estimate the occurrence of furan in prepared coffee and coffee imitate beverages, certain
assumptions were made on the dilution and loss of furan during beverage preparation. On average,
estimations for the major coffee types were consistent with the furan concentrations measured in a
limited number of beverage samples. Considering the wide variety of coffee preparation methods,
uncertainty remains regarding other very speciﬁc preparation methods that may occur in practice. In
addition, possible losses of furan during standing of beverages after brewing could not be considered in
the present assessment because the standing time is highly dependent on consumer behaviour and
therefore not predictable. Overall, these uncertainties may lead to an overestimation or underestimation
of exposure.
Furan may also occur in food additives and ﬂavourings, which may be used in a wide range of food
products. While it is expected that most of the furan concentrations resulting from those uses have
been captured in the ﬁnal data set, some minor food products may not be covered by the available
data hereby resulting in a minor underestimation of the exposure estimates.
Uncertainties and limitations related to the use of the EFSA Comprehensive Food Consumption
Database have already been described by EFSA (EFSA, 2011a) and are not further detailed in this
opinion. However, among those with a particular implication for the dietary exposure to furan, the
uncertainty associated to commercially processed foods should be mentioned because for certain food
groups (e.g. vegetables and vegetables products) consumption data have been mostly reported at the
level of raw commodities (e.g. tomatoes), without systematic information on whether these were
commercially processed products (e.g. canned tomatoes). Following a more detailed analysis of the
Comprehensive Database, the highest contribution of commercially processed products among dietary
surveys was derived for each food category and applied to all consumers, regardless of the dietary
survey. Assuming the same contribution for all consumers may underestimate the upper tail exposures
for high consumers of commercially processed products. However, as this contribution refers to the
maximum contribution observed among dietary surveys, mean exposures are expected to be
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overestimated. Furthermore, eating occasions reported for composite food were assumed to be
commercially processed as no information is available on whether they referred to homemade dishes
or ready-to-eat foods. Also in this case, an overestimation of the exposure is likely.
The Comprehensive Database also contains limited information on consumer’s preferences
regarding coffee consumption (e.g. roasting degree, coffee type). In particular, unspeciﬁed coffee
beverage is the most frequently reported coffee beverage in the Comprehensive Database. While these
coffee beverages were handled as the most frequently consumed coffee within Europe (i.e. Americano
coffee or ﬁltered coffee), these consumption events might in fact refer to other coffee types with
higher or lower furan concentrations. For several surveys, consumption events for coffee and coffee
imitates were reported as the solid. Options for reﬁnement of the exposure through solid coffee were
limited and conservative assumptions were applied. Hence, an overestimation of the exposure is
expected in these surveys.
Additional uncertainty in the exposure assessment to furan is related to the reheating of
commercially processed foods, which may be particularly important for infants where ready-to-eat
meals are the most important contributor to the exposure. While some reheating techniques have a
very limited impact on the concentrations of furan (therefore not considered in the main exposure
scenario), heating of a meal in a hot water bath without lid may decrease the exposure by
approximately 15–30%. Due to the limited information, home-cooking habits were also not considered
in the main exposure scenario but the example of toasting bread was assessed in a separate scenario.
While fully browned toasting of bread was found to increase signiﬁcantly the exposure estimates for
some population groups (up to 116%), the overall impact on the outcome of the assessment was
limited.
The highest level of uncertainty is associated to the lack of occurrence data on 2-methylfuran,
3-methylfuran and 2,5-dimethylfuran. While data for these compounds were too limited for
consideration in the main exposure scenario, an additional scenario was elaborated where EFSA
considered indicative occurrence values for 2- and 3-methylfuran in the food categories contributing
the most to the exposure. This scenario indicated that 2- and 3-methylfuran may increase the
exposure for adults, elderly and very elderly by more than 300%, and it is expected that exposure
estimates would increase even more in case occurrence data for 2,5-dimethylfuran would be available.
In addition to dietary exposure to furan and methylfurans, exposure via inhalation may occur in
humans but this was not taken into account in this risk assessment.
3.5.3. Model input (parameters)
Currently, no ofﬁcial standard methods are available for the analysis of furan and methylfurans in
foods. Analytical results used for the exposure assessment were therefore obtained using different
analytical methods and varying LOQ/LODs. Although a large proportion of left-censored results was
found in certain food groups (i.e. grains and grain-based products, foods for infants and young
children and composite foods), the difference between LB and UB estimates was found to be small,
particularly for adults, elderly and very elderly where coffee is the main contributor to the dietary
exposure. This indicates that the uncertainty due to left-censored data is limited.
Furthermore, analytical methods for furan mostly rely on the use of headspace analysis, while a
limited additional formation of furan during the equilibration of the sample in the headspace vials has
been reported (see Section 1.3.2). This may result in a minor overestimation of furan concentrations in
food.
3.5.4. Other uncertainties
Although many studies on the toxicity of furan have been published, several sources of uncertainty
have been identiﬁed. The greatest degree of uncertainty concerns the carcinogenic MoA of furan i.e.
whether or not furan is directly genotoxic and the extent to which this may contribute to
carcinogenicity at levels to which humans are exposed.
For studies that attempt to estimate concentrations of furan or methylfurans in cell cultures or in
tissues, there is uncertainty regarding the loss via evaporation. This potentially could lead to an
overestimate of exposure both in vitro and in vivo. In vitro studies that used a reduced headspace to
avoid evaporation may have incurred oxygen depletion leading to compromised metabolic capacity,
introducing uncertainty in the interpretation of the results. In tissues of dosed animals, the evaporation
may affect the measured residual concentrations.
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Regarding methylfurans, there are limited studies on absorption, metabolism and toxicity.
Carcinogenicity data are limited to one study on 2,5-dimethylfuran. In addition to the demonstrated
ring opening of methylfurans, there is a theoretical possibility of oxidation of the side-chain leading to
furyl alcohols which can subsequently be activated by sulfonation, aldehydes and acids but this
possibility has not been assessed. Therefore, a conclusion regarding the potential for the methylfurans
to be carcinogenic in a similar way to furan cannot be made. Based on evidence of reactivity of
metabolites and similarity in hepatotoxic potency, it was considered reasonable, despite uncertainty, to
combine furan, 2-methylfuran and 3-methylfuran as an additive in assessment of hepatotoxicity.
3.5.5. Summary of uncertainties
In Table 22, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of furan
is moderate and that the assessment is likely to be conservative. For methylfurans, due to a lack of
data, no full assessment could be performed and the uncertainties in the assessment are large.
4. Conclusions
Furan, 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran are volatile compounds that are formed
in foods during thermal processing. Furan can be formed in food from a variety of precursors including
ascorbic acid, amino acids, carbohydrates, unsaturated fatty acids and carotenoids.
4.1. Occurrence/Exposure
• To estimate chronic dietary exposure to furan, EFSA used a ﬁnal data set containing 9,663 samples
provided by governmental organisations and 7,393 samples provided by commercial
organisations. Governmental data and commercial data were found to be comparable and it was
considered appropriate to merge both data sets.
• Food characteristics, processing and cooking conditions, and the losses which occur mainly due
to evaporation in the preparation of the food at the level of the consumer, determine the ﬁnal
concentration in the food as consumed.
• The highest concentrations of furan were found in whole roasted coffee beans, with a mean
value of 4,579 lg/kg. Mean concentrations in ground roasted coffee (2,361 lg/kg) and
unspeciﬁed coffee solids (2,186 lg/kg) were lower, suggesting a loss of furan during the
process of grinding. High concentrations of furan were also found in coffee imitates for brewing
(1,922 lg/kg), instant coffee powder (310 lg/kg) and instant coffee imitates (127 lg/kg).
Table 22: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of the dietary exposure of furan and methylfurans in food
Sources of uncertainty Direction
Extrapolation of the occurrence data to the whole of Europe +/(a)
Lack of occurrence data in coffee in relation to its roasting degree +/
Assumptions on the preparation of coffee and coffee imitate beverages +/
Assumptions on the contribution of commercially processed foods to the consumption +/
Assumptions on the consumption of unspeciﬁed coffee beverages +/
Exclusion of reheating commercially prepared foods in the baseline exposure scenario +
Exclusion of home-cooking practices in the baseline exposure scenario 
Exclusion of methylfurans in the baseline exposure scenario 
Evaporation of furan in tissues and cell cultures 
Potential for a direct genotoxic mechanism in the carcinogenic mode of action of furan 
Potential genotoxicity and carcinogenicity of methylfurans 
Using an additive approach for furan and methylfurans regarding hepatotoxicity +/
(a): + = uncertainty with potential to cause over-estimation of exposure/risk;  = uncertainty with potential to cause under-
estimation of exposure/risk.
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• During coffee beverage preparation furan concentrations decrease substantially due to a
combination of dilution, evaporation and partial extraction. Highest losses of furan during
beverage preparation were observed for boiled/Turkish coffee (median loss factor of 11.6), and
losses for ﬁlter coffees (median loss factor of 4.2) were also found to be higher compared to
espresso coffees (median loss factor of 2.8). For instant coffees, the loss of furan during
beverage preparation is considered negligible.
• Mean concentrations ranging from 20 to 57 lg/kg were found in composite foods (prepared
salads, cereal-based and vegetable-based), ready-to-eat meals for infants and young children,
soy sauce, bread and rolls, raw pasta, breakfast cereals, ﬁne bakery wares and spirits. In all
remaining samples, including a wide range of mainly commercially prepared foods, mean furan
concentrations were below 20 lg/kg.
• Occurrence data for 2-methylfuran, 3-methylfuran and 2,5-dimethylfuran were not provided,
and from the available literature data on the co-occurrence of furan and methylfurans, a 2-
methylfuran/furan and 3-methylfuran/furan ratio was calculated only for coffee, infant cereals,
jarred baby-food and cereal ﬂakes. Co-occurrence data on 2,5-dimethylfuran were too limited
to derive such a ratio.
• The highest exposures to furan were estimated in the youngest population group, i.e. infants.
The mean dietary exposures calculated for infants ranged from 0.14 to 0.99 lg/kg bw per day
(minimum LB to maximum UB). Regarding the 95th percentile exposures, which refer to highly
exposed consumers within a given dietary survey and age class, the highest estimates were
also observed for infants ranging from 0.27 to 1.8 lg/kg bw per day (minimum LB to
maximum UB).
• Ready-to-eat meals for infants and small children are the main contributor to the dietary
exposure of infants. For adults, elderly and very elderly, the exposure is mainly driven by
coffee. Grains and grain-based products is the most contributing food group for toddlers, other
children and adolescents, and it is also the second largest contributor in all other age classes.
Other important contributors to the exposure of most age classes are ready-to-eat soups, and
to a smaller extent, cereal-based composite foods.
• Overall, the inﬂuence of reheating commercially processed foods on furan concentrations is
limited and depends on the consumer behaviour. Regarding ready-to-eat meals for infants and
young children, reheating the meals in a hot water bath (without lid) may reduce the dietary
exposure of infants by approximately 15–30% depending on the dietary pattern. This results in
an exposure comparable to the exposures in the adult age classes.
• In addition, furan can also be formed during home cooking. A scenario based on toasting
bread, the process that caused the highest increase in the foods studied, showed that
although for some speciﬁc subpopulations a signiﬁcant increase of the exposure was observed
the overall outcome of the exposure assessment (including all subpopulations) was not
impacted.
• In the exposure scenario for the sum of furan, 2-methylfuran and 3-methylfuran, estimates for
adults, elderly and very elderly showed the highest increase compared to the baseline
scenario. The highest mean exposure, calculated for the very elderly, was approximately
3.3 lg/kg bw per day (LB = UB), while the highest 95th percentile exposure was
approximately 6.1 lg/kg bw per day (LB = UB) for the elderly. This exposure was mainly
driven by the high concentrations of 2-methylfuran in coffee (four times higher than furan).
4.2. Hazard identiﬁcation and characterisation
Toxicokinetics
Furan
• After oral exposure to rats, furan is rapidly and extensively absorbed from the GI tract,
distributed throughout the body and extensively metabolised to give carbon dioxide and polar
metabolites in urine or bile/faeces.
• Furan has a very short half–life in liver and blood: approximately 40 min in liver and approximately
1.3 h in blood. Although at 24 h post-dosing some furan-related material could be extracted from
liver tissue, 80% of the residual material in the liver appeared to be non-extractable.
• The major route for elimination of furan is via metabolic conversion, resulting in opening of the furan
ring and formation of BDA which is very reactive. BDA has never been directly measured. However,
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results with trapping agents and the identiﬁcation of urinary and biliary metabolites provide strong
evidence that BDA is indeed a prime reactive intermediate in the metabolism of furan.
• CYP2E1 is by far the most important monooxygenase that catalyses the conversion of furan
into BDA.
• BDA reacts readily with amino acids, GSH and biogenic amines. A plethora of adducts has been
reported. Elimination of these adducts via urine is biphasic: in ﬁrst instance, the main excretion
consists of BDA coupled to free amino acids or GSH. Later, the urinary excretion of furan-related
material is a result from protein turn-over that liberates the furan-damaged amino acid residues.
• BDA has direct reactivity towards DNA. However, the data suggest that BDA reacts readily with
protein and non-protein amino and thiol residues, thereby restricting access to DNA in vivo.
• It is currently impossible to select any furan metabolite as a quantitative biomarker of
exposure. Furan may also be formed endogenously, which may need to be taken into account.
Methylfurans
• No oral studies have been performed with any of the three methylfurans considered in this
opinion to address their kinetics in animals, but it is anticipated that the three methylfurans will
be absorbed from the GI tract.
• Non-extractable association of 2-methylfuran with protein and DNA in the liver was reported after
i.p. administration. For 2- and 3-methylfuran data from in vitro studies are available that show
that they may become associated (non-extractable) with lung and liver microsomal proteins.
• The reactive metabolic intermediates of 2- and 3-methylfuran are the cis-enedials 3-acetylacrolein
(4-oxopent-2-enal) and 2-methylbut-2-enedial, respectively. Also, for 2,5-dimethylfuran, ring
opening results in the formation of a reactive intermediate, the cis-enedione 3(Z)-hexene-2,
5-dione.
• Similar to BDA, the reactive intermediate formed from 2,5-dimethylfuran reacts readily with
amino acids and with GSH and corresponding structures for the adducts formed have been
reported. For 2- and 3-methylfuran metabolites, only very limited information is available, but
from the structures of their primary metabolites and from studies with scavengers, it is
anticipated that these will react with tissue components in a similar way to the primary
metabolites of furan and 2,5-dimethylfuran. For the methylfurans or their metabolites, there is no
direct information on reactivity towards DNA. However, limited genotoxicity studies provide an
indication that such interactions may occur.
Toxicity
Furan
• In experiments of a duration of up to 90 days, furan is strongly hepatotoxic and moderately
nephrotoxic in rodents when applied by oral gavage. Rats seem to be more sensitive towards
furan than mice. Furan leads to characteristic changes in serum markers related to
hepatotoxicity as well as severe histopathological damage in the liver.
• The hepatotoxic effects are particularly pronounced in centrilobular and subcapsular areas and
can be attenuated by suppression of CYP activity.
• After 90 days, signiﬁcant increases in serum thyroid hormones were observed along with
severe histopathological changes in the liver of male rats after a daily dose of 0.12 mg/kg bw,
given 5 days a week.
• In long-term studies, furan was associated with toxicity in the liver. Cholangioﬁbrosis was
observed in rats as an early and sensitive response with signiﬁcant increases after 36 weeks at
doses of 0.44 mg/kg bw and above.
• In mice, hepatocellular adenoma/carcinoma occurred at 104 weeks at doses of 4 mg/kg bw
and above. In rats, cholangiocarcinomas were observed at the top dose of 8 mg/kg bw. No
relevant malignancies were observed at doses at or below 2 mg/kg bw up to 104 weeks.
• Furan did not induce gene mutations in bacteria.
• In the majority of the in vitro studies in mammalian cells, furan was able to induce
chromosomal aberrations and sister chromatid exchanges; contrasting results were reported on
the requirement for microsomal activation.
• BDA, the CYP2E1-mediated metabolite of furan, formed DNA adducts at the exocyclic N atom
of the dC, dG and dA nucleosides in in vitro model systems and in DNA from S. Typhimurium
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TA104. BDA was able to directly induce mutations in bacteria and strand breaks and mutations
in mammalian cells in vitro.
• In rodents, furan induced very low levels of DNA adducts in liver and kidney. The chemical
structures of these adducts could not be deﬁned but were not identical to those induced by
BDA in in vitro model systems.
• Conﬂicting data were reported for the induction of DNA breaks in the liver. These breaks, likely
reﬂecting oxidative stress-induced DNA damage, occurred at doses showing mild liver toxicity.
Chronic exposure to furan-induced chromosomal damage in proliferating splenocytes from mice
and rats. The DNA lesions responsible for these effects remain undeﬁned.
• No clear induction of base substitutions was observed in transgenic rat models. A weak
mutagenic activity was suggested by a single study in a transgenic mouse model.
• An excess of GC > TA transversions was observed at codon 61 of the Ha-ras oncogene in furan-
induced liver tumours in mice. It is uncertain whether these mutations are the consequence of
oxidative damage to DNA or reﬂect an expansion of pre-existing spontaneous Ha-ras mutations.
• Histological changes in the testes, prostate gland, Leydig cells and seminal vesicles were
observed in Wistar rats at 2 mg/kg bw (lowest dose tested) and above given during weaning
and post-puberty. No histological effects in reproductive organs were observed in adult rats
and mice up to 8 mg/kg bw.
Methylfurans
• The liver is the primary target organ with respect to acute and short-term (< 90 days) toxicity of
2- and 3-methylfuran in rodents. Pulmonary toxicity was observed upon inhalation but also upon i.p.
application. There is also indication for kidney toxicity of 3-methylfuran after 90 days of exposure.
• No clear differences in structure–effect relationship for the investigated alkylated furans with
respect to the pattern of adverse effects/the target organs were identiﬁed.
• Liver toxicity in male rats given 3-methylfuran (28 or 90 days) or 2-methylfuran (28 days) by
gavage was found to be the most sensitive adverse endpoint for both compounds. Their toxic
potency was reported to be in the same order of magnitude as that for furan.
• No information on the genotoxic properties of 3-methylfuran and limited information for
2-methylfuran and 2,5-dimethylfuran is available. Both 2-methylfuran and 2,5-dimethylfuran
showed negative results in bacteria. There is some evidence that both compounds induce
chromosomal damage in mammalian cells in vitro and there is little evidence that
2,5-dimethylfuran can induce DNA breaks in vivo.
Mode of action
• Furan induces oxidative stress. BDA binds covalently to a range of target molecules, including
proteins and GSH. These features lead ultimately to cell and tissue damage, mitochondrial
dysfunction and ﬁbrosis, primarily in the liver.
• There is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of
furan. These include epigenetic changes, oxidative damage to DNA and regenerative
hyperplasia, with all of these effects being accompanied by tissue damage.
• There is limited evidence of a direct mechanism (i.e. direct interaction with DNA) in the
carcinogenic action of furan.
• The contributing factors in carcinogenesis are likely to vary according to dose, duration of exposure
and degree of severity of liver cellular damage, inﬂammation and compensatory proliferation.
Considerations of critical effects, dose–response modelling and possibilities for derivation
of a health based guidance value
• Since only few data are available on the effect of furan in humans, the CONTAM Panel used
data in experimental animals for the hazard characterisation.
• For non-neoplastic effects, the CONTAM Panel selected the BMDL10 of 0.09 mg/kg bw per day
(5 days per week dosing regimen) for the induction of cholangioﬁbrosis in male rats after
2 years as reference point. This corresponds to 0.064 mg/kg bw per day (correcting for the
applied dose regimen of 5 days per week).
• For neoplastic effects, the CONTAM Panel considered that the combined data set from NTP
(1993) and Moser et al. (2009) on the incidence of hepatocellular adenomas and carcinomas in
female mice after 2 years is the most robust data set to derive a reference point and selected
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the BMDL10 of 1.84 mg/kg bw per day (5 days per week dosing regimen). This corresponds to
1.31 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week).
• In view of some indications for a direct genotoxic mechanism in the carcinogenic MoA of furan,
the CONTAM Panel decided that it was not appropriate to establish a TDI and used an MOE
approach.
• The available information was insufﬁcient to identify a reference point for the methylfurans.
However, it was considered appropriate to assume dose additivity for hepatotoxicity of furan,
2-methylfuran and 3-methylfuran in the rat.
4.3. Risk characterisation
• For non-neoplastic effects, MOE values that range from 584 (minimum LB) to 65 (maximum
UB) for the mean exposure estimates, and from 338 (minimum LB) to 35 (maximum UB) for
the 95th percentile exposure estimates across dietary surveys and age groups have been
calculated. The calculated MOEs are below 100 in a number of dietary surveys, particularly for
the high percentile exposure estimates for the younger age groups (infants and toddlers) and
adults (including elderly). The CONTAM Panel concluded that these MOEs indicate a health
concern.
• For neoplastic effects, MOE values that range from 11,948 (minimum LB) to 1,328 (maximum
UB) for the mean exposure estimates, and from 6,917 (minimum LB) to 722 (maximum UB)
for the 95th percentile exposure estimates across dietary surveys and age groups have been
calculated.
• The CONTAM Panel noted that, with the exception of some surveys, the calculated MOEs for
neoplastic effects of furan are smaller than 10,000, which, in accordance with the guidance
given by the Scientiﬁc Committee, would indicate a health concern. However, there is
uncertainty regarding the carcinogenic MoA of furan. The CONTAM Panel considered the
resulting MOEs for hepatocellular adenomas and carcinomas as supporting evidence for its
conclusion, based on the hepatotoxicity of furan, that the current exposure to furan indicates a
health concern.
• Based on a scenario for chronic dietary exposure to the sum of furan, 2-methylfuran and 3-
methylfuran, MOE values for the incidence of cholangioﬁbrosis range from approximately 430
(minimum LB) to 20 (maximum UB) for the mean exposure estimates, and from 220 (minimum
LB) to 10 (maximum UB) for the 95th percentile exposure estimates across surveys and age
groups have been calculated. From these ﬁgures, it becomes clear that methylfurans may add
signiﬁcantly to the overall exposure and therefore increase the concern for hepatotoxicity.
5. Recommendations
• There is a need for additional data on the occurrence of methylfurans in food.
• There is a need for additional data on the changes of furan and methylfurans concentrations
during the distinct stages of coffee preparation for all coffee types.
• Studies in vivo on the effect of furan on the genome to clarify the carcinogenic MoA are
needed.
• Further information is needed on the toxicity, including the genotoxic properties, of
methylfurans.
Documentation provided to EFSA
1) Data on the co-occurrence of furan, 2-methylfuran and 3-methylfuran in jarred baby foods,
cereal ﬂakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce.
December 2016. Submitted by FoodDrinkEurope, outside the ad-hoc call for occurrence data
(see Section 2.3.1).
2) Gill S, Kavanagh M, Cherry W, Bourque C, Caldwell D, Wang G and Bondy G. A 90-Day
Subchronic Gavage Toxicity Study in Fischer 344 Rats with 3-methylfuran. August 2017.
Submitted by Health Canada.
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ABT aminobenzotriazole
ACB-PCR allele-speciﬁc competitive blocker-polymerase chain reaction
ADME absorption, distribution, metabolism and excretion
AIC Akaike information criterion
ALP alkaline phosphatase
ALT alanine aminotransaminase
anses Agence nationale de securite sanitaire alimentation, environnement, travail
AP apurinic/apyrimidinic
BDA cis-but-2-ene-1,4-dialdehyde
BMD benchmark dose
BMDL benchmark dose lower conﬁdence limit
BMDU benchmark dose upper conﬁdence limit
BrdU 5-bromo-2-deoxyuridine
BSO buthionine sulfoximine
BUN blood urea nitrogen
bw body weight
CA chromosomal aberrations
CEEREAL European Breakfast Cereal Association (),
CHO Chinese hamster ovary
CONTAM EFSA Panel on Contaminants in the Food Chain
Cys cysteine
CYP cytochrome P450
dA 2’-deoxyadenosine
DATA EFSA Evidence Management Unit
dC 2’-deoxycytidine
DEM diethylmaleate
dG 2’-deoxyguanosine
DPE Documentation provided to EFSA by FoodDrinkEurope
DSB double strand break
dT 2’-deoxythymidine
EC50 half maximal effective concentration
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ELISA enzyme-linked immunosorbent assay
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GC-SRI-TOF-MS gas chromatography-selective reagent ionization-time of ﬂight-mass spectrometry
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GSH glutathione
GST-P glutathione S-transferase placental form
HBGV health-based guidance value
HPLC high-performance liquid chromatography
IARC International Agency for Research on Cancer
ICL inter-strand crosslink
Ig immunoglobulin
IL interleukin
i.p. intraperitoneal
IPCS International Programme on Chemical Safety
JECFA Joint FAO/WHO Expert Committee on Food Additives
Kow octanol/water partition coefﬁcient
LB lower bound
LC left-censored
LC–MS/MS liquid chromatography/tandem mass spectrometry
LC50 lethal concentration, median
LD50 lethal dose, median
LDL low-density lipoprotein
LOAEL lowest-observed-adverse-effect level
LOD limit of detection
LOQ limit of quantiﬁcation
Lys lysine
Max maximum
MB middle-bound
Min minimum
ML maximum level
MoA mode of action
MOE margin of exposure
MS mass spectrometry
MW molecular weight
N Number
n.r. not reported
NADH nicotinamide adenine dinucleotide
NAC N-acetylcysteinyl
NAL N-acetyllysinyl
NAS US National Academy of Sciences
NAT N-acetyltransferase
NIEHS US National Institute of Environmental Health Sciences
NOAEL no-observed-adverse-effect level
NTP National Toxicology Program
OTZ oxothiazolidinecarboxylate
PBPK physiologically based pharmacokinetic
PND post-natal day
PTR-MS proton-transfer reaction mass spectrometry
ROS reactive oxygen species
SCE sister chromatid exchange
SDH sorbitol dehydrogenase
SIM selective ion monitoring
SNE Specialised Nutrition Europe
SPME solid-phase microextraction
SOP standard operational procedure
SSB single strand break
stAR steroidogenic acute regulating protein
SULT sulfotransferase
TDI tolerable daily intake
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TNF tumour necrosis factor
UB upper bound
UDS unscheduled DNA synthesis
UV ultraviolet
VKM Norwegian Scientiﬁc Committee for Food Safety
WG Working group
WHO World Health Organization
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Appendix A – Identiﬁcation and selection of evidence relevant for the risk
assessment of furan and methylfurans in food
A.1. Literature search for supporting information for the assessment
A literature search for recent reviews, in combination with a limited literature search for topics not
sufﬁciently covered by reviews, was used to identify the scientiﬁc literature. The used search strings
and the number of results in web of science and PubMed are given below.
A.1.1. Furan, 2-methylfuran and 3-methylfuran
Search for reviews
A. Web of Science
Used search string: TOPIC: (Furan OR 2-methylfuran OR 3-methylfuran) AND TOPIC: (food)
Reﬁned by: DOCUMENT TYPES: (REVIEW); Timespan=2006–2016; Search language=Auto
Results in Web of Science: 78
B. PubMed
Used search string: ((((Furan OR 2-methylfuran OR 3-methylfuran)) AND food) AND review) AND
(“2006/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in PubMed: 26
Search for information regarding the occurrence, formation and analysis of 2-methylfuran
and 3-methylfuran
A. Web of Science
Used search string: TOPIC: (2-methylfuran OR 3-methylfuran) AND TOPIC: (food OR formation OR
analys*) Timespan=2006–2016; Search language=Auto
Results in Web of Science: 187
B. PubMed
Used search string: (((2-methylfuran OR 3-methylfuran)) AND (food OR formation OR analys*))
AND (“2006/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in PubMed: 60
Search for previous exposure assessments
A. Web of Science
Used search string: TOPIC: (furan OR 2-methylfuran OR 3-methylfuran) AND TOPIC: (exposure and
food) NOT TOPIC: (PCDD OR PCDF); Timespan=2006–2016; Search language=Auto
Results in Web of Science: 228
B. PubMed
Used search string ((((furan OR 2-methylfuran OR 3-methylfuran)) AND (exposure and food)) NOT
(PCDD OR PCDF)) AND (“2006/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in PubMed: 49
Overall results
From these searches, 628 references were identiﬁed and after removal of the duplicates
466 references were screened for relevance.
A.1.2. 2,5-dimethylfuran
Search for reviews
C. Web of Science
Used search string: TOPIC: (2,5-dimethylfuran) AND TOPIC: (food) Reﬁned by: DOCUMENT
TYPES: (REVIEW); Timespan=2006–2016; Search language=Auto
Results in Web of Science: 0
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D. PubMed
Used search string: ((((2,5-dimethylfuran)) AND food) AND review) AND (“2006/01/01”[Date -
Publication] : “3000”[Date - Publication])
Results in PubMed: 0
Search for information regarding the occurrence, formation and analysis of 2,5-
dimethylfuran
C. Web of Science
Used search string: TOPIC: (2,5-dimethylfuran) AND TOPIC: (food OR formation OR analys*)
Timespan=2006–2016; Search language=Auto
Results in Web of Science: 123
D. PubMed
Used search string: (((2,5-dimethylfuran)) AND (food OR formation OR analys*)) AND (“2006/01/01”
[Date - Publication] : “3000”[Date - Publication])
Results in PubMed: 66
Search for previous exposure assessments
C. Web of Science
Used search string: TOPIC: (2,5-dimethylfuran) AND TOPIC: (exposure and food) NOT TOPIC:
(PCDD OR PCDF); Timespan=2006-2016; Search language=Auto
Results in Web of Science: 5
D. PubMed
Used search string ((((2,5-dimethylfuran)) AND (exposure and food)) NOT (PCDD OR PCDF)) AND
(“2006/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in PubMed: 5
Overall results
From these searches, 199 references were identiﬁed and after removal of the duplicates
159 references were screened for relevance.
A.1.3. Coffee
Since most of the occurrence data on coffee were reported for the solid, while most coffee
consumption data were reported as liquid, the WG carried out an additional literature search to identify
papers regarding furan and methylfurans in coffee.
A. Web of Science
Used search string: TOPIC: (coffee) AND TOPIC: (furan or 2-methylfuran or 3-methylfuran or 2,5-
dimethylfuran) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI,
CCR-EXPANDED, IC Timespan=2006–2017
Results in Web of Science: 114
B. PubMed
Used search string: (((“Coffee”[Mesh] or coffee)) AND (furan or 2-methylfuran or 3-methylfuran or
2,5-dimethylfuran)) AND (“2006/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in PubMed: 53
From these searches, 167 references were identiﬁed and after removal of the duplicates 119
references were screened for relevance.
A.2. Literature search for hazard identiﬁcation and characterisation
In addition to the literature search outsourced by EFSA (see NFI, 2017 for further details), some
speciﬁc searches were performed to identify the scientiﬁc literature. The used search strings and the
number of results in web of science and PubMed are given below.
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A.2.1. Search for papers regarding the genotoxicity caused by cis-2-
butene-1,4-dial
A. Web of Science
Used search string: TOPIC: (“cis-2-butene-1,4-dial” OR “maleic dialdehyde”) AND TOPIC: (genotox*
OR muta* OR DNA OR damage OR repair OR clastogen* OR aneugen* OR chromosom*);
Timespan=1990–2016; Search language=Auto
Results in Web of Science: 152
B. PubMed
Used search string: (((“cis-2-butene-1,4-dial” OR “maleic dialdehyde”)) AND (genotox* OR muta*
OR DNA OR damage OR repair OR clastogen* OR aneugen* OR chromosom*)) AND (“1990/01/
01”[Date - Publication] : “3000”[Date - Publication])
Results in Web of Science: 57
From these searches, 209 references were identiﬁed and after removal of the duplicates
141 references were screened for relevance.
A.2.2. Search for papers regarding the toxicity of 2,5-dimethylfuran
A.2.2.1. Toxicokinetics
A. Web of Science
Used search string: TOPIC: (2,5-dimethylfuran) AND TOPIC: (absor* OR tissue* OR metaboli* OR
excret* OR kinetic* OR toxicokinetic* OR pharmacokinetic* OR degrad* OR biotrans*);
Timespan=1990–2016; Search language=Auto
Results in Web of Science: 110
B. PubMed
Used search string: ((2,5-dimethylfuran) AND ((absor* OR tissue* OR metaboli* OR excret* OR
kinetic* OR toxicokinetic* OR pharmacokinetic* OR degrad* OR biotrans*))) AND (“1990/01/01”[Date -
Publication] : “3000”[Date - Publication])
Results in Web of Science: 47
A.2.2.2. Toxicity in experimental animals
A. Web of Science
Used search string: TOPIC: (2,5-dimethylfuran) AND TOPIC: ((oral OR diet* OR gavage OR feed
OR food OR organ* OR tissue* OR cancer* OR carcino* OR tumor* OR tumour* OR tox* OR immun*
OR teratogen* OR rat OR mouse OR mice OR rabbit*)); Timespan=1990–2016; Search language=Auto
Results in Web of Science: 98
B. PubMed
Used search string: ((2,5-dimethylfuran) AND (oral OR diet* OR gavage OR feed OR food
OR organ* OR tissue* OR cancer* OR carcino* OR tumor* OR tumour* OR tox* OR
immun* OR teratogen* OR rat OR mouse OR mice OR rabbit*)) AND (“1990/01/01”[Date -
Publication] : “3000”[Date - Publication])
Results in Web of Science: 68
A.2.2.3. Genotoxicity and mode of action
A. Web of Science
Used search string: TOPIC: ((2,5-dimethylfuran) AND TOPIC: (genotox* OR mode OR action OR
mechanism* OR muta* OR DNA OR damage OR repair OR clastogen* OR aneugen* OR
chromosom*)); Timespan=1990–2016; Search language=Auto
Results in Web of Science: 102
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B. PubMed
Used search string: ((2,5-dimethylfuran) AND (genotox* OR mode OR action OR
mechanism* OR muta* OR DNA OR damage OR repair OR clastogen* OR aneugen* OR
chromosom*)) AND (“1990/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in Web of Science: 36
A.2.2.4. Observations in humans
A. Web of Science
Used search string: TOPIC: (2,5-dimethylfuran) AND TOPIC: (epidemio* OR biomarker* OR
exposure* OR case* OR poison* OR cohort* OR cross-sectional OR random* OR work*);
Timespan=2004–2016; Search language=Auto
Results in Web of Science: 80
B. PubMed
Used search string: ((2,5-dimethylfuran) AND (epidemio* OR biomarker* OR exposure*
OR case* OR poison* OR cohort* OR cross-sectional OR random* OR work*)) AND
(“2004/01/01”[Date - Publication] : “3000”[Date - Publication])
Results in Web of Science: 35
From these searches, 576 references were identiﬁed and after removal of the duplicates
298 references were screened for relevance.
A.2.3. Papers not included in this scientiﬁc opinion
The list below gives an overview of the scientiﬁc papers (excluding abstracts and reviews) related
to the toxicity and toxicokinetics of furan and methylfurans that were identiﬁed in the scientiﬁc
literature (see Section 2.2) but not included in the opinion.
Bas H, Pandir D and Kalender S, 2016. Furan-induced hepatotoxic and hematologic changes in diabetic rats: the
protective role of lycopene. Arhiv za Higijenu Rada i Toksikologiju, 67, 194–203. https://doi.org/10.1515/aiht-
2016-67-2762
Bluhm K, Seiler TB, Anders N, Klankermayer J, Schaeffer A and Hollert H, 2016. Acute embryo toxicity and
teratogenicity of three potential biofuels also used as ﬂavor or solvent. The Science of the Total Environment,
566–567, 786-795. https://doi.org/10.1016/j.scitotenv.2016.05.055
Carrette LL, Gyssels E, De Laet N and Madder A, 2016. Furan oxidation based cross-linking: a new approach for
the study and targeting of nucleic acid and protein interactions. Chemical Communications, 52, 1539–1554.
https://doi.org/10.1039/c5cc08766j
Carrette LL, Morii T and Madder A, 2013. Toxicity inspired cross-linking for probing DNA-peptide interactions.
Bioconjugate Chemistry, 24, 2008–2014. https://doi.org/10.1021/bc400327q
Dang NL, Hughes TB, Miller GP and Swamidass SJ, 2017. Computational approach to structural alerts: furans,
phenols, nitroaromatics, and thiophenes. Chemical Research in Toxicology, 30, 1046–1059. https://doi.org/10.
1021/acs.chemrestox.6b00336
Deferme L, Wolters J, Claessen S, Briede J and Kleinjans J, 2015. Oxidative stress mechanisms do not discriminate
between genotoxic and nongenotoxic liver carcinogens. Chemical Research in Toxicology, 28, 1636–1646.
https://doi.org/10.1021/acs.chemrestox.5b00222
Doyle M, Sexton KG, Jeffries H and Jaspers I, 2007. Atmospheric photochemical transformations enhance 1,3-
butadiene-induced inﬂammatory responses in human epithelial cells: the role of ozone and other
photochemical degradation products. Chemico-Biological Interactions, 166, 163–169. https://doi.org/10.1016/
j.cbi.2006.05.016
Fry JR, Hammond AH, Garle MJ and Lal K, 1993. Comparison of xenobiotic-mediated cytotoxicity in rat cultured-
hepatocytes and the V79 Chinese-Hamster lung ﬁbroblast cell-line - can metabolically-activated hepatotoxins
be identiﬁed by selective cytotoxicity to hepatocytes. Atla-Alternatives to Laboratory Animals, 21, 8–12.
Garcia-Gomez D, Bregy L, Barrios-Collado C, Vidal-de-Miguel G and Zenobi R, 2015. Real-time high-resolution
tandem mass spectrometry identiﬁes furan derivatives in exhaled breath. Analytical Chemistry, 87, 6919–6924.
https://doi.org/10.1021/acs.analchem.5b01509
Hamadeh HK, Jayadev S, Gaillard ET, Huang Q, Stoll R, Blanchard K, Chou J, Tucker CJ, Collins J, Maronpot R,
Bushel P and Afshari CA, 2004. Integration of clinical and gene expression endpoints to explore furan-mediated
hepatotoxicity. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 549, 169–183.
https://doi.org/10.1016/j.mrfmmm.2003.12.021
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Higgins LG, Cavin C, Itoh K, Yamamoto M and Hayes JD, 2008. Induction of cancer chemopreventive enzymes by
coffee is mediated by transcription factor Nrf2. Evidence that the coffee-speciﬁc diterpenes cafestol and
kahweol confer protection against acrolein. Toxicology and Applied Pharmacology, 226, 328–337. https://doi.
org/10.1016/j.taap.2007.09.018
Huang Q, Jin X, Gaillard ET, Knight BL, Pack FD, Stoltz JH, Jayadev S and Blanchard KT, 2004. Gene expression
proﬁling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutation Research, 549, 147–167.
https://doi.org/10.1016/j.mrfmmm.2003.12.020
Inamdar AA, Masurekar P and Bennett JW, 2010. Neurotoxicity of fungal volatile organic compounds in Drosophila
melanogaster. Toxicological Sciences, 117, 418–426. https://doi.org/10.1093/toxsci/kfq222
Kamijima M, Sobue G, Ichihara G, Shibata E, Ono Y, Kondo H, Villanueva MB, Itoh T, Mitsuma T and Takeuchi Y,
1996. Toxic effects of hexane derivatives on cultured rat Schwann cells. Toxicology, 108, 25–31.
Lai GH and Sirica AE, 1999. Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis,
20, 2335–2340.
McMurtry RJ and Mitchell JR, 1977. Renal and hepatic necrosis after metabolic activation of 2-substituted furans
and thiophenes, including furosemide and cephaloridine. Toxicology and Applied Pharmacology, 42, 285–300.
https://doi.org/10.1016/0041-008x(77)90005-9
Muller A, Briviba K, Graf V, Greiner R, Herrmann C, Kuballa T and Stahl MR, 2013. UV-C treatment using a Dean
vortex technology - impact on apple juice enzymes and toxicological potential. Innovative Food Science &
Emerging Technologies, 20, 238–243. https://doi.org/10.1016/j.ifset.2013.07.010
Ochi T and Ohsawa M, 1985. Participation of active oxygen species in the induction of chromosomal aberrations by
cadmium chloride in cultured Chinese hamster cells. Mutation Research, 143, 137–142.
Pandir D, 2015. Assessment of the DNA damage in human sperm and lymphocytes exposed to the carcinogen
food contaminant furan with comet assay. Brazilian Archives of Biology and Technology, 58, 773–780. https://
doi.org/10.1590/s1516-89132015050269
Radaeva S, Ferreira-Gonzalez A and Sirica AE, 1999. Overexpression of C-NEU and C-MET during rat liver
cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.
Hepatology, 29, 1453–1462. https://doi.org/10.1002/hep.510290524
Ramos-Marquez ME, Grijalva G and Armendariz-Borunda J, 2002. Ductular hyperplasia is characterized by an over
expression of c-Myc in bile duct ligation plus furan injured rats: possible role of interleukin-6. Hepatology
Research, 22, 127–138. https://doi.org/10.1016/s1386-6346(01)00121-8
Sahlberg B, Gunnbjornsdottir M, Soon A, Jogi R, Gislason T, Wieslander G, Janson C and Norback D, 2013.
Airborne molds and bacteria, microbial volatile organic compounds (MVOC), plasticizers and formaldehyde in
dwellings in three North European cities in relation to sick building syndrome (SBS). The Science of the Total
Environment, 444, 433–440. https://doi.org/10.1016/j.scitotenv.2012.10.114
Sprankle CS, Goldsworthy TL, Goldsworthy SM, Wilson DM and Butterworth BE, 1994. Expression of the hepatocyte
growth factor and c-MET genes during furan-induced regenerative cell proliferation in the livers of B6C3F1 mice
and F-344 rats. Cell Proliferation, 27, 529–539. https://doi.org/10.1111/j.1365-2184.1994.tb01490.x
Stanley LA, Blackburn DR, Devereaux S, Foley J, Lord PG, Maronpot RR, Orton TC and Anderson MW, 1994. Ras
mutations in methylclofenapate-induced B6C3F1 and C57BL/10J mouse liver tumours. Carcinogenesis, 15,
1125–1131.
Upreti KK, Das M and Khanna SK, 1991. Role of antioxidants and scavengers on argemone oil-induced toxicity in
rats. Archives of Environmental Contamination and Toxicology, 20, 531–537.
Vu CC and Peterson LA, 2005. Synthesis of a 2’-deoxyguanosine adduct of cis-2-butene-1,4-dial, a reactive
metabolite of furan. Chemical Research in Toxicology, 18, 1012–1017. https://doi.org/10.1021/tx049647d
Walinder R, Ernstgard L, Johanson G, Norback D, Venge P and Wieslander G, 2005. Acute effects of a fungal
volatile compound. Environmental Health Perspectives, 113, 1775–1778.
Wang J, Yang Z, Lin L, Zhao Z, Liu Z and Liu X, 2012. Protective effect of naringenin against lead-induced oxidative
stress in rats. Biological Trace Element Research, 146, 354–359. https://doi.org/10.1007/s12011-011-9268-6
Zaidi SI, Agarwal R, Eichler G, Rihter BD, Kenney ME and Mukhtar H, 1993. Photodynamic effects of new silicon
phthalocyanines: in vitro studies utilizing rat hepatic microsomes and human erythrocyte ghosts as model
membrane sources. Photochemistry and Photobiology, 58, 204–210.
A.3. EFSA guidance documents applied for the risk assessment
The following EFSA guidance pertaining to risk assessment were followed for the development of
the risk assessment:
• EFSA (European Food Safety Authority), 2005. Opinion of the Scientiﬁc Committee on a
request from EFSA related to a harmonised approach for risk assessment of substances which
are both genotoxic and carcinogenic. EFSA Journal 2005;282, 1–31.
• EFSA (European Food Safety Authority), 2007. Guidance of the Scientiﬁc Committee on a
request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal
2007;4(12):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.438
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• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
transparency in the scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: general
principles. EFSA Journal 2009;1051, 1–22.
• EFSA (European Food Safety Authority), 2010. Standard sample description for food and feed.
EFSA Journal 2010;8(1):1457, 54 pp. https://doi.org/10.2903/j.efsa.2010.1457
• EFSA (European Food Safety Authority), 2010. Management of left-censored data in dietary
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. https://doi.
org/10.2903/j.efsa.2010.1557
• EFSA (European Food Safety Authority), 2011. Use of the EFSA Comprehensive European Food
Consumption Database in Intakes Assessment. EFSA Journal 2011;9(3):2097, 34 pp. https://
doi.org/10.2903/j.efsa.2011.2097
• EFSA Scientiﬁc Committee 2011. Scientiﬁc Opinion on genotoxicity testing strategies applicable
to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. DOI: https://doi.
org/10.2903/j.efsa.2011.2379
• EFSA Scientiﬁc Committee 2012. Guidance on selected default values to be used by the EFSA
Scientiﬁc Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA
Journal 2012;10(3):2579, 32 pp. https://doi.org/10.2903/j.efsa.2012.2579
• EFSA Scientiﬁc Committee, 2012. Scientiﬁc Opinion on Risk Assessment Terminology. EFSA
Journal 2012;10(5):2664, 43 pp. DOI: https://doi.org/10.2903/j.efsa.2012.2664
• EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S,
Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck
D, Aerts M, Bodin L, Davis A, Edler L, Gundert-Remy U, Sand S, Slob W, Bottex B, Abrahantes
JC, Marques DC, Kass G and Schlatter JR, 2017. Update: use of the benchmark dose approach
in risk assessment. EFSA Journal, 15, n/a-n/a. https://doi.org/10.2903/j.efsa.2017.465
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Appendix B – Effects of different alkylfurans in experimental animals
Compound/
species
Treatment Outcome Reference
2-methylfuran
Rat ≥ 1,218 lmol/kg bw, i.p.
(single exposure)
Liver necrosis, pulmonary
bronchiolar lesions
Ravindranath et al. (1986)
Rat, Fischer 344,
male
5, 18, 37, 73, 146,
305 lmol/kg bw per day
by gavage over 28 days
Mild histological lesions and
inﬂammatory inﬁltrations in the
liver, Changes in serum
cholesterol and T3, T4
Gill et al. (2014)
3-methylfuran
Mouse, NIH
Swiss, male
100–200 mg
(radiolabelled)/kg bw i.p.
single exposure or
200 lmol (radiolabelled)/
L, inhalation, 1 h
Bronchiolar necrosis, binding
of radioactivity in the lung, 8 h
after i.p. injection or 24 h after
inhalation
Boyd et al. (1978)
Rat, CD/CR,
female Syrian
hamster, female
148 and 322 lmol/L,
inhalation, 1 h
Hamster: Bronchiolar necrosis
after 1 day
Rat: Bronchiolar necrosis after
1 day
Haschek et al. (1983)
Mouse, BALB/c,
male
14 and 37 lmol/L,
inhalation, 1 h
Bronchiolar necrosis after
1 day
Haschek et al. (1984)
Mouse, ICR, male 3,094 lmol/kg bw i.p.,
(single exposure)
No effects in liver and kidney
after 24 h
Wiley et al. (1984)
Mouse, ICR, male 2,600 and 3,100 lmol/kg
bw i.p. (single exposure)
Severe bronchiolar necrosis
after 24 h
Gammal et al. (1984)
Syrian hamster,
male and female
344 lmol/L, inhalation,
2 h once a week over
10 weeks
No pulmonary effects Witschi et al. (1985)
Rat, Fischer 344,
male
1, 4, 18, 37, 73, 146 and
305 lmol/kg bw per day
by gavage over 28 days
Histological and gross changes
of the liver, changes in serum
liver enzymes, increase in
serum T3 and T4
Gill et al. (2015)
Rat, Fischer 344,
male and female
0, 0.2, 1, 3, 12 and
49 lmol/kg bw by gavage
over 90 days (5 days per
week)
Liver lesions, kidney lesions,
increase in markers for liver and
kidney injury in serum
Gill et al. (2017, in press)
2-ethylfuran
Mouse, Swiss,
male
2,081 lmol/kg bw, i.p.
(single exposure)
Hepatic centrilobular and
renal proximal tubular necrosis
after 36 h
McMurtry and Mitchell (1977)
Mouse, ICR, male 2,600 lmol/kg bw, i.p. Kidney: proximal tubular
necrosis
liver: focal hydropic
degeneration after 24 h
Wiley et al. (1984)
Mouse, ICR, male 2,600 lmol/kg bw, i.p.
(single exposure)
Severe bronchiolar necrosis
after 24 h
Gammal et al. (1984)
3-ethylfuran
Mouse, ICR, male 3,100 lmol/kg bw, i.p.
(single exposure)
Kidney: proximal tubular
necrosis
liver: focal hydropic
degeneration after 24 h
Wiley et al. (1984)
Mouse, ICR, male 3,100 lmol/kg bw, i.p.
(single exposure)
Severe bronchiolar necrosis,
slight perivascular oedema after
24 h
Gammal et al. (1984)
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Compound/
species
Treatment Outcome Reference
3-pentylfuran
Mouse, ICR, male 1,800 lmol/kg bw, i.p.
(single exposure)
Kidney: proximal tubular
necrosis, liver: centrilobular
necrosis after 24 h
Wiley et al. (1984)
Mouse, ICR, male 1,800 and 2,600 lmol/kg
bw, i.p. (single exposure)
No pulmonary effects after 24 h Gammal et al. (1984)
bw: body weight; i.p.: intraperitoneal.
Furan and methylfurans in food
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Appendix C – Benchmark dose analysis
The text below describes the benchmark dose (BMD) analysis of the incidence of cholangioﬁbrosis
in male rats and the incidence of hepatocellular adenomas/carcinomas in female mice. BMD analysis
was done according to the EFSA guidance (EFSA Scientiﬁc Committee, 2017). The following was
applied in all analyses.
Software used
Results are obtained using the R-package bmdModeling.
• Fitting benchmark dose models is based on the R-package proast61.3.
• Averaging results from multiple ﬁtted benchmark dose models is based on the methodology in
Wheeler and Bailer (2008).
Model averaging
Model averaging was used for all tested endpoints.
Dose–response model sets
No deviation from the recommended defaults. Default set of ﬁtted models:
Model Number of parameters Formula
Null 1 y = a
Full No of groups y = groupmean
Logistic 2
y ¼ 1
1þ expða bxÞ
Probit 2 y ¼ pnormððx aÞ  bÞ
Log-logistic 3 y ¼ aþ 1 a
1þ exp

c  log

b
x

Log-probit 3 y ¼ aþ ð1 aÞ  pnorm

c  log

x
b

Weibull 3 y ¼ aþ ð1 aÞ

1 exp



x
b
c
Gamma 3 y = pgamma(bx; c)
Two-stage 3 y ¼ aþ ð1 aÞ

1 exp

 xb c

x
b
2
Procedure for selection of BMDL
There was no deviation from the procedure described in the ﬂow chart to obtain the ﬁnal BMD
conﬁdence interval.
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C.1. Incidence of cholangioﬁbrosis
C.1.1. Data description
Data from male F344/N NCTR rats treated for 36 weeks or 2 years with furan in corn oil by gavage
5 times per week (NCTR, 2015). Doses used in this BMD analysis were not adjusted for the dose
regimen and the reported results consequently correspond to a 5 days per week dosing regimen.
The analysed endpoints are:
• cholangioﬁbrosis after 36 weeks of treatment (Cholﬁb_36Wk);
• cholangioﬁbrosis after 2 years of treatment (Cholﬁb_2y).
Figure C.1: Flow chart for selection of BMDL
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C.1.2. Selection of the BMR
A default benchmark response (BMR) of 10% (extra risk compared with the background risk) and a
90% interval around the BMD were selected as recommended by EFSA Scientiﬁc Committee (2017).
C.1.3. Results for the incidence of cholangioﬁbrosis after 36 weeks
It was noted that the Probit model of the PROAST version 61.3 was not ﬁtting the data.
Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
Table C.1: Data on the incidence of cholangioﬁbrosis used for BMD analysis
Dose (mg/kg bw per day)(a)
After 36 weeks of treatment After 2 years of treatment
N N total N N total
0.000 0 20 0 149
0.020 0 20 0 150
0.044 0 20 0 99
0.092 0 20 1 100
0.200 0 20 38 50
0.440 6 20 49 49
0.920 17 20 47 50
2.000 19 20 49 49
N: number of animals; bw: body weight.
(a): For a 5 days per week dosing regimen.
Table C.2: Result for the incidence of cholangioﬁbrosis after 36 weeks using model averaging
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 92.10 186.20 NA NA NA Yes
Full 8 24.64 65.28 NA NA NA Yes
Logistic 2 32.17 68.34 0.35 0.27 0.44 Yes No
Log-logistic 3 25.78 57.56 0.31 0.22 0.39 Yes Yes
Log-probit 3 25.97 57.94 0.30 0.21 0.38 Yes Yes
Weibull 3 28.99 63.98 0.24 0.16 0.33 Yes No
Gamma 3 27.38 60.76 0.28 0.19 0.37 Yes No
Two-stage 3 29.27 64.54 0.27 0.23 0.33 No No
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
Table C.3: Model weights used in model averaging
Logistic Log-logistic Log-probit Weibull Gamma
Estimated model weights 0 0.48 0.4 0.02 0.1
Table C.4: Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week
dosing regimen) for the incidence of cholangioﬁbrosis after 36 weeks using model
averaging
BMD BMDL BMDU
0.3 0.22 0.41
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C.1.4. Results for the incidence of cholangioﬁbrosis after 2 years
It was noted that none of the ﬁtted models is at least as good as the full model; all ﬁtted models’
AIC values are larger than full model’s AIC + 2. However, the conﬁdence band contains the observed
values (see Figure C.3), and therefore, it was decided that model averaging can be used.
Nevertheless, it is recommended to generate more data on the incidence of cholangioﬁbrosis in the
dose range 0.092–0.2 mg/kg bw per day to better characterise the dose–response.
It was noted that the Probit model of the PROAST version 61.3 was not ﬁtting the data.
Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
Figure C.2: Averaged dose–response model for the incidence of cholangioﬁbrosis after 36 weeks
Table C.5: Result for the incidence of cholangioﬁbrosis after 2 years using model averaging
Model
Included
covariate
(s)
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 401.99 805.98 NA NA NA Yes
Full 8 44.50 105.00 NA NA NA Yes
Logistic 2 100.79 205.58 0.11 0.10 0.13 Yes No
Log-
logistic
3 60.70 127.40 0.11 0.09 0.12 Yes No
Log-probit 3 66.76 139.52 0.10 0.09 0.11 Yes No
Weibull 3 89.97 185.94 0.08 0.07 0.09 Yes No
Gamma 3 78.53 163.06 0.10 0.08 0.11 Yes No
Two-stage 3 93.07 192.14 0.10 0.09 0.11 No No
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
Table C.6: Model weights used in model averaging
Logistic Log-logistic Log-probit Weibull Gamma
Estimated model weights 0.000 0.998 0.002 0.000 0.000
Furan and methylfurans in food
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C.2. Incidence of hepatocellular adenomas/carcinomas in female mice
C.2.1. Data description
Hepatocellular adenomas and carcinomas in female B6C3F1 mice have been reported in two
separate 2-year carcinogenicity assays with furan (NTP, 1993 and Moser et al., 2009). A combined
analysis of the Moser et al. (2009) and NTP (1993) data was performed (see Table 4 of the opinion),
as well as an analysis for the Moser et al. (2009) data alone. Doses used in this BMD analysis were not
adjusted for the dose regimen and the reported results consequently correspond to a 5-day per week
dosing regimen.
Table C.7: Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5-day per week
dosing regimen) for the incidence of cholangioﬁbrosis after 2 years using model
averaging
BMD BMDL BMDU
0.11 0.09 0.12
Figure C.3: Averaged dose–response model for the incidence of cholangioﬁbrosis after 2 years
Table C.8: Data on the incidence of hepatocellular adenomas/carcinomas in female mice used for
BMD analysis
Dose (mg/kg
bw per day)(a)
n hepatocellular
adenomas and
carcinomas
n hepatocellular
carcinomas
n total Reference
0.0 3 0 36 Moser et al. (2009)
0.0 7 2 50 NTP (1993)
0.5 8 4 72 Moser et al. (2009)
1.0 6 2 53 Moser et al. (2009)
2.0 5 1 41 Moser et al. (2009)
4.0 12 2 36 Moser et al. (2009)
8.0 29 11 39 Moser et al. (2009)
8.0 34 7 50 NTP (1993)
15.0 50 27 50 NTP (1993)
N: number of animals; bw: body weight.
(a): For a 5 days per week dosing regimen.
Furan and methylfurans in food
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C.2.2. Selection of the BMR
A default benchmark response (BMR) of 10% (extra risk compared with the background risk) and a
90% interval around the BMD were selected as recommended by EFSA Scientiﬁc Committee (2017).
C.2.3. Results for the incidence of hepatocellular adenomas and
carcinomas as reported by Moser et al. (2009) and NTP (1993)
A combined analysis of the incidence of hepatocellular adenomas and carcinomas reported in two
separate studies (NTP, 1993; Moser et al., 2009) was performed, using study as a covariate. The effect
of study as covariate was not signiﬁcant and therefore the data from both studies were merged.
Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
Table C.9: Result for the incidence of hepatocellular adenomas and carcinomas reported by Moser
et al. (2009) and NTP (1993) using model averaging
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 279.17 560.34 NA NA NA Yes
Full 7 166.62 347.24 NA NA NA Yes
Logistic 2 168.70 341.40 2.00 1.73 2.30 Yes Yes
Probit 2 168.44 340.88 1.83 1.61 2.09 Yes Yes
Log-
logistic
3 169.19 344.38 3.42 2.45 4.75 Yes No
Log-probit 3 168.54 343.08 3.41 2.50 4.46 Yes No
Weibull 3 167.20 340.40 3.02 2.08 4.20 Yes Yes
Gamma 3 167.79 341.58 3.22 2.23 4.32 Yes Yes
Two-stage 3 167.81 341.62 2.39 2.16 2.66 Yes Yes
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
Table C.10: Model weights used in model averaging
Logistic Probit Log-logistic Log-probit Weibull Gamma Two-stage
Estimated model weights 0.16 0.2 0.04 0.07 0.26 0.14 0.14
Table C.11: Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week
dosing regimen) for the incidence of hepatocellular adenomas/carcinomas reported by
Moser et al. (2009) and NTP (1993) using model averaging
BMD BMDL BMDU
2.6 1.84 4
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Figure C.4: Averaged dose–response model for the incidence of hepatocellular adenomas/carcinomas
after 2 years reported by Moser et al. (2009) and NTP (1993)
Furan and methylfurans in food
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C.2.4. Results for the incidence of hepatocellular carcinomas as reported by Moser et al. (2009) and NTP
(1993)
A combined analysis of the incidence of hepatocellular carcinomas reported in two separate studies (NTP, 1993; Moser et al., 2009) was performed,
using study as a covariate. The effect of study as covariate was signiﬁcant and the studies were therefore not combined.
Table C.12: Result for the incidence of hepatocellular carcinomas reported by Moser et al. (2009) and NTP (1993), using study as a covariate and using
model averaging
Model
Included
covariate(s)
Number of
parameters
Log-
likelihood
AIC
BMD –
study.
Moser
BMDL –
study.
Moser
BMDU –
study.
Moser
BMD –
study.
NTP
BMDL –
study.
NTP
BMDU –
study.
NTP
Converged
Accepted
AIC
1 Null 1 165.92 333.84 NA NA NA NA NA NA Yes
2 Full 7 125.20 264.40 NA NA NA NA NA NA Yes
3 Logistic 2 126.28 256.56 6.26 5.46 7.14 6.26 5.46 7.14 Yes Yes
4 Logistic a 3 126.05 258.10 5.91 5.00 7.19 5.91 5.00 7.19 Yes Yes
5 Logistic b 3 125.22 256.44 5.13 4.22 6.66 6.73 5.75 7.80 Yes Yes
6 Logistic a, b 4 125.20 258.40 5.14 4.22 6.65 6.61 5.30 8.08 Yes Yes
7 Probit 2 126.30 256.60 5.74 5.00 6.59 5.74 5.00 6.59 Yes Yes
11 Log-logistic 3 125.95 257.90 6.44 4.81 7.95 6.44 4.81 7.95 Yes Yes
12 Log-logistic a 4 125.93 259.86 6.45 4.83 7.94 6.45 4.83 7.94 Yes No
13 Log-logistic b 4 124.55 257.10 5.87 4.62 7.19 7.90 5.85 9.91 Yes Yes
14 Log-logistic a, b 5 124.52 259.04 5.88 4.62 7.18 8.01 5.88 10.94 Yes No
15 Log-probit 3 125.87 257.74 6.49 4.94 7.91 6.49 4.94 7.91 Yes Yes
16 Log-probit a 4 125.84 259.68 6.49 4.95 7.90 6.49 4.95 7.90 Yes No
17 Log-probit b 4 124.50 257.00 5.90 4.66 7.22 7.82 5.91 9.59 Yes Yes
18 Log-probit a, b 5 124.49 258.98 5.90 4.66 7.22 7.88 5.91 10.38 Yes No
19 Weibull 3 126.04 258.08 6.36 4.62 7.99 6.36 4.62 7.99 Yes Yes
20 Weibull a 4 126.03 260.06 6.36 4.62 7.99 6.36 4.62 7.99 Yes No
21 Weibull b 4 124.60 257.20 5.80 4.53 7.15 7.99 5.76 10.14 Yes Yes
22 Weibull a, b 5 124.56 259.12 5.82 4.53 7.13 8.13 5.80 11.29 Yes No
23 Gamma 3 125.93 257.86 6.44 4.77 7.94 6.44 4.77 7.94 Yes Yes
24 Gamma a 4 125.91 259.82 6.45 4.78 7.93 6.45 4.78 7.93 Yes No
25 Gamma b 4 124.52 257.04 5.86 4.61 7.19 7.88 5.85 9.73 Yes Yes
26 Gamma a, b 5 124.50 259.00 5.87 4.61 7.18 7.97 5.87 10.57 Yes No
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Model
Included
covariate(s)
Number of
parameters
Log-
likelihood
AIC
BMD –
study.
Moser
BMDL –
study.
Moser
BMDU –
study.
Moser
BMD –
study.
NTP
BMDL –
study.
NTP
BMDU –
study.
NTP
Converged
Accepted
AIC
27 Two-stage 3 126.23 258.46 5.80 5.09 6.71 5.80 5.09 6.71 Yes No
28 Two-stage a 4 126.23 260.46 5.79 5.08 6.72 5.79 5.08 6.72 Yes No
29 Two-stage b 4 125.88 259.76 5.09 3.99 6.96 5.99 5.17 7.06 Yes No
30 Two-stage a, b 5 125.87 261.74 5.07 3.98 6.96 6.01 5.17 7.16 Yes No
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark dose upper conﬁdence limit.
Furan and methylfurans in food
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It was noted that the Probit implementation in PROAST version 61.3 does not support covariate
adjustment.
Given 200 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
C.2.5. Results for the incidence of hepatocellular adenomas and
carcinomas as reported by Moser et al. (2009)
Table C.13: Model weights used in model averaging
Logistic Probit Log-logistic Log-probit Weibull Gamma Two-stage
Estimated model
weights
0.19 0.18 0.14 0.15 0.13 0.14 0.07
Table C.14: Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week
dosing regimen) for the incidence of hepatocellular carcinomas reported by Moser
et al. (2009) and NTP (1993) using model averaging
BMD BMDL BMDU
study.Moser 5.72 4.18 7.24
study.NTP 7.21 4.82 9.10
Figure C.5: Averaged dose–response model for the incidence of hepatocellular carcinomas after
2 years reported by Moser et al. (2009) and NTP (1993)
Table C.15: Result for the incidence of hepatocellular adenomas and carcinomas reported by Moser
et al. (2009) using model averaging
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 148.52 299.04 NA NA NA Yes
Full 6 114.48 240.96 NA NA NA Yes
Logistic 2 114.94 233.88 2.03 1.71 2.41 Yes Yes
Probit 2 115.09 234.18 1.87 1.59 2.21 Yes Yes
Log-
logistic
3 114.65 235.30 2.78 1.76 3.87 Yes Yes
Log-probit 3 114.62 235.24 2.85 1.89 3.88 Yes Yes
Weibull 3 114.73 235.46 2.62 1.53 3.88 Yes Yes
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Given 200 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
C.2.6. Results for the incidence of hepatocellular carcinomas as reported
by Moser et al. (2009)
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Gamma 3 114.66 235.32 2.76 1.65 3.88 Yes Yes
Two-stage 3 114.82 235.64 2.34 2.02 2.77 No Yes
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
Table C.16: Model weights used in model averaging
Logistic Probit Log-logistic Log-probit Weibull Gamma
Estimated model weights 0.26 0.23 0.13 0.13 0.12 0.13
Table C.17: Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week
dosing regimen) for the incidence of hepatocellular adenomas and carcinomas
reported by Moser et al. (2009) using model averaging
BMD BMDL BMDU
2.4 1.45 3.59
Figure C.6: Averaged dose–response model for the incidence of hepatocellular adenomas and
carcinomas reported by Moser et al. (2009)
Table C.18: Result for the incidence of hepatocellular carcinomas reported by Moser et al. (2009),
using model averaging
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 71.83 145.66 NA NA NA Yes
Full 6 59.59 131.18 NA NA NA Yes
Logistic 2 61.78 127.56 5.14 4.22 6.66 Yes Yes
Probit 2 61.94 127.88 4.89 3.92 6.60 Yes Yes
Log-
logistic
3 63.31 132.62 2.85 1.66 5.21 Yes No
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Given 200 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Log-probit 3 61.34 128.68 5.84 4.06 8.24 Yes Yes
Weibull 3 63.19 132.38 2.88 1.69 5.11 Yes No
Gamma 3 61.35 128.70 5.97 4.02 7.95 Yes Yes
Two-stage 3 61.95 129.90 5.07 3.98 6.95 Yes No
AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower conﬁdence limit; BMDU: benchmark
dose upper conﬁdence limit.
Table C.19: Model weights used in model averaging
Logistic Probit Log-logistic Log-probit Weibull Gamma Two-stage
Estimated model
weights
0.29 0.25 0.02 0.16 0.03 0.16 0.09
Table C.20: Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week
dosing regimen) for the incidence of hepatocellular carcinomas reported by Moser
et al. (2009) using model averaging
BMD BMDL BMDU
5.34 3.45 7.55
Figure C.7: Averaged dose–response model for the incidence of hepatocellular carcinomas reported
by Moser et al. (2009)
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Appendix D – Factors inﬂuencing furan and methylfuran levels in food
Table D.1: Inﬂuence of heating by the consumer on furan levels in commercially heat-processed
foods as reported in scientiﬁc literature
Matrix n
Concentration (lg/kg)(e)
Reduction factor(d) Reference
As purchased As consumed
Foods for infants and small children
Varied vegetables 3 7.3  0.6 6.0  0.3(a)
5.2  0.2(a)
4.0  0.2(c)
1.2
1.4
1.8
Altaki et al. (2017)
Vegetables cream
with pasta
3 29  1 25  1(a)
22  1(a)
17  1(c)
1.2
1.3
1.7
Altaki et al. (2017)
Chicken stew with
vegetables
3 38  2 32  2(a)
25  2(a)
18  1(c)
1.2
1.5
2.1
Altaki et al. (2017)
Chicken with rice 3 16  1 15  1(a)
13  1(a)
10  1(c)
1.1
1.2
1.6
Altaki et al. (2017)
Pea with pork
meat
3 53  3 60  3(a)
41  2(a)
32  1(c)
0.9
1.3
1.7
Altaki et al. (2017)
Pork meat with
pasta and
vegetables
3 49  2 46  2(a)
32  3(a)
23  2(c)
1.1
1.5
2.1
Altaki et al. (2017)
Beef meat with
rice
3 44  3 46  2(a)
34  2(a)
25  2(c)
1.0
1.3
1.8
Altaki et al. (2017)
Jardiniere beef
meat
3 51  3 56  2(a)
41  2(a)
35  2(c)
0.9
1.2
1.5
Altaki et al. (2017)
Lamb meat stew
with potato
3 34  2 37  2(a)
25  2(a)
22  2(c)
0.9
1.4
1.5
Altaki et al. (2017)
Lamb meat stew
with green bean
3 43  2 36  3(a)
30  1(a)
23  1(c)
1.2
1.4
1.9
Altaki et al. (2017)
Monkﬁsh with
potato
3 84  4 85  1(a)
65  3(a)
45  3(c)
1.0
1.3
1.9
Altaki et al. (2017)
Hake with rice 3 69  3 76  2(a)
55  2(a)
45  2(c)
0.9
1.3
1.5
Altaki et al. (2017)
Chicken 1(m) 23  6(f) 17  19(g)
18  17(c)
1.4
1.3
Hasnip et al. (2006)
Vegetable 1(m) 32  8(f) 31  35(g)
20  19(c)
1.0
1.6
Hasnip et al. (2006)
Retort packaged
baby food 1
n.r. 28.3  0.5 19.0  1.2(a)
20.8  1.1(b)
1.5
1.4
Kim et al. (2009)
Retort packaged
baby food 2
n.r. 10.8  0.6 9.1  0.5(a)
9.6  0.2(b)
1.2
1.1
Kim et al. (2009)
Soybean milk 1 n.r. 4.3  0.3 4.3  0.2(a)
3.6  0.2(b)
1.0
1.2
Kim et al. (2009)
Soybean milk 2 n.r. 14.9  0.8 12.0  0.4(a)
12.3  0.2(b)
1.2
1.2
Kim et al. (2009)
Infants vegetable
meal
1 45(n) 23(l) 2 DTU (2009)
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Matrix n
Concentration (lg/kg)(e)
Reduction factor(d) Reference
As purchased As consumed
Herbs, spices and condiments
Tomato-based
sauce
1(m) 12  3(f) 6  6(h)
9  10(b)
7  8(a)
6  7(b)
2.0
1.3
1.7
2.0
Hasnip et al. (2006)
Sweet and sour
vegetable sauce
1 13(n) 7(l) 1.8 DTU (2009)
Composite food
Baked beans 1(m) 24  6(f) 31  35(g)
24  23(h)
0.8
1.0
Hasnip et al. (2006)
Baked beans 1 102(n) 42(l) 2.4 DTU (2009)
Stew 1(m) 25  6(f) 17  16(h)
26  30(b)
17  19(a)
16  19(b)
1.5
1.0
1.5
1.6
Hasnip et al. (2006)
Korean seasoned
pork canned
n.r. 45.2  1.5 31.6  4.7(i)
24.3  8.5(j)
1.4
1.9
Kim et al. (2009)
Luncheon meat
canned
n.r. 3.9  0.5 2.9  0.4(i)
2.7  0.9(j)
1.3
1.4
Kim et al. (2009)
Meat sauce 1 40(n) 16(l) 2.5 DTU (2009)
Tomato soup 1 25(n) 32(g)
26(h)
0.8
1.0
Crews (2009)
Vegetable soup 1(m) 17  4(f) 19  11(h)
21  15(g)
0.9
0.8
Hasnip et al. (2006)
Soup 10 7–47 1–16(l) 1.5–12.5 DTU (2009)
Vegetables
canned
1(m) 4  2(f) 4  5(h)
3  5(b)
3  4(a)
3  4(b)
1.0
1.3
1.3
1.3
Hasnip et al. (2006)
Tuna canned n.r. 12.6  0.1 2.5  0.2(k) 5.0 Kim et al. (2009)
Mackerel pike
canned
n.r. 13.7  0.9 3.1  0.3(k) 4.4 Kim et al. (2009)
N: number of samples.
Heating experiments that were not considered relevant for heating carried out by consumers were not added to this table (e.g.
heating baby food for 1 h at 80°C). Experiments for which the furan concentrations were below the LOD/LOQ were not included
in this table.
(a): Microwave; without lid (uncapped jar/dish/open casserole).
(b): Microwave; with lid (glass/plastic lid).
(c): Hot water bath; without lid (uncapped jars).
(d): Calculated from (mean) concentrations reported by the authors by dividing the furan concentration in the food as purchased
by the furan concentration in the food as consumed.
(e): Mean  standard deviation unless stated otherwise.
(f): Mean  measurement uncertainty (including uncertainty due to analysis and heating).
(g): Microwave; without speciﬁcation regarding lid.
(h): Saucepan heating with stirring.
(i): Microwave; heating to 50°C; without speciﬁcation regarding lid.
(j): Microwave; heating to 70°C; without speciﬁcation regarding lid.
(k): Heating without a lid to 100°C.
(l): Calculated based on % of furan left after heating as reported by the authors; heating unspeciﬁed.
(m): Heating experiments were carried out at least in duplicate.
(n): Single concentration.
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Table D.2: Inﬂuence of beverage preparation by the consumer on furan levels as reported in scientiﬁc literature
Coffee type N
Amount of
solid (g)(a)
Volume of
brew
(mL)(a)
Concentration (lg/kg)(a)
Dilution
factor(a)
Loss
factor(a)
Overall
reduction
factor(a),(b)
Reference
Solid Brew
Ground coffee
Boiled/Turkish
coffee
16 50 500 3,457.5 (1,373–5,580) 29 (12–81) 10 11.6 (3.6–45.6) 115.9 (35.9–455.7) Arisseto et al. (2011)
Espresso 7 5 75 1,770 (1,490–2,020) 43 (28–60) 15 2.5 (1.7–4.3) 37.3 (26.1–64.3) Kuballa et al. (2005)
Espresso 5 8 64
(62–67)
3,493 (2,254–5,938) 98 (72–199) 8 (7.8–8.4) 4.6 (2.1–6.4) 37 (17.6–49.6) Zoller et al. (2007)
Filter coffee 20 50 500 3,457.5 (985–5,697) 97.5 (19–279) 10 4 (2–7.8) 39.6 (20–78.4) Arisseto et al. (2011)
Filter coffee 1 32 740 2,080 46.7 23.1 1.9 44.5 Becalski et al. (2016)
Filter coffee 3 40 1,000 1,892 (1,681–1,966) 56.7 (51.5–64.3) 25 1.4 (1–1.5) 34.7 (26.1–36.7) DTU (2009)
Filter coffee 15 40 850 1,790 (790–3,390) 15 (8–66) 21.3 6.4 (1.1–8.9) 135.6 (23.3–190) Kuballa et al. (2005)
Filter coffee 1 8 130 1,438 40 16.3 2.2 36 Zoller et al. (2007)
French press/
infusion
1 51 1,000 2,080 77.6 19.6 1.4 26.8 Becalski et al. (2016)
Coffee beans
Espresso 6 10 150 4,725 (3,510–6,100) 91.5 (57–115) 15 3.5 (2.1–6.2) 52.5 (30.8–93.7) Kuballa et al. (2005)
Filter coffee
(machine)
5 40 850 4,910 (3,600–6,100) 16 (9–33) 21.3 15.7 (5.1–23.9) 333.8 (109.1–508.3) Kuballa et al. (2005)
Filter coffee
(manual)
5 40 850 4,910 (3,600–6,100) 20 (17–24) 21.3 12 (8.1–14) 254.2 (171.4–296.7) Kuballa et al. (2005)
French press/
infusion
5 40 850 4,910 (3,600–6,100) 51 (33–66) 21.3 4.5 (3.5–6.5) 95.4 (74.4–137.6) Kuballa et al. (2005)
Cartridge coffee
Not speciﬁed 3 8
(7–9)
210 2,300 (2,110–2,660) 59.1 (57.6–59.2) 26.3
(23.3–30)
1.5 (1.5–1.5) 38.9 (35.7–46.2) Becalski et al. (2016)
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Coffee type N
Amount of
solid (g)(a)
Volume of
brew
(mL)(a)
Concentration (lg/kg)(a)
Dilution
factor(a)
Loss
factor(a)
Overall
reduction
factor(a),(b)
Reference
Solid Brew
Instant coffee
Instant coffee 2 2 60 960 (820–1,100) 31.5 (28–35) 30 1 30.4 (29.3–31.4) Altaki et al. (2009)
Instant coffee 2 1.4
(1.2–1.5)
112.5
(75–150)
977.5 (625–1,330) 5.5 (4.3–6.6) 81.3
(62.5–100)
2.2 (2–2.3) 173.4 (145.3–201.5) DTU (2009)
Instant coffee 7 10 500 530 (240–2,200) 11 (3–25) 50 1.5 (0.8–3.1) 75.7 (41.8–157.1) Kuballa et al. (2005)
Instant coffee 14 2
(1.7–2)
150
(65–150)
1,702 (44–2,150) 19 (1–51.3) 75
(32.5–89.8)
1.1 (0.6–1.4) 82.4 (41.9–97.9) Zoller et al. (2007)
(a): Median (range).
(b): The overall reduction factor is calculated by dividing the furan concentration in the food as purchased by the furan concentration in the food as consumed. This reduction factor comprises a
dilution and a loss factor.
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Appendix E – Previously reported occurrence data
Table E.1: Levels of furan in home-cooked foods reported in scientiﬁc literature
Processing/matrix
Concentration (lg/kg)
Reference
Raw/as purchased As consumed
Toasting
White bread < 2 39  48(a) (n = 5) Hasnip et al. (2006)
White bread < 3–3 (n = 3) 260 (187–385)(b)
(n = 5)
Crews (2009)
Wholemeal bread < 3–3 (n = 3) 150 (32–229)(b)
(n = 7)
Crews (2009)
Bread < 2.4 (n = 2) < 2.4–179(c),(k)
(n = 11)
DTU (2009)
Toast bread < 2 (n = 2) < 2–18 (n = 4) Zoller et al. (2007)
Baking
Part baked bread < 3 (n = 1) 7 (3–11)(d) (n = 4) Crews (2009)
Cookies < 3 (n = 1) 7 (5–9)(d) (n = 4) Crews (2009)
Pizza (chilled) < 3 (n = 1) 4 (< 3–6)(d) (n = 4) Crews (2009)
Pizza (frozen) 3 (n = 1) 19 (10–27)(d) (n = 4) Crews (2009)
Breaded chicken pieces < 3 (n = 1) 7 (6–8)(d) (n = 4) Crews (2009)
Breaded vegetables < 3 (n = 1) 6 (4–9)(d) (n = 5) Crews (2009)
Breaded ﬁsh < 3 (n = 1) 5 (4–5)(d) (n = 5) Crews (2009)
Cream potatoes n.r. < 2.4–2.4(h) (n = 2) DTU (2009)
Chips (oven) 3 (n = 1) (< 3–3)(d) (n = 4) Crews (2009)
Chips made from industrially made
products (oven)
3–15(g) (n = 9) DTU (2009)
Apple pie 4.4 (n = 1) DTU (2009)
Apple cake 23.4 (n = 1) DTU (2009)
Frying
Fish meat balls < 2.4 (n = 1) < 2.4–3.1(c) (n = 4) DTU (2009)
Candied potatoes 3.3–15.5(h) (n = 3) DTU (2009)
Pancake < 2.4–2.6(c) (n = 5) DTU (2009)
Caramel < 2 (n = 2) 51–570(g),(j) (n = 4) Zoller et al. (2007)
Deep-frying
Chips made from fresh potatoes < 3 (n = 1) 12 (8–16)(e) (n = 4) Crews (2009)
Chips made from industrially made
products
11–21(f) (n = 9) DTU (2009)
Crisps made from fresh potatoes 12–51(f) (n = 10) DTU (2009)
Dried slices of white, purple and sweet
potato
6–43(f),(i) Yuan et al. (2016)
Roasting
Fresh onion < 2 (n = 1) < 3–5 (n = 2) Zoller et al. (2007)
N: number of samples.
(a): Mean  measurement uncertainty; toasting for 4 min in a preheated domestic toaster.
(b): Mean (range); until fully browned.
(c): Range; different toasting/roasting/frying degrees.
(d): Mean (range); baked in a pre-heated oven set at 190–220°C.
(e): Mean (range); fried at 180°C in rapeseed oil for 6 min, followed by 3 min at 190°C.
(f): Range; different time-temperature combinations.
(g): Range; different heating temperatures.
(h): Range; completely home-made or made from an industrially made product.
(i): Numbers read from a graph.
(j): For one sample, a concentration of 1,956 lg/kg was reported; however, the authors indicated that this was unedible due to
the bitter taste.
(k): The level of 179 lg/kg was reported for black toast.
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Table E.2: Co-Occurrence of furan and methylfurans in commercially processed foods
Matrix n
Concentration (lg/kg)(a)
ReferenceFuran 2-Methylfuran 3-Methylfuran 2,5-Dimethylfuran
Range Mean(b) Range Mean Range Mean Range Mean
Grains and grain-based products
Cereal ﬂakes 18 9–63 22.3 12–86 23.5 < RL (5)–6 3.3 n.a. n.a. DPE(c)
Vegetables and vegetable products (including fungi)
Artichoke hearts 1 8.5 8.5 4.6 4.6 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Asparagus 4 2.8–11.4 5.5 < LOD (1)–
3.2
2.3 < LOD (1)–4.4 2.6 n.a. n.a. Becalski et al. (2010)
Beets 4 11.7–338 100.4 1.6–30.0 9.0 < LOD (1)–4.3 3.2 n.a. n.a. Becalski et al. (2010)
Mushrooms 5 11.3–26.0 17.2 8.4–12.4 10.2 < LOD (1)–1.2 0.6 n.a. n.a. Becalski et al. (2010)
Tomatoes 5 6.3–19.6 14.3 16.5–42.0 24.8 86.9–144 111.8 n.a. n.a. Becalski et al. (2010)
Carrots 5 26.9–70.9 43.9 4.1–22.0 8.9 < LOD (1)–11.8 4.3 n.a. n.a. Becalski et al. (2010)
Corn 5 28.1–52.1 36.1 5.9–14.2 8.9 57.9–151 116 n.a. n.a. Becalski et al. (2010)
Hearts of palm 2 1.1–1.6 1.4 < LOD (1) 0.5 1.4–2.7 2.1 n.a. n.a. Becalski et al. (2010)
Ground roasted coffee 1 4,590 4,590 8,680 8,680 450 450 n.a. n.a. Becalski et al. (2010)
Ground roasted coffee 117 762–5434 3,145 4,724–
34,378
18,338 190–2,597 694 n.a. n.a. DPE(c)
Regular ground coffee 15 715–2800 2,200 4,890–
13,100
9,470 311–615 447 n.a. n.a. Becalski et al. (2016)
Cartridge ground coffee 3 2,110–
2,660
2,360 9,440–
13,100
10,700 427–555 508 n.a. n.a. Becalski et al. (2016)
Decaffeinated ground coffee 7 1,640–
3,450
2,450 6,570–
13,500
10,400 274–628 463 n.a. n.a. Becalski et al. (2016)
Decaffeinated instant coffee
powder
7 32.0–896 329 129–6,150 1,800 9.01–213 75.2 n.a. n.a. Becalski et al. (2016)
Instant coffee 2 279–547 413 759–764 761.5 40.4–48.6 44.5 n.a. n.a. Becalski et al. (2010)
Regular instant coffee
powder
7 46.8–742 233 200–6,200 1,595 11.9–270 72.9 n.a. n.a. Becalski et al., 2016)
Instant coffee 64 17–3,394 627 135–15,932 2,472 10–1,853 161 n.a. n.a. DPE(c)
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Matrix n
Concentration (lg/kg)(a)
ReferenceFuran 2-Methylfuran 3-Methylfuran 2,5-Dimethylfuran
Range Mean(b) Range Mean Range Mean Range Mean
Starchy roots and tubers
Potatoes 4 20.2–114 65.2 < LOD (1)–
2.7
1.7 < LOD (1)–1.5 1.0 n.a. n.a. Becalski et al. (2010)
Legumes, nuts and oilseeds
Green and waxy beans 5 48.5–69.7 59.8 9.1–29.3 17.9 7.1–20.9 13.2 n.a. n.a. Becalski et al. (2010)
Beans 5 29.6–83.8 54.7 3.0–15.5 8.6 3.9–7.6 5.8 n.a. n.a. Becalski et al. (2010)
Chick peas 5 26.8–73.5 40.3 13.9–21.6 18.2 5.5–8.8 7.2 n.a. n.a. Becalski et al. (2010)
Kidney beans 5 18.2–195 75.5 3.4–15.6 6.9 4.7–10.9 6.8 n.a. n.a. Becalski et al. (2010)
Fruit and fruit products
Applesauce 5 6.3–19.2 11.1 3.7–14.3 7.7 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Mixed fruit 4 4.8–51.2 27.2 1.6–7.1 5.0 < LOD (1)–1.1 0.7 n.a. n.a. Becalski et al. (2010)
Peaches 2 13.4–21.9 17.7 4.6–9.6 7.1 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Pineapple 3 3.4–6.7 4.8 1.9–3.8 2.9 1.2–2.5 2.0 n.a. n.a. Becalski et al. (2010)
Meat and meat products (including edible offal)
Flakes of chicken 1 29.8 29.8 152 152 2.9 2.9 n.a. n.a. Becalski et al. (2010)
Flakes of ham 3 13.9–14.6 14.2 58.1–85.7 76.1 < LOD (1)–1.6 1.1 n.a. n.a. Becalski et al. (2010)
Luncheon meat 1 39.0 39.0 24.4 24.4 1.7 1.7 n.a. n.a. Becalski et al. (2010)
Meat products 11 < LOQ (1.0)
–1.3
0.6 < LOQ (1.0)
–2.6
0.7 n.a. n.a. < LOQ (1.0) 0.5 Shen et al. (2016)
Meat spreads 5 51.0–172 100.7 26.2–54.8 36.9 10.4–28.8 17.9 n.a. n.a. Becalski et al. (2010)
Fish and other seafood (including amphibians, reptiles, snails and insects)
Oysters 1 171 171 149 149 28.3 28.3 n.a. n.a. Becalski et al. (2010)
Salmon 5 9.3–18.1 13.4 38.8–109 65.3 7.9–16.1 12.2 n.a. n.a. Becalski et al. (2010)
Sardines in water, oil or
sauce
4 17.5–65.5 33.5 15.9–21.6 18.0 1.3–5.2 2.5 n.a. n.a. Becalski et al. (2010)
Tuna 5 15.4–27.9 21.8 14.4–39.6 24.8 1.2–1.7 1.5 n.a. n.a. Becalski et al. (2010)
Milk and dairy products
Milk and milk beverages 15 < LOQ (1.0)
–8.0
2.2 < LOQ (1.0)
–7.9
2.1 n.a. n.a. < LOQ (1.0)–88.8 8.7 Shen et al. (2016)
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Matrix n
Concentration (lg/kg)(a)
ReferenceFuran 2-Methylfuran 3-Methylfuran 2,5-Dimethylfuran
Range Mean(b) Range Mean Range Mean Range Mean
Sugar and confectionary
Chocolates 6 < LOQ (1.0) 0.5 < LOQ (1.0)
–1.4
0.7 n.a. n.a. < LOQ (1.0) 0.5 Shen et al. (2016)
Fruit and vegetable juices
Juice and drinks 3 6.7–16.7 13.1 1.3–2.0 1.6 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Clamato 3 6.7–9.5 8.3 < LOD (1) 0.5 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Cocktail 1 10.8 10.8 3.7 3.7 2.6 2.6 n.a. n.a. Becalski et al. (2010)
Fruit juices 15 < LOQ (0.5)
–1.9
0.5 < LOQ (0.5)
–2.0
0.8 n.a. n.a. < LOQ (0.5)–0.5 0.3 Shen et al. (2016)
Tomato drinks 4 4.3–14.1 8.0 9.5–20.6 13.5 22.9–55.7 42.0 n.a. n.a. Becalski et al. (2010)
Non-alcoholic beverages (excepting milk-based beverages)
Brewed coffee 1 820 820 3,900 3,900 n.a. n.a. n.a. n.a. Ochiai et al. (2014)
Brewed medium roast or
bold roast coffee
16 25.1–69.5 38.7 109–287 172 5.0–9.5 6.4 n.a. n.a. Becalski et al. (2016)
Coffee 15 47–2,821 885 117–5,982 1,328 n.a. n.a. 32–466 217 Fromberg et al. (2014)
Decaffeinated coffee 12 6.63–121 53.1 24.4–365 184 1.1–12.0 6.7 n.a. n.a. Becalski et al. (2016)
Espresso coffee 12 34.9–352 157 135–1,360 583 6.5–39.3 19.0 n.a. n.a. Becalski et al. (2016)
Alcoholic beverages
Alcoholic drinks 3 < LOQ (0.5) 0.3 < LOQ (0.5)
–2.0
0.9 n.a. n.a. < LOQ (0.5)–0.5 0.3 Shen et al. (2016)
Beer 13 < LOQ (0.5)
–0.8
0.4 < LOQ (0.5)
–2.4
0.9 n.a. n.a. < LOQ (0.5) –3.4 0.6 Shen et al. (2016)
Herbs, spices and condiments
Ketchup 4 28.7–286 101.6 2.5–18.1 8.9 < LOD (1)–11.3 6.7 n.a. n.a. Becalski et al. (2010)
Tomato ketchup 2 1.8–2.1 2.0 < LOQ (1.0)
–2.7
1.6 n.a. n.a. < LOQ (1.0) 0.5 Shen et al. (2016)
Chilli sauce 2 72.8–89.2 81.0 5.4–13.5 9.5 3.8–17.3 10.6 n.a. n.a. Becalski et al. (2010)
Seafood sauce 2 7.7–77.3 42.5 1.2–20.6 10.9 < LOD (1)–7.3 3.9 n.a. n.a. Becalski et al. (2010)
Soy sauce 14 7.3–63.8 33.1 1.7–43.6 15.2 n.a. n.a. < LOQ (0.5)–10.8 2.9 Shen et al. (2016)
Worcestershire sauce 1 17.4 17.4 4.2 4.2 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
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Matrix n
Concentration (lg/kg)(a)
ReferenceFuran 2-Methylfuran 3-Methylfuran 2,5-Dimethylfuran
Range Mean(b) Range Mean Range Mean Range Mean
Vinegar 15 < LOQ (0.5)
–34.3
10.3 < LOQ (0.5)
–34.5
8.5 n.a. n.a. < LOQ (0.5)–2.0 0.5 Shen et al. (2016)
Food for infants and small children
Baby-food purees 11 < LOQ (1.0)
–16.2
5.1 < LOQ (1.0)
–13.5
3.6 n.a. n.a. < LOQ (1.0) 0.5 Shen et al. (2016)
Banana graham pie 1 43.9 43.9 4.9 4.9 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Chicken cacciatore 1 331 331 35.5 35.5 22.9 22.9 n.a. n.a. Becalski et al. (2010)
Junior oatmeal with mixed
fruit
1 120 120 9.5 9.5 5.1 5.1 n.a. n.a. Becalski et al. (2010)
Infant formulas 12 < LOQ (1.0)
–27.8
10.5 < LOQ (1.0)
–4.4
1.3 n.a. n.a. < LOQ (1.0)–17.1 3.9 Shen et al. (2016)
Infant formula with iron
(add water)
1 26.7 26.7 8.7 8.7 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Squash 1 66.2 66.2 7.5 7.5 1.6 1.6 n.a. n.a. Becalski et al. (2010)
Strained blueberry 1 32.1 32.1 2.6 2.6 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Strained carrots 1 27.8 27.8 2.6 2.6 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Strained creamed corn 1 51.5 51.5 16.6 16.6 4.3 4.3 n.a. n.a. Becalski et al. (2010)
Strained custard 1 199 199 50.2 50.2 1.0 1.0 n.a. n.a. Becalski et al. (2010)
Strained green beans 1 78.3 78.3 7.4 7.4 3.2 3.2 n.a. n.a. Becalski et al. (2010)
Strained strawberries 1 8.5 8.5 1.18 1.18 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Strained mixed vegetables 1 54.0 54.0 4.2 4.2 1.6 1.6 n.a. n.a. Becalski et al. (2010)
Strained peas 1 82.4 82.4 10.5 10.5 3.1 3.1 n.a. n.a. Becalski et al. (2010)
Strawberries 1 27.4 27.4 1.41 1.41 < LOD (1) 0.5 n.a. n.a. Becalski et al. (2010)
Sweet potatoes 1 239 239 15.7 15.7 17.5 17.5 n.a. n.a. Becalski et al. (2010)
Commercial baby foods
based on ﬂour or cereals
6 22.7–88.2 38.6 30.5–88.8 68.3 n.a. n.a. 69.4–230.3 153.1 Habibi et al. (2013)
Vegetable and beef jars 1 128 128 18.8 18.8 6.6 6.6 n.a. n.a. Becalski et al. (2010)
Vegetable/chicken jars 1 121 121 14.3 14.3 9.5 9.5 n.a. n.a. Becalski et al. (2010)
Baby food in jar 35 20–67 35.6 < RL (5)–12 6.8 < RL (5)–12 5.2 n.a. n.a. DPE(c)
Infant cereals 28 < RL (5)–32 8.3 7–118 15.4 < RL (5)–9 3.4 n.a. n.a. DPE(c)
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Matrix n
Concentration (lg/kg)(a)
ReferenceFuran 2-Methylfuran 3-Methylfuran 2,5-Dimethylfuran
Range Mean(b) Range Mean Range Mean Range Mean
Composite food (including frozen products)
Baked beans 5 368–824 580.6 61.4–152 91.3 9.3–20.4 13.5 n.a. n.a. Becalski et al. (2010)
Pasta sauce 3 15.2–42.7 32.8 4.1–13.2 9.1 3.6–8.6 5.8 n.a. n.a. Becalski et al. (2010)
Peanut butter 1 10.6 10.6 9.2 9.2 3.2 3.2 n.a. n.a. Becalski et al. (2010)
Pizza sauce 4 24.2–111 59.6 10.7–25.6 16.1 7.9–11.9 9.8 n.a. n.a. Becalski et al. (2010)
Salsa 3 10.8–25.8 19.3 4.8–7.9 6.5 7.4–12.5 9.1 n.a. n.a. Becalski et al. (2010)
Canned food 12 < LOD (2.4)
–47
20.5 < LOD (2.4)
–8.0
4.7 n.a. n.a < LOD (2.4) – 105 67(d) Fromberg et al. (2014)
Chilli con carne 5 241–863 386.4 35.9–73.0 51.8 25.2–55.7 38.8 n.a. n.a. Becalski et al. (2010)
Gourmet antipasto 1 27.0 27.0 46.4 46.4 9.1 9.1 n.a. n.a. Becalski et al. (2010)
Pasta meals 5 151–1,230 396.4 22.9–105 41.9 10.2–49.5 18.8 n.a. n.a. Becalski et al. (2010)
Stew and meatball entrees 4 34.6–1,030 308.6 6.6–132 46.5 2.0–58.9 17.6 n.a. n.a. Becalski et al. (2010)
Cream of mushroom (soup) 1 93.5 93.5 11.5 11.5 1.7 1.7 n.a. n.a. Becalski et al. (2010)
Tomato paste 5 59.7–200 123.0 24.2–76.8 50.4 14.9–98.2 51.6 n.a. n.a. Becalski et al. (2010)
Tomato sauce 5 17.0–35.5 23.6 3.1–45.7 15.8 5.8–86.8 24.5 n.a. n.a. Becalski et al. (2010)
Tomato sauce 3 < RL (5) 0.3 6–10 8.3 5–7 6.3 n.a. n.a. DPE(c)
DPE: documentation provided to EFSA by FoodDrinkEurope; LOD: limit of detection; LOQ: limit of quantiﬁcation; n.a. not analysed n: number of samples; RL: reporting limit.
(a): Applied method of analysis was headspace sampling followed by analysis using GC–MS unless stated otherwise.
(b): The mean values were calculated by EFSA using the middle bound approach if they were not provided in the publication.
(c): Data on the co-occurrence of furan, 2-methylfuran and 3-methylfuran in jarred baby foods, cereal ﬂakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce.
December 2016. Submitted by FoodDrinkEurope to EFSA, outside the ad hoc call for occurrence data
(d): Calculated using mean values reported by the authors.
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Table E.3: 2-Methylfuran/furan and 3-methylfuran/furan ratios in commercially processed foods
Food n
Concentration (lg/kg)(a) Mean ratio(b) Median ratio
ReferenceFuran 2-Methylfuran 3-Methylfuran
2MF/F 3MF/F 2MF/F 3MF/F
Range Mean(c) Range Mean Range Mean
Grains and grain-based products
Cereal ﬂakes 18 9–63 22.3 12–86 23.5 < RL (5)–6 3.3 1.10 0.17
(n = 5)
1.12 0.15
(n = 5)
DPE(d)
Vegetables and vegetable products (including fungi)
Ground roasted
coffee
1 4,590 4,590 8,680 8,680 450 450 1.89 0.10 – – Becalski et al. (2010)
Ground roasted
coffee
117 762–5,434 3,145 4,724–34,378 18,338 190–2,597 694 5.9 0.2 5.7 0.2 DPE(d)
Regular ground
coffee
15 715–2,800 2,200 4,890–13,100 9,470 311–615 447 4.30 0.20 n.r. n.r. Becalski et al. (2016)
Cartridge ground
coffee
3 2,110–2,660 2,360 9,440–13,100 10,700 427–555 508 4.53 0.22 n.r. n.r. Becalski et al. (2016)
Decaffeinated
ground coffee
7 1,640–3,450 2,450 6,570–13,500 10,400 274–628 463 4.24 0.19 n.r. n.r. Becalski et al. (2016)
Decaffeinated
instant coffee
powder
7 32.0–896 329 129–6,150 1,800 9.01–213 75.2 5.47 0.23 n.r. n.r. Becalski et al. (2016)
Instant coffee 2 279–547 413 759–764 761.5 40.4–48.6 44.5 2.06 0.12 n.r. n.r. Becalski et al. (2010)
Regular instant
coffee powder
7 46.8–742 233 200–6,200 1,595 11.9–270 72.9 6.84 0.31 n.r. n.r. Becalski et al. (2016)
Instant coffee 64 17–3,394 627 135–15,932 2,472 10–1,853 161 4.26 0.39 3.85 0.22 DPE(d)
Non-alcoholic beverages (excepting milk-based beverages)
Brewed coffee 1 820 820 3,900 3,900 n.a. n.a. 4.76 – – – Ochiai et al. (2014)
Brewed medium
roast or bold
roast coffee
16 25.1–69.5 38.7 109–287 172 5.0–9.5 6.4 4.4 0.17 4.2 0.17 Becalski et al. (2016)
Coffee 15 47–2,821 885 117–5,982 1,328 n.a. n.a. 1.50(e) – n.r. – Fromberg et al. (2014)
Decaffeinated
coffee
12 6.63–121 53.1 24.4–365 184 1.1–12.0 6.7 3.5 0.13 3.7 0.15 Becalski et al. (2016)
Espresso coffee 12 34.9–352 157 135–1,360 583 6.5–39.3 19.0 3.7 0.12 3.9 0.14 Becalski et al. (2016)
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Food n
Concentration (lg/kg)(a) Mean ratio(b) Median ratio
ReferenceFuran 2-Methylfuran 3-Methylfuran
2MF/F 3MF/F 2MF/F 3MF/F
Range Mean(c) Range Mean Range Mean
Food for infants and small children
Baby food in jar 35 20–67 35.6 < RL (5)–12 6.8 < RL (5)–12 5.2 0.24
(n = 22)
0.19
(n = 19)
0.23
(n = 22)
0.17
(n = 19)
DPE(d)
Infant cereals 28 < RL (5)–32 8.3 7–118 15.4 < RL (5)–9 3.4 1.71
(n = 15)
0.33
(n = 5)
1.4
(n = 15)
0.26
(n = 5)
DPE(d)
2MF/F: 2-methylfuran/furan ratio; 3MF/F: 3-methylfuran/furan ratio; DPE: Documentation provided to EFSA by FoodDrinkEurope; n.a.: not analysed; n.c.: not calculated; n.r. not reported; n:
number of samples; RL: reporting limit.
(a): Applied method of analysis was Headspace sampling followed by analysis using GC–MS unless otherwise stated.
(b): The ratios were estimated by EFSA, with the exception of those food products reported in Becalski et al. (2016) where the ratios were provided and are reproduced in this table. Ratios were
only calculated when both furan and the methylfuran was quantiﬁed.
(c): The mean values were calculated by EFSA using the middle bound approach if they were not provided in the publication.
(d): Data on the co-occurrence of furan, 2-methylfuran and 3-methylfuran in jarred baby foods, cereal ﬂakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce.
December 2016. Submitted by FoodDrinkEurope to EFSA, outside the ad hoc call for occurrence data.
(e): Calculated using mean values reported by the authors.
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Annex A – Occurrence data submitted to EFSA and dietary exposure
assessment for humans
Annex A can be found in the online version of this output, under the section ‘Supporting
information’, at: http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.5005/full
Description: The annex is an excel ﬁle which presents tables from Tables A1–A10 on furan
occurrence and dietary exposure assessment for humans.
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